Atezolizumab Clinical Trials (2026): 746 Studies for Hepatocellular Carcinoma & Non-Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
746 Atezolizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 339 indications (including Hepatocellular Carcinoma & Non-Small Cell Lung Cancer) and 150,522 total planned enrollment. 106 Phase 3 Atezolizumab trials and 323 Phase 2, 7 Phase 4 are listed. 180 Atezolizumab clinical trials are actively recruiting at 1,934 U.S. sites across 51 states. Most recent activity: NCT04817956 (Apr 2045).
Where to Participate: All Atezolizumab Trial Sites in the U.S. (1,934 sites across 51 states)
Every actively recruiting Atezolizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | The Kirklin Clinic of University of Alabama Birmingham Hospital | Birmingham35233 | NCT05440708 | Map |
| AL | University of Alabama -Birmingham | Birmingham35233 | NCT06362252 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06294548 | Map |
| AL | University of Alabama at Birmingham (UAB) | Birmingham35233 | NCT06031441 | Map |
| AL | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham35294 | NCT02693535 | Map |
| AL | Southern Cancer Center, PC | Daphne36526 | NCT06646276 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT04402788 | Map |
| AZ | Pioneer Research Center, LLC | Bullhead City86442 | NCT06463665 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT04402788 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT05058651 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT06632327 | Map |
| AZ | Cancer Treatment Centers of America-Phoenix | Phoenix85338 | NCT02693535 | Map |
| AZ | Mayo Clinic Arizona | Phoenix85054 | NCT06362252 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT06632327 | Map |
| AZ | Research Site | Phoenix85054 | NCT06921785 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT05168163 | Map |
| AZ | ACRC Arizona Clinical Research Center | Tucson85715 | NCT06712355 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT01810913 | Map |
| AZ | University of Arizona Cancer Center | Tucson85724 | NCT06096779 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT01810913 | Map |
| AR | Highlands Oncology Group | Fayetteville72703 | NCT07226999 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT06632327 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT04402788 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT06632327 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT06632327 | Map |
| AR | Highlands Oncology Group | Rogers72758 | NCT07226999 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT07226999 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT05058651 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT06632327 | Map |
| CA | Sutter Auburn | Auburn95602 | NCT02693535 | Map |
| CA | Sutter Auburn Faith Hospital | Auburn95602 | NCT05058651 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT01810913 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT05058651 | Map |
| CA | Kaiser Permanente-Baldwin Park | Baldwin Park91706 | NCT05058651 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT05058651 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT05058651 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT07166406 | Map |
| CA | Sutter Alta Bates | Berkeley94705 | NCT02693535 | Map |
| CA | Beverly Hills Cancer Center | Beverly Hills90211 | NCT05733598 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT01810913 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT01810913 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT05058651 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT07166406 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT05058651 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT06632327 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT01810913 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT05058651 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT06632327 | Map |
| CA | Enloe Medical Center | Chico95926 | NCT06632327 | Map |
| CA | UC Irvine Medical Center | Costa Mesa92627 | NCT04524871 | Map |
| CA | City of Hope | Duarte91010 | NCT04802759 | Map |
| CA | City of Hope | Duarte91010 | NCT04524871 | Map |
| CA | City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte91010 | NCT05652686 | Map |
| CA | City of Hope /ID# 261468 | Duarte91010 | NCT06109272 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06287775 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT05085496 | Map |
| CA | Zai Lab Site 2005 | Duarte91010 | NCT06179069 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT05058651 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT06632327 | Map |
| CA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #002 | Fair Oaks95628 | NCT05434234 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT05058651 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT05058651 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT07166406 | Map |
| CA | ClinRé 001-022 (Premier Cancer Care and Infusion Center) | Fresno93710 | NCT07195695 | Map |
| CA | OPN Healthcare, Inc. | Glendale91203 | NCT07195695 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT05058651 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center | Irvine92618-2377 | NCT04802759 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT06287775 | Map |
| CA | City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669 | Irvine92618 | NCT06109272 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT05058651 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT04402788 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT07166406 | Map |
| CA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #001 | La Jolla92093-0698 | NCT05434234 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT04981509 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92037 | NCT05733598 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06096779 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06287775 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06632327 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT01810913 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT05058651 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT05058651 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05333458 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05333458 | Map |
| CA | Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05440708 | Map |
| CA | The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles90025 | NCT02693535 | Map |
| CA | UCLA | Los Angeles90095 | NCT04929223 | Map |
| CA | University of California Los Angeles - Jonsson Comprehensive Cancer Center | Los Angeles90095 | NCT04302025 | Map |
| CA | University of Southern California-Keck School of Medicine -1975 Zonal Ave | Los Angeles90089-5601 | NCT06096779 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05333458 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05968326 | Map |
| CA | USC/Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06444815 | Map |
| CA | Fremont - Rideout Cancer Center | Marysville95901 | NCT06632327 | Map |
| CA | Mercy Cancer Center | Merced95340 | NCT06632327 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT01810913 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT05058651 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT05058651 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT07166406 | Map |
| CA | Hoag Memorial Hospital Presbyterian | Newport Beach92663 | NCT06362252 | Map |
| CA | University of Southern California | Newport Beach92663 | NCT06096779 | Map |
| CA | USC Norris Cancer Center | Newport Beach92663 | NCT05968326 | Map |
| CA | Kaiser Permanente - Oakland Medical Center | Oakland94611 | NCT02693535 | Map |
| CA | Kaiser Permanente-Ontario | Ontario91761 | NCT05058651 | Map |
| CA | The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange | Orange92868 | NCT04302025 | Map |
| CA | UC Irvine /ID# 255673 | Orange92868 | NCT06109272 | Map |
| CA | UC Irvine Health | Orange92868 | NCT06444815 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT07166406 | Map |
| CA | UC Irvine Medical Center | Orange92868 | NCT04524871 | Map |
| CA | University of California Irvine Medical Center | Orange92868 | NCT05440708 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT07166406 | Map |
| CA | Research Site | Palo Alto94304 | NCT06921785 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT01810913 | Map |
| CA | Sutter Palo Alto Medical Foundation: Palo Alto | Palo Alto94301 | NCT02693535 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT05058651 | Map |
| CA | California Liver Research Institute | Pasadena91105-2561 | NCT06096779 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT05058651 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT05058651 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT06632327 | Map |
| CA | Kaiser Permanente - Roseville Medical Center | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT01810913 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT05058651 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT07166406 | Map |
| CA | Sutter Roseville | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT05058651 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT07166406 | Map |
| CA | Kaiser Permanente - Sacramento Medical Center | Sacramento95814 | NCT02693535 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT05058651 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT06632327 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT01810913 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT05058651 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT07166406 | Map |
| CA | Sutter Sacramento | Sacramento95816 | NCT02693535 | Map |
| CA | UC Davis Comprehensive Cancer Center | Sacramento95817 | NCT04302025 | Map |
| CA | University of California Davis | Sacramento95817 | NCT04812366 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06287775 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06632327 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT07166406 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT05058651 | Map |
| CA | University of California San Diego Medical Center | San Diego92103 | NCT04524871 | Map |
| CA | California Pacific Medical Center Research Institute | San Francisco94115 | NCT02693535 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT05058651 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT07166406 | Map |
| CA | Kaiser Permanente - San Francisco Medical Center | San Francisco94115 | NCT02693535 | Map |
| CA | Kaiser Permanente - South San Francisco Medical Center | San Francisco94080 | NCT02693535 | Map |
| CA | Stanford University | San Francisco94305 | NCT05581004 | Map |
| CA | Sutter Cancer Research Consortium | San Francisco94115 | NCT02693535 | Map |
| CA | University of California San Francisco | San Francisco94115 | NCT04434040 | Map |
| CA | University of California San Francisco Cancer Center | San Francisco94115 | NCT04524871 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT03821246 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT06069726 | Map |
| CA | University of California, San Francisco (UCSF) | San Francisco94143 | NCT04802759 | Map |
| CA | University of California, San Francisco (UCSF) | San Francisco94158-2350 | NCT05968326 | Map |
| CA | University of San Francisco, California | San Francisco94143 | NCT03708224 | Map |
| CA | Kaiser Permanente - San Jose Medical Center | San Jose95119 | NCT02693535 | Map |
| CA | Kaiser Permanente - San Leandro Medical Center | San Leandro94577 | NCT02693535 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT06632327 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT05058651 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT01810913 | Map |
| CA | Sutter Sansum Clinic | Santa Barbara93105 | NCT02693535 | Map |
| CA | Kaiser Permanente - Santa Clara Medical Center | Santa Clara95051 | NCT02693535 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT05058651 | Map |
| CA | Sutter Palo Alto Medical Foundation: Fremont | Santa Cruz994538 | NCT02693535 | Map |
| CA | Sutter Palo Alto Medical Foundation: Santa Cruz | Santa Cruz95065 | NCT02693535 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT06632327 | Map |
| CA | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Santa Monica90404 | NCT04802759 | Map |
| CA | UCLA Center for East | Santa Monica90404 | NCT04524871 | Map |
| CA | University of California Los Angeles | Santa Monica90404 | NCT05968326 | Map |
| CA | University of California Los Angeles | Santa Monica90404 | NCT07195695 | Map |
| CA | Providence Medical Foundation ( Site 0124) | Santa Rosa95403 | NCT07227597 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT05058651 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT07166406 | Map |
| CA | GSK Investigational Site | Stanford94063 | NCT06551142 | Map |
| CA | Stanford Cancer Institute (SCI) | Stanford94305 | NCT04802759 | Map |
| CA | Stanford Health Care | Stanford94305 | NCT06096779 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT06632327 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT05058651 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT07166406 | Map |
| CA | Sutter Palo Alto Medical Foundation: Sunnyvale | Sunnyvale94086 | NCT02693535 | Map |
| CA | Harbor UCLA Medical Center | Torrance90502-2006 | NCT06096779 | Map |
| CA | Kaiser Permanente - Vallejo Medical Center | Vallejo94589 | NCT02693535 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT05058651 | Map |
| CA | Kaiser Permanente - Walnut Creek Medical Center | Walnut Creek94596 | NCT02693535 | Map |
| CA | Cedars Sinai Comprehensive Transplant Center | West Hollywood90048-2422 | NCT06096779 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT05058651 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT06632327 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT05058651 | Map |
| CO | Cherry Creek Medical Center | Aurora80045 | NCT04524871 | Map |
| CO | University Of Colorado | Aurora80045 | NCT05581004 | Map |
| CO | University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora80045 | NCT04524871 | Map |
| CO | University of Colorado Hospital - Anschutz Medical Campus | Aurora80045 | NCT05440708 | Map |
| CO | University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP) | Aurora80045 | NCT07235293 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT01810913 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT06632327 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT06632327 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT06632327 | Map |
| CO | AdventHealth Porter | Denver80210 | NCT01810913 | Map |
| CO | AdventHealth Porter | Denver80210 | NCT05058651 | Map |
| CO | GSK Investigational Site | Denver80218 | NCT06551142 | Map |
| CO | Rocky Mountain Cancer Centers (Williams) - USOR | Denver80218-1237 | NCT06096779 | Map |
| CO | Sarah Cannon Research Institute at HealthONE | Denver80218 | NCT05652686 | Map |
| CO | CommonSpirit Cancer Center Mercy | Durango81301 | NCT06632327 | Map |
| CO | Mercy Medical Center | Durango81301 | NCT06632327 | Map |
| CO | Shaw Cancer Center | Edwards81632 | NCT01810913 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT07166406 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT07166406 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT07166406 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT07166406 | Map |
| CO | UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital | Highlands Ranch80129-6694 | NCT04524871 | Map |
| CO | University of Colorado Cancer Center - Highlands Ranch Hospital | Highlands Ranch80129 | NCT07235293 | Map |
| CO | CommonSpirit Saint Anthony Hospital Cancer Center | Lakewood80228 | NCT06632327 | Map |
| CO | AdventHealth Littleton | Littleton80122 | NCT05058651 | Map |
| CO | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #003 | Lone Tree80124 | NCT05434234 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Lone Tree80124 | NCT04929223 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Lone Tree80124 | NCT05703971 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT01810913 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT06632327 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT07166406 | Map |
| CO | AdventHealth Parker | Parker80138 | NCT01810913 | Map |
| CO | AdventHealth Parker | Parker80138 | NCT05058651 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT06632327 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT06632327 | Map |
| CT | Saint Vincent's Medical Center (SVMC) | Bridgeport06606 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Hamden Care Center | Hamden06518 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital-Hamden Care Center | Hamden06518 | NCT07166406 | Map |
| CT | Hartford Healthcare Cancer Institute at Hartford Hospital | Hartford06106 | NCT06096779 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05333458 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT07166406 | Map |
| CT | St. Francis Hospital and Medical Center | Hartford06105 | NCT05968326 | Map |
| CT | Midstate Medical Center (MSMC) | Meriden06451 | NCT02693535 | Map |
| CT | The Hospital of Central Connecticut (HOCC) Cancer Center | New Britain06053 | NCT02693535 | Map |
| CT | GSK Investigational Site | New Haven06511 | NCT06551142 | Map |
| CT | Research Site | New Haven06520 | NCT06921785 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital at Yale New Haven | New Haven06510 | NCT04524871 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT04929223 | Map |
| CT | Yale Cancer Center | New Haven06511 | NCT04302025 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT05968326 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT06031441 | Map |
| CT | Yale University | New Haven06520 | NCT05333458 | Map |
| CT | Yale University | New Haven06520 | NCT04402788 | Map |
| CT | Yale University | New Haven06520 | NCT01810913 | Map |
| CT | Yale University | New Haven06520 | NCT05058651 | Map |
| CT | Yale University | New Haven06520 | NCT06287775 | Map |
| CT | Yale University | New Haven06510 | NCT07113691 | Map |
| CT | Yale University | New Haven06520 | NCT07166406 | Map |
| CT | Yale University School of Medicine /ID# 278181 | New Haven06510 | NCT07155174 | Map |
| CT | Zai Lab Site 2030 | New Haven06519 | NCT06179069 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT04402788 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT05058651 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT06287775 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT07166406 | Map |
| CT | William W. Backus Hospital | Norwich06360 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT07166406 | Map |
| CT | Charlotte Hungerford | Torrington06790 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center at Trumbull | Trumbull06611 | NCT05968326 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05333458 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT06287775 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT07166406 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT04402788 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT01810913 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT05058651 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT07166406 | Map |
| CT | Windham Hospital (WH) | Willimantic06226 | NCT02693535 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT06632327 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT04402788 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT06632327 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT06632327 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT04402788 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06632327 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT04402788 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06632327 | Map |
| DE | Research Site | Newark19713 | NCT06921785 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT04402788 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT06632327 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT06632327 | Map |
| DC | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #004 | Washington D.C.20007 | NCT05434234 | Map |
| DC | George Washington University Medical Center | Washington D.C.20037 | NCT01810913 | Map |
| DC | Georgetown Lombardi Comprehensive Cancer Center | Washington D.C.20007 | NCT05482516 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT04524871 | Map |
| DC | Johns Hopkins University: Sibley Memorial Hospital | Washington D.C.20016 | NCT05312671 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT05333458 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06287775 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06632327 | Map |
| DC | MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) | Washington D.C.20007 | NCT04302025 | Map |
| DC | Medstar Washington Hospital Center | Washington D.C.20010 | NCT05482516 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT06632327 | Map |
| DC | Washington DC VA Medical Center | Washington D.C.20422-0001 | NCT06096779 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Aventura | Aventura33180 | NCT02693535 | Map |
| FL | Clermont Oncology Center | Clermont34711 | NCT06463665 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04402788 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Lennar | Coral Gables33146 | NCT02693535 | Map |
| FL | BRCR Coral Springs | Coral Springs33065 | NCT07226999 | Map |
| FL | Oncology & Hematology Associates of West Broward | Coral Springs33065 | NCT06463665 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04402788 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Deerfield Beach | Deerfield Beach33442 | NCT02693535 | Map |
| FL | Mayo Clinic | Florida City32224 | NCT07235293 | Map |
| FL | Helios Clinical Research | Fort Lauderdale33316 | NCT06463665 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT02693535 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT01810913 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT05058651 | Map |
| FL | Florida Cancer Specialists - South | Fort Myers33901 | NCT06646276 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06287775 | Map |
| FL | University of Florida | Gainesville32608 | NCT05000294 | Map |
| FL | University of Florida Health | Gainesville32610 | NCT02693535 | Map |
| FL | Bioresearch Partner | Hialeah33013 | NCT06463665 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05058651 | Map |
| FL | Mayo Clinic-Jacksonville | Jacksonville32224 | NCT06362252 | Map |
| FL | Research Site | Jacksonville32224 | NCT06921785 | Map |
| FL | Orlando Health Cancer Institute - Lake Mary | Lake Mary32746 | NCT06632327 | Map |
| FL | Bioresearch Partner | Miami33155 | NCT06463665 | Map |
| FL | Miami Cancer Institute at Baptist Health | Miami33176 | NCT05317858 | Map |
| FL | Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics) | Miami33136 | NCT05733598 | Map |
| FL | University of Miami | Miami33136 | NCT06444815 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Center | Miami33136 | NCT06463665 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04402788 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Alex's Place | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Kendall | Miami33176 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Sole Mia | Miami33181 | NCT02693535 | Map |
| FL | Ocala Oncology Center /ID# 278269 | Ocala34474 | NCT07155174 | Map |
| FL | Health Central | Ocoee34761 | NCT06632327 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT06463665 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT06646276 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT07195695 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT07226999 | Map |
| FL | Advent Health Orlando | Orlando32804 | NCT06362252 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT01810913 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT06632327 | Map |
| FL | Orlando Health Cancer Institute ( Site 0108) | Orlando32806 | NCT07227597 | Map |
| FL | Orlando Health Inc. | Orlando32806 | NCT06096779 | Map |
| FL | Cancer Care Centers of Brevard, Inc | Palm Bay32901 | NCT06712355 | Map |
| FL | BRCR Medical Center, Inc. | Plantation33322 | NCT06463665 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Plantation | Plantation33324 | NCT02693535 | Map |
| FL | Moffitt Cancer Center at SouthShore | Ruskin33570 | NCT01810913 | Map |
| FL | Florida Cancer Specialists - Sarasota | Sarasota34232 | NCT05581004 | Map |
| FL | Zai Lab Site 2026 | Sarasota34232 | NCT06179069 | Map |
| FL | Florida Cancer Specialists - North | St. Petersburg33705 | NCT06646276 | Map |
| FL | BRCR Global - Tamarac | Tamarac33321 | NCT07226999 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05317858 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05440708 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT04302025 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05733598 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT01810913 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05058651 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06362252 | Map |
| FL | Moffitt Cancer Center /ID# 277573 | Tampa33612 | NCT07155174 | Map |
| FL | Moffitt Cancer Center-International Plaza | Tampa33607 | NCT01810913 | Map |
| GA | Cancer Treatment Centers of America - Atlanta | Atlanta30265 | NCT02693535 | Map |
| GA | Chilldren's Healthcare of Atlanta | Atlanta30322 | NCT06492954 | Map |
| GA | Emory Proton Therapy Center | Atlanta30308 | NCT07166406 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT04981509 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT04402788 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06287775 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT07166406 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT04981509 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT04402788 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT01810913 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06287775 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06731270 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT07166406 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT04981509 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT04402788 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT01810913 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06287775 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06731270 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07166406 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322 | NCT02693535 | Map |
| GA | Grady Health System | Atlanta30303 | NCT04402788 | Map |
| GA | Grady Health System | Atlanta30303 | NCT07166406 | Map |
| GA | Piedmont Cancer Institute | Atlanta30318 | NCT07195695 | Map |
| GA | Research Site | Atlanta30318 | NCT06921785 | Map |
| GA | Winship Cancer Institute at Emory University | Atlanta30322 | NCT06043674 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT01810913 | Map |
| GA | Northwest Georgia Oncology Centers | Marietta30060 | NCT07195695 | Map |
| GA | Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta30060 | NCT06646276 | Map |
| GA | CTCA at Southeastern Regional Medical Center | Newnan30265 | NCT04402788 | Map |
| GA | CTCA at Southeastern Regional Medical Center | Newnan30265 | NCT06632327 | Map |
| GA | Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute | Savannah31405 | NCT02693535 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT01810913 | Map |
| GA | Summit Cancer Care | Savannah31405 | NCT02693535 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05058651 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT02693535 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT05058651 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05058651 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT05058651 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT05058651 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT05058651 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05058651 | Map |
| HI | The Queen's Medical Center - Kuakini | Honolulu96817 | NCT02693535 | Map |
| HI | The Queen's Medical Center - POB I | Honolulu96813 | NCT02693535 | Map |
| HI | The Queen's Medical Center - Punchbowl | Honolulu96813 | NCT02693535 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04402788 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04402788 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06632327 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04402788 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT01810913 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05058651 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06632327 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06632327 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT06632327 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT04929223 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05058651 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06632327 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT06632327 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT06632327 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT06632327 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT06632327 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT06632327 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05058651 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT06632327 | Map |
| IL | Alliance for Clinical Trials in Oncology | Chicago60606 | NCT05001880 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago60611 | NCT04796012 | Map |
| IL | Cancer Treatment Centers of America-Chicago | Chicago60099 | NCT02693535 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT01810913 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT06632327 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT05968326 | Map |
| IL | Northwestern University | Chicago60611 | NCT04981509 | Map |
| IL | Northwestern University | Chicago60611 | NCT04302025 | Map |
| IL | Northwestern University | Chicago60611 | NCT05620771 | Map |
| IL | Northwestern University | Chicago60611 | NCT05058651 | Map |
| IL | Northwestern University | Chicago60611-2908 | NCT06096779 | Map |
| IL | Northwestern University | Chicago60611 | NCT06632327 | Map |
| IL | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago60611 | NCT06362252 | Map |
| IL | The Duchossois Center for Advanced Medicine | Chicago60637-1426 | NCT06096779 | Map |
| IL | The University of Chicago Medical Center /ID# 255674 | Chicago60637-1443 | NCT06109272 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05001880 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05058651 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06287775 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT07166406 | Map |
| IL | University of Illinois | Chicago60612 | NCT04402788 | Map |
| IL | University of Illinois | Chicago60612 | NCT06632327 | Map |
| IL | University of Illinois Cancer Center | Chicago60612 | NCT04919382 | Map |
| IL | University of Illinois Health Outpatient Care Center | Chicago60612-4795 | NCT06096779 | Map |
| IL | University of Illinois Hospital and Health Sciences System | Chicago60612 | NCT07195695 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05001880 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04402788 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06632327 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05058651 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06632327 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04402788 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT01810913 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05058651 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06632327 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT04302025 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05058651 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06632327 | Map |
| IL | Northwestern Medicine Kishwaukee Hospital | DeKalb60115 | NCT05620771 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT06632327 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05001880 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04402788 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06632327 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04402788 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT01810913 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05058651 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06632327 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT04402788 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT06632327 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT01810913 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT06632327 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT04302025 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05058651 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06632327 | Map |
| IL | Northwestern Medicine Delnor Hospital | Geneva60134 | NCT05620771 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT01810913 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05058651 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06632327 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05620771 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05058651 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06632327 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05058651 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT01810913 | Map |
| IL | Edward Hines Jr VA Hospital | Hines60141 | NCT06632327 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT06632327 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05620771 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05058651 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06632327 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT06632327 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05001880 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04402788 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06632327 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT06632327 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT04402788 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05058651 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT06287775 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT07166406 | Map |
| IL | Illinois Cancer Specialists | Niles60714 | NCT06712355 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT05058651 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05058651 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05058651 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06632327 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT04402788 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT01810913 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT06632327 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT06632327 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05620771 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05058651 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT06632327 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05058651 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT06287775 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT07166406 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT06632327 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT06632327 | Map |
| IL | Illinois Cancer Care | Peoria61615 | NCT06646276 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT06632327 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT06632327 | Map |
| IL | OSF Saint Francis Medical Center | Peoria61637 | NCT01810913 | Map |
| IL | OSF Saint Francis Radiation Oncology at Peoria Cancer Center | Peoria61615 | NCT01810913 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT06632327 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT06632327 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT04402788 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT06632327 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT04402788 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT01810913 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05058651 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT06632327 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT06632327 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT07166406 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05058651 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06632327 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05058651 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06632327 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04402788 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT01810913 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05058651 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06632327 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05001880 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04402788 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT01810913 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06632327 | Map |
| IL | Carle Cancer Center NCI Community Oncology Research Program | Urbana61801 | NCT05168163 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT05001880 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT04302025 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05058651 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06632327 | Map |
| IL | Northwestern Medicine Warrenville | Warrenville60555 | NCT05620771 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT06632327 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05058651 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT06632327 | Map |
| IL | Midwestern Regional Medical Center | Zion60099 | NCT06632327 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05058651 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT06287775 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT07166406 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 277336 | Fort Wayne46804 | NCT07155174 | Map |
| IN | Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne46804 | NCT06712355 | Map |
| IN | GSK Investigational Site | Fort Wayne46804 | NCT06551142 | Map |
| IN | Goshen Center for Cancer Care | Goshen46526 | NCT06632327 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT04402788 | Map |
| IN | Community Health Network | Indianapolis46250 | NCT06444815 | Map |
| IN | Community Health Network (The University of Texas MD Anderson Cancer Center) | Indianapolis46250 | NCT02693535 | Map |
| IN | Indiana University Health Melvin & Bren Simon Cancer Center | Indianapolis46202 | NCT05968326 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT04919382 | Map |
| IN | Baptist Health Floyd | New Albany47150 | NCT04402788 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05058651 | Map |
| IA | McFarland Clinic | Ames50010 | NCT06712355 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04402788 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT07166406 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT05058651 | Map |
| IA | Helen G. Nassif Community Cancer Center | Cedar Rapids52403 | NCT06712355 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06632327 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06632327 | Map |
| IA | Physicians' Clinic of Iowa PC | Cedar Rapids52402 | NCT04402788 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT04402788 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT05058651 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04402788 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT07166406 | Map |
| IA | Heartland Oncology and Hematology LLP | Council Bluffs51503 | NCT04402788 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT04402788 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT05058651 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT07166406 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04402788 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT05058651 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04402788 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05058651 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT07166406 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04402788 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05058651 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04402788 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT07166406 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04402788 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT07166406 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05058651 | Map |
| IA | University of Iowa Hospitals and Clinics | Iowa City52242 | NCT04919382 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04402788 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05058651 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT07166406 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT04402788 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT05058651 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT07166406 | Map |
| IA | The Iowa Clinic PC | West Des Moines50266 | NCT07166406 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT06287775 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT06632327 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT06632327 | Map |
| KS | HaysMed | Hays67601 | NCT06632327 | Map |
| KS | The University of Kansas Cancer Center, Westwood Campus | Kansas City66205 | NCT04467723 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT01810913 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06287775 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT01810913 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT06632327 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT01810913 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT06632327 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT01810913 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT06287775 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT06632327 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT01810913 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT06632327 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT06632327 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06287775 | Map |
| KS | Ascension Via Christi Hospitals Wichita | Wichita67214 | NCT04402788 | Map |
| KY | King's Daughter's Medical Center | Ashland41101 | NCT06632327 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT06632327 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT06632327 | Map |
| KY | Saint Elizabeth Medical Center Edgewood ( Site 0112) | Edgewood41017 | NCT07227597 | Map |
| KY | Baptist Health Hardin Cancer Center | Elizabethtown42701 | NCT06712355 | Map |
| KY | Baptist Health Lexington /ID# 277729 | Lexington40503 | NCT07155174 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT06632327 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT04402788 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT06632327 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT06632327 | Map |
| KY | University of Kentucky - Markey Cancer Center | Lexington40536-7001 | NCT04524871 | Map |
| KY | University of Kentucky - Markey Cancer Center | Lexington40536-7001 | NCT06096779 | Map |
| KY | University of Kentucky Medical Center | Lexington40536 | NCT05968326 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT06287775 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT07166406 | Map |
| KY | Saint Joseph London | London40741 | NCT06632327 | Map |
| KY | Baptist Health Louisville | Louisville40207 | NCT04402788 | Map |
| KY | Norton Cancer Institute /ID# 260775 | Louisville40217-1395 | NCT06109272 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT04402788 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT01810913 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT04402788 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT01810913 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT06632327 | Map |
| KY | Owensboro Health Mitchell Memorial Cancer Center | Owensboro42303 | NCT06632327 | Map |
| LA | LSU Health Baton Rouge | Baton Rouge70805 | NCT06096779 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT01810913 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT05058651 | Map |
| LA | Mary Bird Perkins Cancer Ctr | Baton Rouge70809 | NCT04929223 | Map |
| LA | Our Lady of the Lake Cancer Institute | Baton Rouge70808-4300 | NCT06096779 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT01810913 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT05058651 | Map |
| LA | East Jefferson General Hospital | Metairie70006 | NCT05058651 | Map |
| LA | LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie70006 | NCT05058651 | Map |
| LA | Touro Infirmary | New Orleans70115 | NCT01810913 | Map |
| LA | Tulane University School of Medicine | New Orleans70112 | NCT06632327 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT01810913 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT05058651 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT05168163 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT06632327 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT02693535 | Map |
| ME | Jackson Laboratory - Maine Cancer Genomics Initiative | Augusta04330 | NCT02693535 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT06632327 | Map |
| ME | MaineHealth Coastal Cancer Treatment Center | Bath04530 | NCT04402788 | Map |
| ME | Waldo County General Hospital | Belfast04915 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Biddeford | Biddeford04005 | NCT02693535 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT06632327 | Map |
| ME | Northern Light Cancer Care | Brewer04412 | NCT02693535 | Map |
| ME | Raish Peavey Haskell Children's Cancer and Treatment Center | Brewer04412 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -Brunswick | Brunswick04011 | NCT02693535 | Map |
| ME | New England Cancer Specialist | Kennebunk04043 | NCT02693535 | Map |
| ME | York Hopsital Oncology & Infusion Care in Kittery | Kittery03904 | NCT02693535 | Map |
| ME | Stephens Memorial Hospital | Norway04268 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT04402788 | Map |
| ME | Penobscot Bay Medical Center | Rockport04856 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care Center of York County | Sanford04073 | NCT04402788 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Sandford | Sanford04073 | NCT02693535 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT02693535 | Map |
| ME | Maine Medical Partner's Women's Health | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT04402788 | Map |
| ME | New England Cancer Specialist | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -South Portland | South Portland04106 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT04402788 | Map |
| ME | New England Cancer Specialist | Topsham04086 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in Wells | Wells04090 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in York | York Village03909 | NCT02693535 | Map |
| MD | Greater Baltimore Medical Center | Baltimore21204 | NCT01810913 | Map |
| MD | Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center | Baltimore21287 | NCT05312671 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT01810913 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06287775 | Map |
| MD | MedStar Franklin Square Medical Center/Weinberg Cancer Institute | Baltimore21237 | NCT06632327 | Map |
| MD | MedStar Good Samaritan Hospital | Baltimore21239 | NCT06632327 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore21287 | NCT05652686 | Map |
| MD | The Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT05440708 | Map |
| MD | University of Maryland | Baltimore21201 | NCT05317858 | Map |
| MD | University of Maryland Medical Center | Baltimore21201 | NCT05733598 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT01810913 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT06287775 | Map |
| MD | UM Upper Chesapeake Medical Center | Bel Air21014 | NCT01810913 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT05333458 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06066138 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06161532 | Map |
| MD | NCI - Center for Cancer Research | Bethesda20892 | NCT04981509 | Map |
| MD | Central Maryland Radiation Oncology in Howard County | Columbia21044 | NCT01810913 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT06632327 | Map |
| MD | Frederick Health Hospital- James M Stockman Cancer Institute | Frederick21704 | NCT06712355 | Map |
| MD | UM Baltimore Washington Medical Center/Tate Cancer Center | Glen Burnie21061 | NCT01810913 | Map |
| MA | Beverly Hospital | Beverly01915 | NCT06632327 | Map |
| MA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #005 | Boston02114 | NCT05434234 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06096779 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT04796012 | Map |
| MA | Boston Medical Center | Boston02118 | NCT04402788 | Map |
| MA | Boston Medical Center | Boston02118 | NCT01810913 | Map |
| MA | Boston Medical Center (BMC) - Cancer Care Center | Boston02118 | NCT05968326 | Map |
| MA | Brigham & Women's Hospital | Boston02115 | NCT04812366 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT06043674 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05581004 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06043674 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04302025 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04434040 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05652686 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05019703 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05096715 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07195695 | Map |
| MA | Dana-Farber Cancer Institute /ID# 277732 | Boston02215 | NCT07155174 | Map |
| MA | GSK Investigational Site | Boston02114 | NCT06551142 | Map |
| MA | Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center | Boston02114-2621 | NCT05968326 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT04802759 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05652686 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05096715 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06096779 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT06632327 | Map |
| MA | Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center | Burlington01805 | NCT06712355 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT05058651 | Map |
| MA | Lahey Hospital and Medical Center | Burlington01805 | NCT06632327 | Map |
| MA | Addison Gilbert Hospital | Gloucester01930 | NCT06632327 | Map |
| MA | Lowell General Hospital | Lowell01854 | NCT04402788 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT05058651 | Map |
| MA | Lahey Medical Center-Peabody | Peabody01960 | NCT06632327 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT06632327 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT04402788 | Map |
| MI | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #006 | Ann Arbor48109 | NCT05434234 | Map |
| MI | Michigan Cancer Research Consortium NCORP | Ann Arbor48106 | NCT05168163 | Map |
| MI | Trinity Health Ann Arbor Hospital | Ann Arbor48106 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT01810913 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05058651 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT04302025 | Map |
| MI | University of Michigan Health | Ann Arbor48109-5946 | NCT04812366 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05440708 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05058651 | Map |
| MI | Veterans Affairs Ann Arbor Healthcare System | Ann Arbor48105 | NCT06096779 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05058651 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04402788 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05058651 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04402788 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT01810913 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05058651 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT01810913 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT05058651 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT07166406 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04402788 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05058651 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04402788 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05058651 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04402788 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05058651 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04402788 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05058651 | Map |
| MI | McLaren Cancer Institute-Clarkston | Clarkston48346 | NCT04402788 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT01810913 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT05058651 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05058651 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT01810913 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT05058651 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT07166406 | Map |
| MI | Michigan Hematology and Oncology Consultants | Dearborn48126 | NCT06463665 | Map |
| MI | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #007 | Detroit48292 | NCT05434234 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT05440708 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT06096779 | Map |
| MI | GSK Investigational Site | Detroit48201 | NCT06551142 | Map |
| MI | Henry Ford Cancer- Detroit | Detroit48202 | NCT07339059 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT02693535 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT05058651 | Map |
| MI | Henry Ford Health System | Detroit48202-2610 | NCT05968326 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06096779 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05581004 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT01810913 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT05058651 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT07166406 | Map |
| MI | Henry Ford Hospital /ID# 255803 | Detroit48202 | NCT06109272 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT04402788 | Map |
| MI | Zai Lab Site 2013 | Detroit48201 | NCT06179069 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06632327 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05058651 | Map |
| MI | Oakland Medical Group | Farmington Hills48336 | NCT06463665 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT04402788 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05058651 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT02693535 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04402788 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05058651 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04402788 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05058651 | Map |
| MI | McLaren Cancer Institute-Flint | Flint48532 | NCT04402788 | Map |
| MI | Cancer Research Consortium of West Michigan | Grand Rapids49503 | NCT02693535 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT01810913 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05058651 | Map |
| MI | Research Site | Grand Rapids49503 | NCT06921785 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05058651 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT05058651 | Map |
| MI | Allegiance Health | Jackson49201 | NCT01810913 | Map |
| MI | Allegiance Health | Jackson49201 | NCT05058651 | Map |
| MI | Allegiance Health | Jackson49201 | NCT07166406 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04402788 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05058651 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT04402788 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT01810913 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05058651 | Map |
| MI | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing48910 | NCT04402788 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT02693535 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04402788 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT01810913 | Map |
| MI | McLaren Cancer Institute-Lapeer Region | Lapeer48446 | NCT04402788 | Map |
| MI | Trinity Health Livonia Hospital | Livonia48154 | NCT02693535 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04402788 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT01810913 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05058651 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05058651 | Map |
| MI | McLaren Cancer Institute-Macomb | Mount Clemens48043 | NCT04402788 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05058651 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05058651 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05058651 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT04402788 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT01810913 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT05058651 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT07166406 | Map |
| MI | McLaren Cancer Institute-Northern Michigan | Petoskey49770 | NCT04402788 | Map |
| MI | Trinity Health Oakland Hospital | Pontiac48341 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05058651 | Map |
| MI | McLaren-Port Huron | Port Huron48060 | NCT04402788 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05058651 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT04402788 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05058651 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT02693535 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04402788 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT01810913 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05058651 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT05058651 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT04402788 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04402788 | Map |
| MI | Michigan Cancer Research Consortium | Traverse City48341 | NCT02693535 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05058651 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT04402788 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05058651 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT02693535 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT05058651 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT05058651 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT01810913 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT05058651 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT07166406 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT01810913 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT05058651 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT07166406 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT01810913 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05058651 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05058651 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05058651 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05001880 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT04402788 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT01810913 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT06632327 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT07166406 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT01810913 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT05058651 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT06632327 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT06632327 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05001880 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04402788 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06632327 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT06632327 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT07166406 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT07166406 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT07166406 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT01810913 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT07166406 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05001880 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05058651 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06632327 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT06632327 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT07166406 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT06632327 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT06632327 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04402788 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT06632327 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05001880 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04402788 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05058651 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06632327 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT06632327 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT01810913 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05058651 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT06632327 | Map |
| MN | Regents of the University of Minnesota | Minneapolis55455 | NCT06362252 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT06632327 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT06632327 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT06632327 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT01810913 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT06632327 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT04302025 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06362252 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05001880 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT03942328 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT01810913 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05058651 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05168163 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06632327 | Map |
| MN | Mayo Clinic Rochester | Rochester55902 | NCT04929223 | Map |
| MN | Research Site | Rochester55905 | NCT06921785 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT04402788 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT01810913 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT06632327 | Map |
| MN | Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041 | Saint Louis Park55416 | NCT06109272 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05001880 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04402788 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05058651 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06632327 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05001880 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04402788 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05058651 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06632327 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05001880 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05058651 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06632327 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT07166406 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05058651 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT06632327 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT06632327 | Map |
| MN | Sanford Thief River Falls Medical Center | Thief River Falls56701 | NCT06632327 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT07166406 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT06632327 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT05001880 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT06632327 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT06632327 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT05001880 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT06632327 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06632327 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06632327 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06632327 | Map |
| MS | Baptist Cancer Center | Southaven38671 | NCT06712355 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT04402788 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06632327 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT06632327 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT06632327 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT06632327 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT06632327 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04402788 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT01810913 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05058651 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06632327 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT01810913 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06632327 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT07166406 | Map |
| MO | Ellis Fischel Cancer Center | Columbia65201 | NCT04302025 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT01810913 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06632327 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT07166406 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04402788 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT06632327 | Map |
| MO | Freeman Health System | Joplin64804 | NCT06632327 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT05058651 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT06632327 | Map |
| MO | Saint Luke?s Hospital of Kansas City | Kansas City64111 | NCT06096779 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT06632327 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT01810913 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT01810913 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT06632327 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT06632327 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT01810913 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT06632327 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT06632327 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04402788 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT06632327 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT01810913 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT05058651 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT06632327 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT01810913 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05058651 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT06632327 | Map |
| MO | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #008 | St Louis63110 | NCT05434234 | Map |
| MO | Alvin J. Siteman Cancer Center at Washington University | St Louis63110 | NCT03821246 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04402788 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT01810913 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06632327 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05058651 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT06632327 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT06632327 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04402788 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT01810913 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06632327 | Map |
| MO | Siteman Cancer Center - Washington University Medical Campus | St Louis63108 | NCT04302025 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06632327 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT07166406 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06632327 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT07166406 | Map |
| MO | Veteran's Affairs Medical Center - Saint Louis | St Louis63125 | NCT06632327 | Map |
| MO | Washington University in St. Louis | St Louis63129 | NCT05440708 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT01810913 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06632327 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06712355 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07166406 | Map |
| MO | Washington University School of Medicine - Siteman Cancer Center | St Louis63110 | NCT05703971 | Map |
| MO | Washington University School of Medicine ( Site 0134) | St Louis63110 | NCT07227597 | Map |
| MO | Washington University School of Medicine (Siteman Cancer Center) | St Louis63108 | NCT05652686 | Map |
| MO | Washington University-School of Medicine /ID# 255720 | St Louis63110 | NCT06109272 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04402788 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT06632327 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT04402788 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT06632327 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT06632327 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06632327 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06632327 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT05058651 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT04402788 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06632327 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT04402788 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06632327 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT06632327 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT06632327 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT06632327 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06632327 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06632327 | Map |
| NE | CHI Health Saint Francis | Grand Island68803 | NCT06632327 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT01810913 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT06632327 | Map |
| NE | Nebraska Hematology-Oncology (NHO) | Lincoln68506 | NCT06712355 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT01810913 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT06632327 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT06632327 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT06632327 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT06632327 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT04402788 | Map |
| NE | University of Nebraska | Omaha68198-5300 | NCT05968326 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT02693535 | Map |
| NV | Cancer Care Specialists | Reno89511 | NCT07195695 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT04402788 | Map |
| NH | NH Oncology - Hematology, PA | Concord03103 | NCT02693535 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT04302025 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04402788 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT01810913 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT05058651 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06632327 | Map |
| NH | Dartmouth-Hitchcock Medical Center | Lebanon03766 | NCT06362252 | Map |
| NH | Dartmouth Cancer Center - Manchester/ DCC Manchester | Manchester03104 | NCT06632327 | Map |
| NH | Solinsky Center for Cancer Care | Manchester03103 | NCT02693535 | Map |
| NH | Dartmouth Cancer Center - Nashua | Nashua03063 | NCT06632327 | Map |
| NH | New England Cancer Specialist | Portsmouth03801 | NCT02693535 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT01810913 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT06287775 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06807632 | Map |
| NJ | Memorial Sloan Kettering Cancer Center Basking Ridge | Basking Ridge07920 | NCT05968326 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT06632327 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT06362252 | Map |
| NJ | Englewood Hospital and Medical Center | Englewood07631 | NCT04402788 | Map |
| NJ | John Theurer Cancer Center At Hackensack Umc | Hackensack07601 | NCT06362252 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT05482516 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601-2191 | NCT07291076 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) | Hackensack07601 | NCT07227597 | Map |
| NJ | Zai Lab Site 2001 | Hackensack07601 | NCT06179069 | Map |
| NJ | The Cancer Institute of New Jersey Hamilton | Hamilton08690 | NCT01810913 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT01810913 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT01810913 | Map |
| NJ | Memorial Sloan Kettering Cancer Center | Middletown07748 | NCT05968326 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT01810913 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06287775 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06807632 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT01810913 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06287775 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06807632 | Map |
| NJ | Memorial Sloan Kettering Cancer Center at Bergen | Montvale07645 | NCT05968326 | Map |
| NJ | MorristownMedicalCenter | Morristown07962 | NCT06096779 | Map |
| NJ | Cooper CyberKnife Center | Mount Laurel08054 | NCT06632327 | Map |
| NJ | Inspira Medical Center Mullica Hill | Mullica Hill08062 | NCT06463665 | Map |
| NJ | Jersey Shore Medical Center | Neptune City07753 | NCT06632327 | Map |
| NJ | GSK Investigational Site | New Brunswick08903 | NCT06551142 | Map |
| NJ | Research Site | New Brunswick08901 | NCT06921785 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT05581004 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT04981509 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT01810913 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06096779 | Map |
| NJ | Rutgers Cancer Institute of New Jersey at University Hospital | Newark07103 | NCT06096779 | Map |
| NJ | Rutgers New Jersey Medical School | Newark07101 | NCT01810913 | Map |
| NJ | The Valley Hospital - Luckow Pavilion | Paramus07652 | NCT06632327 | Map |
| NJ | Capital Health Medical Center-Hopewell | Pennington08534 | NCT04402788 | Map |
| NJ | Valley Health System Ridgewood Campus | Ridgewood07450 | NCT06632327 | Map |
| NJ | Robert Wood Johnson University Hospital Somerset | Somerville08876 | NCT01810913 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT01810913 | Map |
| NJ | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township08043 | NCT06632327 | Map |
| NM | Lovelace Medical Center - Saint Joseph Square | Albuquerque87102 | NCT02693535 | Map |
| NM | New Mexico Oncology Hematology Consultants | Albuquerque87109 | NCT01810913 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT02693535 | Map |
| NM | The University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT02693535 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT01810913 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06632327 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT07166406 | Map |
| NM | University of New Mexico Comprehensive Cancer Center | Albuquerque87106 | NCT06646276 | Map |
| NM | Memorial Medical Center | Las Cruces88011 | NCT02693535 | Map |
| NM | Memorial Medical Center-Las Cruces | Las Cruces88011 | NCT06632327 | Map |
| NM | Presbyterian Rust Medical Center | Rio Rancho87124 | NCT02693535 | Map |
| NM | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #009 | Santa Fe87505-699 | NCT05434234 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT04696575 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05168163 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14236 | NCT05733598 | Map |
| NY | Zai Lab Site 2002 | Buffalo14263 | NCT06179069 | Map |
| NY | Hematology Oncology Associates of CNY at Camillus | Camillus13031 | NCT04402788 | Map |
| NY | Sands Cancer Center | Canandaigua14424 | NCT01810913 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Commack | Commack11725 | NCT05968326 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT01810913 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06287775 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06807632 | Map |
| NY | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse13057 | NCT04402788 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT06632327 | Map |
| NY | Memorial Sloan Kettering Cancer Center at Westchester | Harrison10604 | NCT05968326 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT01810913 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06287775 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06807632 | Map |
| NY | Northwell Health | Lake Success11042 | NCT05968326 | Map |
| NY | Northwell Health Monter Cancer Center | Lake Success11042 | NCT02693535 | Map |
| NY | New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone | Mineola11501 | NCT06362252 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT01810913 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501-4064 | NCT06096779 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06362252 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT02693535 | Map |
| NY | Cohen Children's Medical Center | New Hyde Park11040 | NCT02693535 | Map |
| NY | New York Cancer & Blood Specialists - New Hyde Park | New Hyde Park11042-1116 | NCT04929223 | Map |
| NY | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #010 | New York10029 | NCT05434234 | Map |
| NY | Columbia University Hervert Irving Comprehensive Cancer Center | New York10032 | NCT06362252 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT04302025 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT05968326 | Map |
| NY | Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center | New York10065 | NCT06712355 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06096779 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT07059494 | Map |
| NY | Icahn School of Medicine at Mount Sinai (ISMMS) | New York10029 | NCT06031441 | Map |
| NY | Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT07195695 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT01810913 | Map |
| NY | Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York10016 | NCT04302025 | Map |
| NY | Manhattan Eye, Ear, and Throat Hospital | New York10065 | NCT02693535 | Map |
| NY | MEETH-LHH Northwell Health Cancer Clinical Trials Office at MEETH-LHH | New York10065-7471 | NCT05968326 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04302025 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05968326 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT01810913 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06287775 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT06362252 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06807632 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York | New York10065 | NCT05440708 | Map |
| NY | Memorial Sloan-Kettering Cancer Center | New York10065 | NCT07195695 | Map |
| NY | Montefiore Medical Center | New York10461 | NCT06362252 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT04402788 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT07166406 | Map |
| NY | Mount SInai Medical Center | New York10029 | NCT05968326 | Map |
| NY | Mount Sinai Union Square | New York10003 | NCT01810913 | Map |
| NY | New York Cancer and Blood Specialists-Central Park Hematology & Oncology | New York10028 | NCT04929223 | Map |
| NY | NYU Langone Medical Center | New York10016-9451 | NCT06096779 | Map |
| NY | Research Site | New York10029 | NCT06921785 | Map |
| NY | Staten Island University Hospital | New York10305 | NCT02693535 | Map |
| NY | New York Cancer & Blood Specialists | Port Jefferson Station11776 | NCT04929223 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT02693535 | Map |
| NY | Highland Hospital | Rochester14620 | NCT01810913 | Map |
| NY | University of Rochester | Rochester14642 | NCT01810913 | Map |
| NY | University of Rochester | Rochester14642 | NCT06632327 | Map |
| NY | Wilmot Cancer Institute Radiation Oncology at Greece | Rochester14606 | NCT01810913 | Map |
| NY | Phelps Hospital | Sleepy Hollow10591 | NCT02693535 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT05423210 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT04402788 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT04402788 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT01810913 | Map |
| NY | James J Peters VA Medical Center | The Bronx10468 | NCT06632327 | Map |
| NY | James J Peters Veterans Administration Medical Center - NAVREF | The Bronx10468-3904 | NCT06096779 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT06096779 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT01810913 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT07166406 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT01810913 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT07166406 | Map |
| NY | Montefiore Medical CenterMontefiore Medical Park | The Bronx10461 | NCT05733598 | Map |
| NY | New York Cancer & Blood Specialists - Bronx | The Bronx10469-5930 | NCT04929223 | Map |
| NY | Memorial Sloan Kettering Cancer Center at Nassau | Uniondale11553 | NCT05968326 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT01810913 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT06287775 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06807632 | Map |
| NY | Westchester Medical Center | Valhalla10595 | NCT04402788 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT06632327 | Map |
| NY | White Plains Hospital | White Plains10601 | NCT06712355 | Map |
| NC | Atrium Health Stanly/LCI-Albemarle | Albemarle28002 | NCT04402788 | Map |
| NC | Atrium Health Stanly/LCI-Albemarle | Albemarle28002 | NCT01810913 | Map |
| NC | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #011 | Chapel Hill27514 | NCT05434234 | Map |
| NC | Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT02693535 | Map |
| NC | Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05542407 | Map |
| NC | The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06043674 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT01810913 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT05652686 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT04402788 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT01810913 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT05058651 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT04402788 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT01810913 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT05058651 | Map |
| NC | Atrium Health's Levine Cancer Institute | Charlotte28277 | NCT02693535 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04402788 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT01810913 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT05058651 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06287775 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT04802759 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06096779 | Map |
| NC | Levine Cancer Institute-Ballantyne | Charlotte28277 | NCT04402788 | Map |
| NC | Levine Cancer Institute-Ballantyne | Charlotte28277 | NCT05058651 | Map |
| NC | Levine Cancer Institute-SouthPark | Charlotte28211 | NCT04402788 | Map |
| NC | Levine Cancer Institute-SouthPark | Charlotte28211 | NCT05058651 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT05058651 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT04402788 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT01810913 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT05058651 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT06287775 | Map |
| NC | Duke Cancer Institute | Durham27710-4000 | NCT05968326 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT06646276 | Map |
| NC | Duke University | Durham27705 | NCT06069726 | Map |
| NC | Duke University Medical Center - Duke Cancer Center | Durham27710 | NCT07235293 | Map |
| NC | Zai Lab Site 2018 | Durham27710 | NCT06179069 | Map |
| NC | Levine Cancer Institute - Rutherford | Forest City28043 | NCT04402788 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT04402788 | Map |
| NC | Levine Cancer Institute-Gaston | Gastonia28054 | NCT05058651 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT05058651 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT04402788 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT05058651 | Map |
| NC | ECU Health Oncology Kinston | Kinston28501 | NCT01810913 | Map |
| NC | Atrium Health Lincoln/LCI-Lincolnton | Lincolnton28092 | NCT04402788 | Map |
| NC | Levine Cancer Institute - Union West | Matthews28104 | NCT04402788 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT04402788 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT01810913 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT05058651 | Map |
| NC | Atrium Health Cleveland/LCI-Cleveland | Shelby28150 | NCT04402788 | Map |
| NC | Atrium Health Cleveland/LCI-Cleveland | Shelby28150 | NCT05058651 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27103 | NCT05317858 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06287775 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05001880 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT04402788 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT01810913 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT06632327 | Map |
| ND | Sanford Health- Bismarck | Bismarck58501 | NCT02693535 | Map |
| ND | Sanford Medical Center | Bismarck58501 | NCT06646276 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05001880 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT04402788 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06632327 | Map |
| ND | Sanford Fargo Medical Center | Fargo58102 | NCT06646276 | Map |
| ND | Sanford Health- Fargo | Fargo58122 | NCT02693535 | Map |
| ND | Sanford Medical Center Fargo | Fargo58104 | NCT06632327 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05001880 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT04402788 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT01810913 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT06632327 | Map |
| ND | Sanford South University Medical Center | Fargo58103 | NCT06632327 | Map |
| ND | Southpointe-Sanford Medical Center Fargo | Fargo58103 | NCT06632327 | Map |
| OH | Cleveland Clinic - Akron General Hematology & Oncology | Akron44302 | NCT06712355 | Map |
| OH | UH Seidman Cancer Center at UH Avon Health Center | Avon44011 | NCT01810913 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT01810913 | Map |
| OH | Aultman Health Foundation | Canton44710 | NCT04402788 | Map |
| OH | Cleveland Clinic Mercy Hospital Cancer Center | Canton44708 | NCT06712355 | Map |
| OH | Gabrail Cancer and Research Center | Canton44718 | NCT06463665 | Map |
| OH | Gabrail Cancer Center Research | Canton44718 | NCT05703971 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT04402788 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT01810913 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT01810913 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT06632327 | Map |
| OH | Cincinnati Children's Hospital | Cincinnati45229 | NCT04796012 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT06632327 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT06646276 | Map |
| OH | Oncology_Hematology Care Clinical Trials, LLC | Cincinnati45211 | NCT05703971 | Map |
| OH | Oncology_Hematology Care Clinical Trials, LLC | Cincinnati45236 | NCT05703971 | Map |
| OH | Oncology_Hematology Care Clinical Trials, LLC | Cincinnati45242 | NCT05703971 | Map |
| OH | Oncology_Hematology Care Clinical Trials, LLC | Cincinnati45245 | NCT05703971 | Map |
| OH | The Christ Hospital Cancer Center | Cincinnati45219 | NCT06712355 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT06632327 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT06632327 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT04402788 | Map |
| OH | University of Cincinnati Cancer Institute | Cincinnati45219 | NCT05968326 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT02693535 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT01810913 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT06287775 | Map |
| OH | Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland44111 | NCT04402788 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT04402788 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT01810913 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195-0001 | NCT06712355 | Map |
| OH | Cleveland Clinic Lerner College of Medicine | Cleveland44195 | NCT05440708 | Map |
| OH | MetroHealth Medical Center | Cleveland44109 | NCT04402788 | Map |
| OH | The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion | Cleveland44111 | NCT06712355 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06712355 | Map |
| OH | University Hospitals Cleveland Medical Center /ID# 277556 | Cleveland44106 | NCT07155174 | Map |
| OH | Zai Lab Site 2024 | Cleveland44106 | NCT06179069 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT04402788 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT04402788 | Map |
| OH | Ohio State University | Columbus43210 | NCT04302025 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05333458 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04919382 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04981509 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05001880 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04402788 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT01810913 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05058651 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06287775 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06616623 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07166406 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT04402788 | Map |
| OH | The Ohio State University | Columbus43221-3502 | NCT06031441 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06043674 | Map |
| OH | Dayton VA Medical Center - NAVREF - PPDS | Dayton45428-9000 | NCT06096779 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT04402788 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT04402788 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT04402788 | Map |
| OH | Oncology_Hematology Care Clinical Trials, LLC | Fairfield45014 | NCT05703971 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT04402788 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT04402788 | Map |
| OH | Cleveland Clinic Cancer Center Independence | Independence44131 | NCT04402788 | Map |
| OH | Kettering Health | Kettering45429 | NCT02693535 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT06712355 | Map |
| OH | Cleveland Clinic Cancer Center Mansfield | Mansfield44906 | NCT04402788 | Map |
| OH | Cleveland Clinic - Hillcrest Hospital | Mayfield Heights44124 | NCT06712355 | Map |
| OH | Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT04402788 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT01810913 | Map |
| OH | UH Seidman Cancer Center at Southwest General Hospital | Middleburg Heights44130 | NCT01810913 | Map |
| OH | University Hospitals Parma Medical Center | Parma44129 | NCT01810913 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT01810913 | Map |
| OH | University Hospitals Portage Medical Center | Ravenna44266 | NCT01810913 | Map |
| OH | North Coast Cancer Care | Sandusky44870 | NCT04402788 | Map |
| OH | UH Seidman Cancer Center at Firelands Regional Medical Center | Sandusky44870 | NCT01810913 | Map |
| OH | Cleveland Clinic Cancer Center Strongsville | Strongsville44136 | NCT04402788 | Map |
| OH | Cleveland Clinic Cancer Center Strongsville | Strongsville44136 | NCT01810913 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT04402788 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT04402788 | Map |
| OH | West Chester Hospital | West Chester45069 | NCT02693535 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT04402788 | Map |
| OH | UHHS-Westlake Medical Center | Westlake44145 | NCT01810913 | Map |
| OH | Cleveland Clinic Wooster Family Health and Surgery Center | Wooster44691 | NCT04402788 | Map |
| OH | Cleveland Clinic Wooster Family Health and Surgery Center | Wooster44691 | NCT01810913 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT04402788 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT04402788 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT05058651 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT06632327 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04402788 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT05058651 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT06632327 | Map |
| OK | Sarah Cannon Research Institute University of Oklahoma | Oklahoma City73104 | NCT05652686 | Map |
| OK | The University of Oklahoma Health Sciences Center | Oklahoma City73104-5020 | NCT06096779 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05333458 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05440708 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05001880 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04402788 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT01810913 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05058651 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06632327 | Map |
| OK | University of Oklahoma Health Stephenson Cancer Center | Oklahoma City73104 | NCT04486352 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05058651 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT01810913 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT07166406 | Map |
| OR | Willamette Valley Cancer Institute (Oregon) | Eugene97401 | NCT05703971 | Map |
| OR | Legacy Mount Hood Medical Center | Gresham97030 | NCT04402788 | Map |
| OR | Legacy Mount Hood Medical Center | Gresham97030 | NCT06632327 | Map |
| OR | Kaiser Permanente Westside Medical Center | Hillsboro97124-5806 | NCT06096779 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04402788 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05058651 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT07166406 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05058651 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT07166406 | Map |
| OR | Legacy Good Samaritan Hospital and Medical Center | Portland97210 | NCT04402788 | Map |
| OR | Legacy Good Samaritan Hospital and Medical Center | Portland97210 | NCT06632327 | Map |
| OR | Northwest Cancer Specialists, P.C. | Portland97213-2982 | NCT05703971 | Map |
| OR | Northwest Cancer Specialists, P.C. | Portland97227 | NCT05703971 | Map |
| OR | OHSU Knight Cancer Institute Hematology Oncology | Portland97239-3011 | NCT06096779 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT05317858 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT04524871 | Map |
| OR | Providence Cancer Institute | Portland97213 | NCT05703971 | Map |
| OR | Providence Cancer Institute | Portland97213 | NCT07195695 | Map |
| OR | Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) | Portland97213 | NCT07227597 | Map |
| OR | Providence Health & Services | Portland97213 | NCT02693535 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04402788 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05652686 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT01810913 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05058651 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT07166406 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT07291076 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04402788 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT01810913 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05058651 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT07166406 | Map |
| OR | Providence St. Vincent Medical Center | Portland97225 | NCT07291076 | Map |
| OR | Salem Hospital | Salem97301 | NCT06632327 | Map |
| OR | Northwest Cancer Specialists, P.C. | Tigard97223 | NCT05703971 | Map |
| OR | Legacy Meridian Park Hospital | Tualatin97062 | NCT04402788 | Map |
| OR | Legacy Meridian Park Hospital | Tualatin97062 | NCT06632327 | Map |
| PA | Lehigh Valley Hospital - Cedar Crest | Allentown18103 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04402788 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT01810913 | Map |
| PA | Saint Luke's Cancer Center - Allentown | Allentown18104 | NCT01810913 | Map |
| PA | UPMC Altoona | Altoona16601 | NCT01810913 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT04402788 | Map |
| PA | UPMC-Heritage Valley Health System Beaver | Beaver15009 | NCT01810913 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT04402788 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT01810913 | Map |
| PA | Lehigh Valley Hospital- Muhlenberg | Bethlehem18017 | NCT02693535 | Map |
| PA | Bryn Mawr Hospital | Bryn Mawr19010 | NCT04402788 | Map |
| PA | Carlisle Regional Cancer Center | Carlisle17015 | NCT04402788 | Map |
| PA | Carlisle Regional Cancer Center | Carlisle17015 | NCT01810913 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT04402788 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT06632327 | Map |
| PA | Chambersburg Hospital | Chambersburg17201 | NCT04402788 | Map |
| PA | WellSpan Medical Oncology and Hematology | Chambersburg17201 | NCT05058651 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT04402788 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06632327 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT07166406 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT04402788 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT06632327 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT02693535 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT01810913 | Map |
| PA | Saint Luke's Hospital-Anderson Campus | Easton18045 | NCT01810913 | Map |
| PA | Ephrata Cancer Center | Ephrata17522 | NCT04402788 | Map |
| PA | Ephrata Cancer Center | Ephrata17522 | NCT05058651 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT04402788 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT01810913 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT04402788 | Map |
| PA | UPMC Cancer Center at UPMC Horizon | Farrell16121 | NCT01810913 | Map |
| PA | St. Luke's Physician Group - St. Luke's Cancer Care Associates | Fountain Hill18015-1153 | NCT06712355 | Map |
| PA | Adams Cancer Center | Gettysburg17325 | NCT04402788 | Map |
| PA | Adams Cancer Center | Gettysburg17325 | NCT05058651 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT04402788 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT01810913 | Map |
| PA | UPMC Hillman Cancer Center in Greenville/UPMC Horizon | Greenville16125 | NCT04402788 | Map |
| PA | Magee-Woman's Hospital | Harrisburg17109 | NCT06031441 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT04402788 | Map |
| PA | UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg17109 | NCT01810913 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT06632327 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT02693535 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT04402788 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT04402788 | Map |
| PA | IRMC Cancer Center | Indiana15701 | NCT01810913 | Map |
| PA | UPMC-Johnstown/John P. Murtha Regional Cancer Center | Johnstown15901 | NCT01810913 | Map |
| PA | Lancaster General Hospital - Ann B Barshinger Cancer Institute | Lancaster17601 | NCT06362252 | Map |
| PA | Sechler Family Cancer Center | Lebanon17042 | NCT04402788 | Map |
| PA | Sechler Family Cancer Center | Lebanon17042 | NCT05058651 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT04402788 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT06632327 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT07166406 | Map |
| PA | UPMC Cancer Center at UPMC McKeesport | McKeesport15132 | NCT01810913 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT04402788 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT01810913 | Map |
| PA | Riddle Memorial Hospital | Media19063 | NCT04402788 | Map |
| PA | UPMC Cancer Center - Monroeville | Monroeville15146 | NCT04402788 | Map |
| PA | UPMC Cancer Center - Monroeville | Monroeville15146 | NCT01810913 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT04402788 | Map |
| PA | UPMC Hillman Cancer Center in Coraopolis | Moon Township15108 | NCT01810913 | Map |
| PA | UPMC Hillman Cancer Center - New Castle | New Castle16105 | NCT04402788 | Map |
| PA | Paoli Memorial Hospital | Paoli19301 | NCT04402788 | Map |
| PA | Abramson Cancer Center of the University of Pennsylvania | Philadelphia19104-4283 | NCT05488522 | Map |
| PA | Abramson Cancer Center of the University of Pennsylvania | Philadelphia19104 | NCT04691817 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT04796012 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT02693535 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT01810913 | Map |
| PA | Jefferson Health Honickman Center | Philadelphia19107 | NCT06096779 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT04402788 | Map |
| PA | Temple University Hospital | Philadelphia19140 | NCT01810913 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT04802759 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT04402788 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT01810913 | Map |
| PA | Thomas Jefferson University Hospital - Central | Philadelphia19107 | NCT06362252 | Map |
| PA | University of Pennsylvania-Abramson Cancer Center | Philadelphia19104 | NCT04434040 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT05733598 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT06362252 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT04402788 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT01810913 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT05168163 | Map |
| PA | Research Site | Pittsburgh15232 | NCT06921785 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05333458 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04981509 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05001880 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04402788 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT06287775 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT05538091 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT05733598 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07235293 | Map |
| PA | UPMC- Hillman Cancer Center | Pittsburgh15232 | NCT06444815 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT01810913 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT04402788 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT01810913 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT04402788 | Map |
| PA | UPMC-Saint Clair Hospital Cancer Center | Pittsburgh15243 | NCT01810913 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT04402788 | Map |
| PA | UPMC-Saint Margaret | Pittsburgh15215 | NCT01810913 | Map |
| PA | UPMC-Shadyside Hospital | Pittsburgh15232 | NCT04402788 | Map |
| PA | UPMC-Shadyside Hospital | Pittsburgh15232 | NCT01810913 | Map |
| PA | Saint Luke's Hospital - Upper Bucks Campus | Quakertown18951 | NCT01810913 | Map |
| PA | Guthrie Medical Group PC-Robert Packer Hospital | Sayre18840 | NCT04402788 | Map |
| PA | UPMC Cancer Center at UPMC Northwest | Seneca16346 | NCT01810913 | Map |
| PA | Saint Luke's Hospital - Monroe Campus | Stroudsburg18360 | NCT01810913 | Map |
| PA | UPMC Uniontown Hospital Radiation Oncology | Uniontown15401 | NCT01810913 | Map |
| PA | UPMC Cancer Center-Washington | Washington15301 | NCT04402788 | Map |
| PA | UPMC Washington Hospital Radiation Oncology | Washington15301 | NCT04402788 | Map |
| PA | UPMC Washington Hospital Radiation Oncology | Washington15301 | NCT01810913 | Map |
| PA | Wexford Health and Wellness Pavilion | Wexford15090 | NCT01810913 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT04402788 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06632327 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT07166406 | Map |
| PA | Divine Providence Hospital | Williamsport17754 | NCT04402788 | Map |
| PA | Lankenau Medical Center | Wynnewood19096 | NCT04402788 | Map |
| PA | Cancer Care Associates of York | York17403 | NCT05058651 | Map |
| PA | UPMC Memorial | York17408 | NCT04402788 | Map |
| PA | WellSpan Health-York Cancer Center | York17403 | NCT04402788 | Map |
| PA | WellSpan Health-York Cancer Center | York17403 | NCT05058651 | Map |
| PA | WellSpan Health-York Hospital | York17403 | NCT04402788 | Map |
| RI | Miriam Hospital | Providence02906 | NCT05968326 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05317858 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05968326 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT04402788 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT05058651 | Map |
| SC | SC Cancer Specialists at St. Joseph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | St. Joseph's/Candler Smith | Bluffton29910 | NCT02693535 | Map |
| SC | Summit Cancer Care at St. Josph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04402788 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT01810913 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06632327 | Map |
| SC | Zai Lab Site 2012 | Charleston29425 | NCT06179069 | Map |
| SC | McLeod Regional Medical Center | Florence29506 | NCT06632327 | Map |
| SC | Gibbs Cancer Center-Gaffney | Gaffney29341 | NCT06632327 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT01810913 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT01810913 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT04402788 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT06632327 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT04402788 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT06632327 | Map |
| SC | Self Regional Healthcare | Greenwood29646 | NCT04402788 | Map |
| SC | Self Regional Healthcare | Greenwood29646 | NCT06632327 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT04402788 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT01810913 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT06632327 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT01810913 | Map |
| SC | South Carolina Cancer Specialists | Hilton Head Island29926 | NCT02693535 | Map |
| SC | GSK Investigational Site | Myrtle Beach29572 | NCT06551142 | Map |
| SC | Levine Cancer Institute-Rock Hill | Rock Hill29732 | NCT04402788 | Map |
| SC | Levine Cancer Institute-Rock Hill | Rock Hill29732 | NCT05058651 | Map |
| SC | Rock Hill Radiation Therapy Center | Rock Hill29730 | NCT04402788 | Map |
| SC | Rock Hill Radiation Therapy Center | Rock Hill29730 | NCT01810913 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT01810913 | Map |
| SC | North Grove Medical Park | Spartanburg29303 | NCT06632327 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT04402788 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT01810913 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT06632327 | Map |
| SC | Spartanburg Medical Center - Mary Black Campus | Spartanburg29307 | NCT06632327 | Map |
| SC | SMC Center for Hematology Oncology Union | Union29379 | NCT06632327 | Map |
| SD | Avera Cancer Institute at Pierre | Pierre57501 | NCT04402788 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05058651 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05168163 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT04402788 | Map |
| SD | Avera Cancer Institute- Research ( Site 0104) | Sioux Falls57105 | NCT07227597 | Map |
| SD | Sanford Cancer Center | Sioux Falls57104 | NCT06646276 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05001880 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT04402788 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT06632327 | Map |
| SD | Sanford Cancer Center Oncology Clinic and Pharmacy | Sioux Falls57104 | NCT02693535 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05001880 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT04402788 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT01810913 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06632327 | Map |
| SD | Avera Cancer Institute at Yankton | Yankton57078 | NCT04402788 | Map |
| TN | Tennessee Oncology - Chattanooga Oncology & Hematology Associates | Chattanooga37404 | NCT03424005 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06632327 | Map |
| TN | The West Clinic | Germantown38138 | NCT05733598 | Map |
| TN | The West Clinic | Germantown38138 | NCT03424005 | Map |
| TN | The West Clinic - Memphis (Union Ave) | Germantown38138 | NCT05581004 | Map |
| TN | West Cancer Center | Germantown38138 | NCT04802759 | Map |
| TN | The University of Tennessee Medical Center ( Site 0120) | Knoxville37920 | NCT07227597 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT05733598 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT06712355 | Map |
| TN | Baptist Clinical Research Institute | Memphis38120 | NCT04302025 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT04402788 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06632327 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT05468359 | Map |
| TN | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #012 | Nashville37203 | NCT05434234 | Map |
| TN | GSK Investigational Site | Nashville37203 | NCT06551142 | Map |
| TN | Nashville General Hospital at Meharry | Nashville37208-2918 | NCT06096779 | Map |
| TN | Scri Oncology Partners | Nashville37203 | NCT06362252 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT05581004 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT04929223 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06031441 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06646276 | Map |
| TN | SCRI Oncology Partners ( Site 7000) | Nashville37203 | NCT07227597 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT07291076 | Map |
| TN | Tennessee Oncology - Nashville / Sarah Cannon Research Institute | Nashville37203 | NCT02693535 | Map |
| TN | Tennessee Oncology PLLC | Nashville37203 | NCT03424005 | Map |
| TN | Vanderbilt University Medical Center | Nashville37212 | NCT03424005 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT07291076 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05501665 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05058651 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06110572 | Map |
| TN | Vanderbilt-Ingram Cancer Center | Nashville37232 | NCT04434040 | Map |
| TX | Hendrick Health | Abilene79601 | NCT07195695 | Map |
| TX | Texas Oncology - Abilene - Antilley Road /ID# 265820 | Abilene79606 | NCT06109272 | Map |
| TX | Research Site | Amarillo79124 | NCT06921785 | Map |
| TX | GSK Investigational Site | Austin78705 | NCT06551142 | Map |
| TX | Research Site | Austin78705 | NCT06921785 | Map |
| TX | Texas Oncology - Austin Central | Austin78745 | NCT06463665 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT06646276 | Map |
| TX | World Research Link | Baytown77521 | NCT06463665 | Map |
| TX | Texas Oncology - Gulf Coast | Beaumont77702 | NCT07226999 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT05001880 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT04402788 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT01810913 | Map |
| TX | Baylor Scott and White Research Institute /ID# 260853 | Dallas76508-0001 | NCT06109272 | Map |
| TX | GSK Investigational Site | Dallas75230 | NCT06551142 | Map |
| TX | Harold C. Simmons Comprehensive Cancer Center | Dallas75390 | NCT05440708 | Map |
| TX | Liver Institute at Methodist Dallas | Dallas75203-1260 | NCT06096779 | Map |
| TX | Mary Crowley Cancer Research | Dallas75230 | NCT06444815 | Map |
| TX | Moody Outpatient Center ? Parkland Health | Dallas75235 | NCT06096779 | Map |
| TX | Parkland Health & Hospital System | Dallas75235 | NCT04524871 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05058651 | Map |
| TX | Texas Oncology - Dallas - Worth Street /ID# 265806 | Dallas75246 | NCT06109272 | Map |
| TX | Texas Oncology - DFW | Dallas75246 | NCT05703971 | Map |
| TX | Texas Oncology (Worth) - USOR | Dallas75246-2008 | NCT06096779 | Map |
| TX | The University of Texas Southwestern Medical Center | Dallas75235 | NCT04796012 | Map |
| TX | The University of Texas Southwestern Medical Center at Dallas | Dallas75390 | NCT04524871 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390-0001 | NCT06096779 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05058651 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05058651 | Map |
| TX | Texas Oncology - Denison Cancer Center | Denison75020-0084 | NCT06096779 | Map |
| TX | Texas Oncology - Northeast Texas | Denton76201 | NCT04929223 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05058651 | Map |
| TX | Texas Oncology - San Antonio | Fredericksburg78624 | NCT07226999 | Map |
| TX | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #014 | Houston77030 | NCT05434234 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05058651 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT05058651 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT06096779 | Map |
| TX | Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) | Houston77030 | NCT07227597 | Map |
| TX | Houston Methodist Hospital Cancer Center | Houston77030 | NCT05733598 | Map |
| TX | Houston Methodist Research Institute | Houston77030 | NCT05185505 | Map |
| TX | Kelsey Research Foundation | Houston77025-1669 | NCT06096779 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05333458 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05394337 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04981509 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05001880 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04402788 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT01810913 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05019703 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05039281 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05092373 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05907980 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06439485 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT05001880 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT04402788 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT01810913 | Map |
| TX | Michael E Debakey VA Medical Center - NAVREF - PPDS | Houston77030-4211 | NCT06096779 | Map |
| TX | Research Site | Houston77030 | NCT06921785 | Map |
| TX | Site 1005 | Houston77030 | NCT07407933 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT04796012 | Map |
| TX | Texas Oncology - Gulf Coast | Houston77024 | NCT07226999 | Map |
| TX | Texas Oncology - Gulf Coast | Houston77054 | NCT07226999 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT07049848 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT02693535 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06712355 | Map |
| TX | The University of Texas MD Anderson Cancer Center /ID# 277929 | Houston77030 | NCT07155174 | Map |
| TX | U.T. MD Anderson Cancer Center | Houston77030 | NCT04812366 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030-4000 | NCT05440708 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030-4008 | NCT04302025 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06444815 | Map |
| TX | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #015 | Irving75039 | NCT05434234 | Map |
| TX | MD Anderson League City | League City77573 | NCT05001880 | Map |
| TX | MD Anderson League City | League City77573 | NCT04402788 | Map |
| TX | MD Anderson League City | League City77573 | NCT01810913 | Map |
| TX | DHR Health Institute for Research and Development | McAllen78504 | NCT05440708 | Map |
| TX | Texas Oncology - San Antonio | New Braunfels78130 | NCT07226999 | Map |
| TX | Texas Oncology - Gulf Coast | Pearland77584 | NCT07226999 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05058651 | Map |
| TX | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #013 | San Antonio78229 | NCT05434234 | Map |
| TX | GSK Investigational Site | San Antonio78229 | NCT06551142 | Map |
| TX | Mays Cancer Center / University of Texas, San Antonio | San Antonio78229 | NCT05652686 | Map |
| TX | Research Site | San Antonio78240 | NCT06921785 | Map |
| TX | South Texas Accelerated Research Therapeutics (START) | San Antonio98229 | NCT05581004 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78217 | NCT07226999 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT07226999 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78258 | NCT07226999 | Map |
| TX | University of Texas Health Science Center - San Antonio | San Antonio78229 | NCT05440708 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT05001880 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT04402788 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT01810913 | Map |
| TX | Texas Oncology - Gulf Coast | Sugar Land77479 | NCT07226999 | Map |
| TX | Texas Oncology Cancer Center | Sugar Land77479 | NCT06712355 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Texas City77030 | NCT07235293 | Map |
| TX | Texas Oncology - Gulf Coast | The Woodlands77380 | NCT07226999 | Map |
| TX | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #016 | Tyler75701 | NCT05434234 | Map |
| TX | GSK Investigational Site | Tyler75702 | NCT06551142 | Map |
| TX | Research Site | Tyler75702 | NCT06921785 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT05703971 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT06646276 | Map |
| TX | Texas Oncology - Gulf Coast | Webster77598-4420 | NCT04929223 | Map |
| TX | Texas Oncology - Gulf Coast | Webster77598 | NCT07226999 | Map |
| UT | Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center | Cedar City84720 | NCT02693535 | Map |
| UT | Intermountain Healthcare | Murray84107-5741 | NCT06096779 | Map |
| UT | Community Cancer Trials of Utah | Ogden84405 | NCT07195695 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06069726 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04402788 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT01810913 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05058651 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05168618 | Map |
| UT | Intermountain Healthcare | Salt Lake City84107 | NCT02693535 | Map |
| UT | Dixie Regional Medical Center-River Road Campus | St. George84770 | NCT02693535 | Map |
| UT | Intermountain Cancer Center | St. George84790 | NCT06096779 | Map |
| UT | GSK Investigational Site | West Valley City84119 | NCT06551142 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT04402788 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT04402788 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT04402788 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT04402788 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT01810913 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT05058651 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT06632327 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT07166406 | Map |
| VA | Research Site | Arlington22201 | NCT06921785 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Blacksburg24060 | NCT07226999 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06287775 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06632327 | Map |
| VA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #017 | Fairfax22031 | NCT05434234 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT07166406 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22042 | NCT02693535 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT04402788 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT07166406 | Map |
| VA | Inova Schar Cancer Institute - Fair Oaks | Fairfax22033 | NCT06789757 | Map |
| VA | NEXT Oncology | Fairfax22031 | NCT05907980 | Map |
| VA | NEXT Oncology | Fairfax22031 | NCT06332755 | Map |
| VA | Next Virginia | Fairfax22031 | NCT06362252 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT05652686 | Map |
| VA | Site 1002 | Fairfax22031 | NCT07407933 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT06712355 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278298 | Fairfax22031 | NCT07155174 | Map |
| VA | Virginia Cancer Specialists (Fairfax) - USOR | Fairfax22031 | NCT04302025 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT05703971 | Map |
| VA | Zai Lab Site 2006 | Fairfax22031 | NCT06179069 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT07166406 | Map |
| VA | Inova Health Care Service | Falls Church22042 | NCT06789757 | Map |
| VA | Hematology Oncology Associates of Fredericksburg, Inc. | Fredericksburg22408 | NCT06712355 | Map |
| VA | Inova Loudoun Hospital | Leesburg20176 | NCT07166406 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Low Moor24457 | NCT07226999 | Map |
| VA | GSK Investigational Site | Norfolk23502 | NCT06551142 | Map |
| VA | Bon Secours St. Mary's Hospital | Richmond23226-1925 | NCT06096779 | Map |
| VA | Johnston Willis Hospital | Richmond23235 | NCT05317858 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06287775 | Map |
| VA | VCU Medical Center North Hospital | Richmond23298-5028 | NCT06096779 | Map |
| VA | Virginia Commonwealth University School of Medicine | Richmond23298 | NCT06712355 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc. | Roanoke24014 | NCT06646276 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Roanoke24014 | NCT07226999 | Map |
| VA | Oncology and Hematology Associates of Southwest Virginia /ID# 265834 | Roanoke98684 | NCT06109272 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Salem24153 | NCT07226999 | Map |
| VA | Research Site | Salem24153 | NCT06921785 | Map |
| VA | Shenandoah Oncology | Winchester22601 | NCT06712355 | Map |
| VA | Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Wytheville24382 | NCT07226999 | Map |
| WA | Northwest Medical Specialties | Bonney Lake98391 | NCT02693535 | Map |
| WA | Swedish Cancer Institute - Edmonds | Edmonds98026 | NCT06646276 | Map |
| WA | Northwest Medical Specialties | Federal Way98003 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Gig Harbor98332 | NCT02693535 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT01810913 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT01810913 | Map |
| WA | Northwest Medical Specialties | Olympia98502 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Puyallup98373 | NCT02693535 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT04812366 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT05058651 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109 | NCT05968326 | Map |
| WA | Seattle Children's | Seattle98105 | NCT04796012 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT02693535 | Map |
| WA | Swedish Medical Center | Seattle98104 | NCT06646276 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT01810913 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT05058651 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT05440708 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT06096779 | Map |
| WA | Saint Joseph Medical Center Hematology and Oncology - Silverdale | Silverdale98383 | NCT06632327 | Map |
| WA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #018 | Spokane99208 | NCT05434234 | Map |
| WA | Summit Cancer Centers - North Spokane | Spokane99208 | NCT05440708 | Map |
| WA | MediLink Therapeutics (Suzhou) Co., Ltd. Investigator Site #019 | Tacoma98405 | NCT05434234 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT02693535 | Map |
| WA | Legacy Cancer Institute Medical Oncology and Day Treatment | Vancouver98684 | NCT04402788 | Map |
| WA | Legacy Cancer Institute Medical Oncology and Day Treatment | Vancouver98684 | NCT06632327 | Map |
| WA | Legacy Salmon Creek Hospital | Vancouver98686 | NCT04402788 | Map |
| WA | Legacy Salmon Creek Hospital | Vancouver98686 | NCT06632327 | Map |
| WA | Northwest Cancer Specialists, P.C.-Vancouver | Vancouver98684 | NCT06362252 | Map |
| WA | Wenatchee Valley Hospital and Clinics | Wenatchee98801 | NCT01810913 | Map |
| WV | United Hospital Center | Bridgeport26330 | NCT05058651 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT04402788 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT04402788 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT01810913 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT05058651 | Map |
| WV | Camden Clark Medical Center | Parkersburg26101 | NCT01810913 | Map |
| WV | Wheeling Hospital/Schiffler Cancer Center | Wheeling26003 | NCT04402788 | Map |
| WV | Wheeling Hospital/Schiffler Cancer Center | Wheeling26003 | NCT01810913 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT04402788 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT01810913 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05001880 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT06632327 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT07166406 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Berlin | Berlin54923 | NCT06632327 | Map |
| WI | Aurora Cancer Care - Burlington | Burlington53105 | NCT02693535 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT06632327 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05001880 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04402788 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05058651 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT06632327 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT07166406 | Map |
| WI | Aurora Health Care - Germantown Health Center | Germantown53022 | NCT02693535 | Map |
| WI | Aurora Cancer Care - Grafton | Grafton53024 | NCT02693535 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT02693535 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06632327 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT04402788 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06632327 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT07166406 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Johnson Creek | Johnson Creek53038 | NCT01810913 | Map |
| WI | Aurora Cancer Care - Kenosha South | Kenosha53142 | NCT02693535 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05058651 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Ladysmith | Ladysmith54848 | NCT06632327 | Map |
| WI | University of Wisconsin | Madison53705 | NCT04919382 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT01810913 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT01810913 | Map |
| WI | Aurora Bay Area Medical Center | Marinette54143 | NCT02693535 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05001880 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04402788 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05058651 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06632327 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT07166406 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT04402788 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT01810913 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT06632327 | Map |
| WI | Aurora Cancer Care Milwaukee | Milwaukee53209 | NCT02693535 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53223 | NCT02693535 | Map |
| WI | Aurora St. Luke's Medical Center | Milwaukee53215 | NCT02693535 | Map |
| WI | Aurora West Allis Medical Center | Milwaukee53227 | NCT02693535 | Map |
| WI | Froedtert and the Medical College of Wisconsin LAPS | Milwaukee53226 | NCT05168163 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT04402788 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT01810913 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05058651 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT05168163 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06362252 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06632327 | Map |
| WI | Research Site | Milwaukee53226 | NCT06921785 | Map |
| WI | Zablocki Veterans Administration Medical Center | Milwaukee53295 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05001880 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04402788 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05058651 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT06632327 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06632327 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT07166406 | Map |
| WI | ThedaCare Regional Medical Center - Neenah | Neenah54956 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Neillsville | Neillsville54456 | NCT06632327 | Map |
| WI | ThedaCare Cancer Care - New London | New London54961 | NCT06632327 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT01810913 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT06632327 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT04402788 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT01810913 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT06632327 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06632327 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06632327 | Map |
| WI | ThedaCare Cancer Care - Oshkosh | Oshkosh54904 | NCT06632327 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT02693535 | Map |
| WI | Aurora Cancer Care - Racine | Racine53406 | NCT02693535 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT04402788 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT01810913 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05001880 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT04402788 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05058651 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT06632327 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Shawano | Shawano54166 | NCT06632327 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT04402788 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06632327 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06632327 | Map |
| WI | Vince Lombardi Cancer Center | Sheboygan53081 | NCT02693535 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT07166406 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT04402788 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05001880 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04402788 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05058651 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06632327 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT07166406 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT04402788 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06632327 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT02693535 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT07166406 | Map |
| WI | Vince Lombardi Cancer Clinic - Two Rivers | Two Rivers54241 | NCT02693535 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06632327 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06632327 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT07166406 | Map |
| WI | ThedaCare Cancer Care - Waupaca | Waupaca54981 | NCT06632327 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT04402788 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT01810913 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT06632327 | Map |
| WI | Aurora Cancer Care - Milwaukee West | Wauwatosa53226 | NCT02693535 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT04402788 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT01810913 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05001880 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04402788 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05058651 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06632327 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT07166406 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT04402788 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT01810913 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT06632327 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT06632327 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT06632327 | Map |
Atezolizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | approved for marketing | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 3 | 1 | 1 | 2 | 3 | 1 | 11 | ||||
| P1 | 22 | 28 | 55 | 23 | 5 | 2 | 3 | 138 | |||
| P1/P2 | 30 | 13 | 32 | 25 | 5 | 1 | 2 | 108 | |||
| P2 | 71 | 78 | 85 | 43 | 20 | 1 | 7 | 18 | 323 | ||
| P2/P3 | 9 | 4 | 2 | 1 | 16 | ||||||
| P3 | 15 | 30 | 43 | 12 | 1 | 4 | 1 | 106 | |||
| P4 | 3 | 1 | 2 | 1 | 7 | ||||||
| N/A | 9 | 4 | 12 | 2 | 4 | 4 | 1 | 1 | 37 |
Recruiting Atezolizumab clinical trials (180)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04817956 | IMPRESS-NImproving Public Cancer Care by Implementing Precision Medicine in Norway | P2 | Cancer Metastatic | 3,000 | Apr 2021 |
| NCT05620771 | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | P2 | Hepatocellular Carcinoma | 200 | Nov 2022 |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | P1/P2 | Refractory Solid Tumor | 64 | Nov 2022 |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | P3 | Non-small Cell Lung Cancer | 400 | Jan 2026 |
| NCT07153445 | ATHENEANeoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) | P2 | Non Small Cell Lung Cancer | 97 | Jul 2025 |
| NCT07293468 | BIIRTHComparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) | P2/P3 | Hepatocellular Carcinoma (HCC) | 106 | Apr 2024 |
| NCT06725121 | MacroTransUsing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant | P1/P2 | Hepatocellular Carcinoma (HCC) | 48 | Dec 2024 |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | P2/P3 | Small Cell Lung Cancer (SCLC) | 550 | Dec 2025 |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | P2 | Platinum-Resistant Fallopian Tube Carcinoma | 48 | May 2023 |
| NCT05862285 | UmbrellaMAXA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | P3 | Cancer | 100 | Jun 2023 |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | Chronic Lymphocytic Leukemia | 70 | Jan 2024 |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | P1 | Unresectable Hepatocellular Carcinoma | 20 | Aug 2022 |
| NCT07322341 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | P2 | Advanced Lung Non-Small Cell Carcinoma | 32 | Sep 2026 |
| NCT07291076 | HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | P1/P2 | Hepatocellular Carcinoma (HCC) | 198 | Mar 2026 |
| NCT07155174 | SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer | 180 | Nov 2025 |
| NCT06646276 | TIGOSA Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | P3 | Extensive-Stage Small Cell Lung Cancer | 530 | Feb 2025 |
| NCT06339424 | PhotonABAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 45 | Mar 2024 |
| NCT04727307 | AB-LATE02Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial | P2 | Hepatocellular Carcinoma | 202 | Feb 2021 |
| NCT03548428 | StereosarcStereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) | P2 | Sarcoma | 103 | Jun 2020 |
| NCT05968326 | IMCODE003A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | P2 | Adenocarcinoma, Pancreatic Ductal | 260 | Oct 2023 |
| NCT07170592 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients | P1 | Treatment-Refractory Solid Tumors | 24 | Jan 2027 |
| NCT07190833 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) | P1 | Treatment-Refractory Solid Tumors | 27 | Mar 2026 |
| NCT07263438 | PhenixEfficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial | P2 | Glioblastoma | 59 | Nov 2025 |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma | P3 | Advanced Hepatocellular Carcinoma | 590 | Oct 2024 |
| NCT05332561 | COGNITION-GUIDEGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | P2 | Early-stage Breast Cancer | 240 | Jun 2023 |
| NCT07227597 | MK-6070A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | P1/P2 | Small Cell Lung Cancer Extensive Stage | 170 | Jan 2026 |
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 158 | Dec 2025 |
| NCT07018947 | ASPIREStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC | P2 | Resectable Hepatocellular Carcinoma | 90 | Nov 2025 |
| NCT07239245 | ATTACHStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo | P2 | Resectable Hepatocellular Carcinoma With High Risk of Recurrence | 30 | Nov 2025 |
| NCT06109272 | LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | P2/P3 | Hepatocellular Carcinoma | 660 | Jan 2024 |
| NCT06133062 | ProtonABAtezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma Non-resectable | 45 | Nov 2023 |
| NCT03424005 | Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | P1/P2 | Metastatic Breast Cancer | 792 | Mar 2018 |
| NCT04929223 | INTRINSICA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | P1 | Metastatic Colorectal Cancer | 542 | Oct 2021 |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | P3 | Hepatocellular Carcinoma (HCC) | 740 | Dec 2025 |
| NCT04302025 | NAUTIKA1A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | P2 | Non-small Cell Lung Cancer | 99 | Nov 2020 |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | P3 | Resectable Lung Non-Small Cell Carcinoma | 1,100 | Dec 2024 |
| NCT04341181 | ProTargetProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | P2 | Cancer | 300 | Aug 2020 |
| NCT05300282 | FIL_A-BEGEVStudy of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients | P1/P2 | Relapsed or Refractory Hodgkin's Lymphoma | 122 | Feb 2023 |
| NCT06342037 | TONIC-3NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial | P2 | Metastatic Breast Cancer | 60 | Jun 2024 |
| NCT06921785 | ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | P3 | Hepatocellular Carcinoma | 1,220 | May 2025 |
| NCT05528952 | TERTIOEvaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 105 | Sep 2022 |
| NCT06439485 | Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | P1/P2 | Advanced Cholangiocarcinoma | 25 | Nov 2024 |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | P1 | Small-cell Lung Cancer | 20 | Jul 2026 |
| NCT07113691 | TIARAIadademstat + SBRT With Atezo in ES-SCLC | P1 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 15 | Jan 2026 |
| NCT07049848 | SATURN-STSSATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma | P2 | Soft Tissue Sarcoma | 50 | Sep 2025 |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | P3 | Hepato Cellular Carcinoma (HCC) | 30 | Mar 2026 |
| NCT07281664 | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma | N/A | Hepatocellular Carcinoma | 30 | Jan 2026 |
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer ( SCLC ) | 35 | Jun 2026 |
| NCT05770102 | DETERMINEDETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | P2/P3 | Malignancy | 30 | Oct 2023 |
| NCT05722886 | DETERMINEDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | P2/P3 | Haematological Malignancy | 825 | Mar 2023 |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | P2 | Small Cell Neuroendocrine Carcinoma of Bladder | 63 | Jun 2022 |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | P3 | Lung Non-Small Cell Carcinoma | 336 | Jun 2026 |
| NCT07543510 | Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | N/A | Hepatocellular Carcinoma | 38 | May 2026 |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Early P1 | Glioblastoma Multiforme | 12 | Oct 2022 |
| NCT03942328 | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | P1/P2 | Stage III Hepatocellular Carcinoma AJCC v8 | 85 | Sep 2019 |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | N/A | Hepatocellular Carcinoma | 234 | Aug 2023 |
| NCT06463665 | VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | P2 | Advanced Non-squamous Non-small-cell Lung Cancer | 142 | Sep 2024 |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy | P3 | Small Cell Lung Cancer (SCLC) | 670 | Apr 2026 |
| NCT06287775 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | P1/P2 | Extensive Stage Lung Small Cell Carcinoma | 45 | Apr 2025 |
| NCT04996017 | AtezoMesoAtezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) | P3 | Mesotheliomas Pleural | 162 | Dec 2021 |
| NCT06551142 | PanTumor-101A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | P1 | Neoplasms | 845 | Sep 2024 |
| NCT06663098 | CARRY-ONAtezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). | P2 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 142 | Jan 2025 |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | P1/P2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | 316 | Jun 2021 |
| NCT06733038 | AtezoTRIBE2FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | P3 | Colorectal Cancer | 238 | Nov 2024 |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | P3 | Extensive-stage Small-cell Lung Cancer | 621 | Feb 2025 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | Advanced Hepatocellular Carcinoma | 226 | Feb 2026 |
| NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | P1/P2 | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 118 | Mar 2026 |
| NCT05703997 | FASTIMMUNEFASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | P2 | Small Cell Lung Carcinoma | 20 | Jan 2023 |
| NCT07276100 | Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab | P2 | Hepato Cellular Carcinoma (HCC) | 15 | Jan 2026 |
| NCT07172412 | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | P2 | Extensive Stage Lung Small Cell Cancer | 165 | Nov 2025 |
| NCT07284121 | A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice | — | Lung Cancer, Hepatocellular Carcinoma | 700 | Jul 2025 |
| NCT06031233 | MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | Oncology | 776 | Sep 2023 |
| NCT05482516 | MRD-GIEvaluating Novel Therapies in ctDNA Positive GI Cancers | P3 | Colon Adenocarcinoma | 20 | Mar 2023 |
| NCT05394337 | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | P1/P2 | Metastatic Malignancy | 10 | Feb 2023 |
| NCT02693535 | TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | Lymphoma, Non-Hodgkin | 4,200 | Mar 2016 |
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | P2 | Extensive Stage Lung Small Cell Carcinoma | 56 | Jan 2022 |
| NCT06719336 | STONE-001Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | P3 | Extensive-stage Small Cell Lung Cancer | 182 | Dec 2024 |
| NCT06717243 | STRATUSGenomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | — | Small Cell Lung Cancer | 111 | Feb 2025 |
| NCT06161532 | SMARTSacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... | P2 | Small Cell Carcinoma of the Bladder | 60 | Aug 2024 |
| NCT06003621 | MoST-TAPTiragolumab and Atezolizumab in Advanced Pan-cancer Patients | P2 | Solid Tumor, Adult | 96 | Dec 2023 |
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | P2/P3 | Advanced Extrapulmonary Neuroendocrine Carcinoma | 189 | Jun 2022 |
| NCT05652686 | PT217A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | P1/P2 | Small Cell Lung Cancer (SCLC) | 203 | Sep 2023 |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | P1/P2 | Hepatocellular Carcinoma | 45 | Jul 2025 |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | P4 | Hepatocellular Carcinoma | 40 | Jun 2026 |
| NCT06823375 | SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis | P2 | HCC | 40 | Jul 2025 |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | P1 | Endometrial Cancer | 58 | Oct 2023 |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | Locally Advanced or Metastatic Solid Tumors | 450 | Oct 2022 |
| NCT06908993 | COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | P3 | Advanced Non Small Cell Lung Cancer | 133 | Dec 2025 |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | P2 | Hepatocellular Carcinoma | 60 | Aug 2024 |
| NCT04423185 | PLATFORM Study of Precision Medicine for Rare Tumors | P2 | Rare Tumor | 770 | Aug 2020 |
| NCT07093762 | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | — | Non Small Cell Lung Cancer | 35 | Aug 2025 |
| NCT05859217 | Cabatezo-1A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | P2 | Lung Cancer | 40 | Dec 2024 |
| NCT06110572 | TESSERACTPhase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | P1/P2 | Extensive Stage Lung Small Cell Carcinoma | 18 | Apr 2024 |
| NCT05661188 | TIRANUSTiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) | P2 | Squamous Cell Carcinoma of the Anal Canal | 45 | Feb 2023 |
| NCT03708224 | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | P2 | Cancer | 55 | Mar 2019 |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | P1 | Hepatocellular Carcinoma | 70 | Jul 2024 |
| NCT05690048 | FLORAFecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) | P2 | Immunotherapy | 48 | Jul 2025 |
| NCT06332755 | LB-LR1109Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC | P1 | Non-small Cell Lung Cancer(NSCLC) | 76 | Jun 2024 |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | P1 | Locally Advanced Alveolar Soft Part Sarcoma | 30 | Nov 2025 |
| NCT05377034 | STRATUMMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients | P2 | Locally Advanced Hepatocellular Carcinoma | 100 | Oct 2022 |
| NCT06789757 | (HCC)The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) | P2 | Hepatocellular Carcinoma | 19 | Feb 2025 |
| NCT06731270 | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | P2 | Advanced Lung Non-Small Cell Carcinoma | 20 | Apr 2025 |
| NCT06069726 | MOABA Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | P2 | Recurrent Glioblastoma | 80 | Mar 2024 |
| NCT06584071 | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | P1/P2 | HCC | 140 | Dec 2024 |
| NCT06444815 | STEALTH-001A Study of VET3-TGI in Patients With Solid Tumors | P1 | Solid Tumor, Adult | 60 | Sep 2024 |
| NCT06031441 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | Locally Advanced Solid Tumors | 250 | Nov 2023 |
| NCT05019703 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | P2 | Locally Advanced Osteosarcoma | 40 | Apr 2023 |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | P1/P2 | Recurrent Glioblastoma | 6 | Sep 2022 |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | P2 | Hereditary Leiomyomatosis and Renal Cell Carcinoma | 65 | Jun 2022 |
| NCT04819243 | Young-PALETTAPALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study | P2 | Premenopausal HR+/HER2- Metastatic Breast Cancer | 178 | Aug 2021 |
| NCT03915678 | AGADIRAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | P2 | Solid Tumor, Adult | 247 | Mar 2021 |
| NCT02925234 | DRUPThe Drug Rediscovery Protocol (DRUP Trial) | P2 | Cancer | 1,550 | Aug 2016 |
| NCT06096779 | KirrosA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | P2 | Hepatocellular Carcinoma | 30 | Jul 2024 |
| NCT04434040 | ASPRIAAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | P2 | Breast Cancer | 40 | Jul 2020 |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | P1 | Metastatic Lung Non-Small Cell Carcinoma | 24 | Dec 2024 |
| NCT05317858 | LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | P3 | Brain Tumor | 30 | Aug 2022 |
| NCT05765084 | Immuno-MESODECIntegration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | P1/P2 | Malignant Pleural Mesothelioma | 15 | Feb 2023 |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | P4 | Hepatocellular Carcinoma | 24 | Jan 2023 |
| NCT05152472 | ATEZOGISTA Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | P2 | Unresectable Gastrointestinal Stromal Tumor (GIST) | 110 | Jan 2022 |
| NCT04486352 | EndoMAPA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | P1/P2 | Endometrial Cancer | 148 | Oct 2021 |
| NCT04273061 | CAPTIV-8Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | P2 | Breast Cancer | 200 | Jun 2020 |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | P1/P2 | Advanced Solid Tumor | 312 | May 2022 |
| NCT05483400 | TIRACANOpen Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors | P2 | Head and Neck Neoplasms | 97 | Oct 2023 |
| NCT04691817 | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | P1/P2 | Lung Cancer, Nonsmall Cell | 28 | Jul 2023 |
| NCT04524871 | MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | P1/P2 | Advanced Liver Cancers | 518 | Nov 2020 |
| NCT05085496 | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC | P1 | Locally Advanced Skin Squamous Cell Carcinoma | 12 | Apr 2022 |
| NCT05703971 | Acclaim-3Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | P1/P2 | Small Cell Lung Cancer Extensive Stage | 62 | May 2024 |
| NCT04467723 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | P1/P2 | NSCLC Stage IV | 25 | May 2022 |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | SCLC | 339 | Jan 2024 |
| NCT04803994 | TACEThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | P3 | Hepatocellular Carcinoma | 434 | Jul 2021 |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | P2 | Extensive Stage Lung Small Cell Carcinoma | 28 | Jul 2021 |
| NCT06492954 | AflacST2301Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma | P1 | Osteosarcoma | 12 | Jul 2026 |
| NCT06830694 | AMG757Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | P2 | Small Cell Carcinoma of Lung | 50 | May 2025 |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | HCC - Hepatocellular Carcinoma | 300 | Feb 2025 |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | P1/P2 | Neoplasms | 150 | Jul 2023 |
| NCT05797493 | PICASSOPanomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | — | Small Cell Lung Cancer | 100 | Oct 2022 |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | P1/P2 | Bile Duct Cancer | 29 | Dec 2021 |
| NCT05333458 | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial | P2 | Advanced Alveolar Soft Part Sarcoma | 27 | Aug 2022 |
| NCT07235293 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | P2 | Colorectal Cancer | 90 | Jan 2026 |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | P2/P3 | Extensive Stage Lung Small Cell Carcinoma | 138 | Jan 2021 |
| NCT03821246 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | P2 | Prostate Adenocarcinoma | 68 | Oct 2019 |
| NCT05516628 | EMPHASISDeep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 30 | Feb 2023 |
| NCT05525858 | KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | Solid Tumor | 1,000 | Sep 2022 |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | P1 | Advanced Solid Tumor | 50 | Jul 2024 |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | P1/P2 | Advanced Neuroendocrine Carcinoma | 178 | Dec 2023 |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | P1/P2 | Hepatocellular Carcinoma | 193 | Mar 2023 |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | P2 | Hepatocellular Carcinoma (HCC) | 30 | Sep 2025 |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 20 | Mar 2025 |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | Early P1 | Recurrent Glioblastoma | 10 | Jan 2025 |
| NCT06690840 | AZALEAAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients | P2 | Triple Negative Breast Cancer | 45 | Mar 2025 |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | Lung Non-Small Cell Carcinoma | 25 | May 2023 |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | P1 | Extensive-stage Small-cell Lung Cancer | 24 | Jan 2025 |
| NCT04796012 | VITASVITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | P1/P2 | Solid Tumor | 23 | Apr 2023 |
| NCT05168618 | AtezoCabCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | P2 | Castration-Resistant Prostate Carcinoma | 33 | Mar 2022 |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | P2/P3 | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | 613 | Mar 2013 |
| NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | P1 | Solid Tumor | 219 | May 2023 |
| NCT05488522 | SBRT With Atezo/Bev for HCC | P1 | Hepatocellular Carcinoma | 18 | Sep 2022 |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | P2 | Locally Advanced Hepatocellular Carcinoma | 122 | May 2022 |
| NCT06362252 | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | P1/P2 | Extensive Stage-small Cell Lung Cancer | 123 | Jul 2024 |
| NCT04865250 | iRePPredicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC | P2 | NSCLC Stage II | 20 | Jan 2021 |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | P2 | Small Cell Lung Cancer | 37 | Dec 2021 |
| NCT03767075 | BoBA Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | P2 | Advanced Solid Tumor | 1,000 | Dec 2018 |
| NCT05159245 | FINPROVEThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | P2 | Advanced Cancer | 250 | Dec 2021 |
| NCT05092373 | TTFPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | P1 | Advanced Breast Carcinoma | 43 | Apr 2022 |
| NCT07285850 | ABATE-MASLDThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD | P2/P3 | HCC - Hepatocellular Carcinoma | 20 | Oct 2025 |
| NCT05001880 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | P2 | Peritoneal Malignant Mesothelioma | 66 | Mar 2022 |
| NCT06012734 | CoLBAtLB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients | P1 | Metastatic Microsatellite-stable Colorectal Cancer | 37 | Jun 2024 |
| NCT06971237 | IMSIRTSIRT and Peri-immunotherapy : a New Concept | — | Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy | 60 | Jun 2025 |
| NCT06097962 | Safety and Efficacy of NK510 to Treat NSCLC | Early P1 | NSCLC | 12 | Jul 2023 |
| NCT04624399 | ABACUS-2Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer | P2 | Urogenital Cancer | 58 | Jun 2021 |
| NCT04812366 | GUNSGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | P2 | Prostate Cancer | 315 | Sep 2021 |
| NCT05992220 | ALERT-HCCAtezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion | P2 | Hepatocellular Carcinoma | 138 | Oct 2022 |
| NCT05751343 | Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial | P2 | Hepatocellular Carcinoma | 55 | Mar 2023 |
| NCT06323382 | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | Advanced Hepatocellular Carcinoma | 240 | Jan 2021 |
| NCT05713994 | CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | May 2020 |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | — | Lung Cancer, Small Cell | 1,430 | Aug 2024 |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | P2 | Non Small Cell Lung Cancer | 120 | Feb 2023 |
| NCT04224636 | DEMANDAtezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab | P2 | Hepatocellular Carcinoma Non-resectable | 106 | Jun 2020 |
| NCT05717738 | CCGLC-008Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | Jan 2022 |
Atezolizumab clinical trials by indication
Hepatocellular Carcinoma (43)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05620771 | — | P2 | recruiting | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk |
| NCT06339424 | PhotonAB | P2 | recruiting | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma |
| NCT04727307 | AB-LATE02 | P2 | recruiting | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial |
| NCT07317414 | — | P2 | recruiting | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma |
| NCT06109272 | LIVIGNO-2 | P2/P3 | recruiting | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
| NCT06921785 | ARTEMIDE-HCC01 | P3 | recruiting | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma |
| NCT05528952 | TERTIO | P2 | recruiting | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
| NCT07281664 | — | N/A | not yet recruiting | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma |
| + 35 more, see All trials below. | ||||
Breast Cancer (24)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04873362 | Astefania | P3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
| NCT01898117 | Triple-B | P2 | active not recruiting | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer |
| NCT04434040 | ASPRIA | P2 | recruiting | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) |
| NCT04273061 | CAPTIV-8 | P2 | recruiting | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity |
| NCT04759248 | ATREZZO | P2 | active not recruiting | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer |
| NCT04158258 | — | N/A | active not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America |
| NCT04732598 | AMBITION | P3 | completed | A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer |
| NCT03483012 | — | P2 | completed | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis |
| + 16 more, see All trials below. | ||||
Non-Small Cell Lung Cancer (22)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03228667 | — | P2 | active not recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors |
| NCT04449874 | — | P1 | active not recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation |
| NCT02486718 | MPDL3280A | P3 | active not recruiting | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] |
| NCT05047250 | — | P3 | active not recruiting | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer |
| NCT03178552 | B-FAST | P2/P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) |
| NCT04294810 | SKYSCRAPER-01 | P3 | completed | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer |
| NCT05240131 | NSCLC | P1/P2 | unknown | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). |
| NCT03735121 | — | P3 | completed | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| + 14 more, see All trials below. | ||||
Urothelial Carcinoma (20)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03170960 | — | P1 | active not recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
| NCT03093922 | — | P2 | active not recruiting | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer |
| NCT03782207 | IMreal | N/A | active not recruiting | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice |
| NCT03869190 | MORPHEUS-UC | P1/P2 | completed | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) |
| NCT03502785 | — | P1/P2 | completed | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma |
| NCT03473756 | FORT-2 | P1 | completed | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma |
| NCT02807636 | IMvigor130 | P3 | completed | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma |
| NCT03511391 | CHEERS | P2 | completed | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors |
| + 12 more, see All trials below. | ||||
Non-small Cell Lung Cancer (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07195695 | — | P3 | recruiting | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations |
| NCT04302025 | NAUTIKA1 | P2 | recruiting | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) |
| NCT05825625 | — | P2 | active not recruiting | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing |
| NCT05867121 | — | P1 | active not recruiting | A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 |
| NCT05007769 | RAN | P2 | withdrawn | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC |
| NCT03563716 | — | P2 | completed | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT05746481 | NSCLC | P2 | terminated | Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases |
| NCT04911166 | — | P1 | terminated | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy |
| + 7 more, see All trials below. | ||||
Non Small Cell Lung Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07153445 | ATHENEA | P2 | recruiting | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) |
| NCT07093762 | — | N/A | not yet recruiting | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC |
| NCT05781308 | ADAPTABLE | P2 | active not recruiting | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
| NCT03520686 | — | P3 | terminated | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer |
| NCT05295212 | — | P2 | recruiting | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB |
| NCT04432207 | — | P1 | terminated | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer |
| NCT03836066 | TELMA | P2 | completed | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients |
| NCT04512430 | — | P2 | terminated | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients |
| + 4 more, see All trials below. | ||||
Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05862285 | UmbrellaMAX | P3 | recruiting | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study |
| NCT04341181 | ProTarget | P2 | recruiting | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling |
| NCT03148418 | — | P3 | active not recruiting | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) |
| NCT06754501 | — | P2 | active not recruiting | A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary |
| NCT03768063 | IMbrella B | P3 | active not recruiting | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study |
| NCT03708224 | — | P2 | recruiting | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck |
| NCT02925234 | DRUP | P2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT05694013 | ORIGAMA | P2/P3 | terminated | Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice |
| + 4 more, see All trials below. | ||||
Solid Tumor (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05525858 | KOSMOSII | N/A | recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II |
| NCT04796012 | VITAS | P1/P2 | recruiting | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors |
| NCT05907980 | — | P1 | recruiting | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors |
| NCT03673787 | IceCAP | P1/P2 | active not recruiting | A Trial of Ipatasertib in Combination With Atezolizumab |
| NCT04185831 | MEGALiT | P2 | active not recruiting | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial |
| NCT06416436 | — | P1 | withdrawn | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients |
| NCT04101357 | — | P1/P2 | terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 |
| NCT04276376 | ARIANES | P2 | terminated | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors |
| + 4 more, see All trials below. | ||||
Bladder Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04138628 | TOMBOLA | P2 | active not recruiting | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy |
| NCT04630730 | — | P2 | active not recruiting | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC |
| NCT03697850 | BladderSpar | P2 | active not recruiting | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy |
| NCT03799835 | ALBAN | P3 | active not recruiting | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients |
| NCT04186013 | — | P2 | active not recruiting | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer |
| NCT02989584 | — | P1/P2 | active not recruiting | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer |
| NCT04289779 | ABATE | P2 | active not recruiting | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer |
| NCT02108652 | — | P2 | completed | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) |
| + 4 more, see All trials below. | ||||
Solid Tumors (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04589845 | TAPISTRY | P2 | active not recruiting | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study |
| NCT06331598 | IMperator | P2 | withdrawn | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) |
| NCT04250155 | — | P1 | active not recruiting | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT04303858 | RO7284755 | P1 | terminated | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors |
| NCT04857138 | — | P1 | completed | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors |
| NCT04642365 | — | P1 | terminated | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. |
| NCT03264066 | — | P2 | completed | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors |
| NCT02650713 | CEA | P1 | completed | A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors |
| + 3 more, see All trials below. | ||||
Advanced Solid Tumor (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05434234 | — | P1/P2 | recruiting | A Study of YL201 in Patients With Advanced Solid Tumors |
| NCT05878691 | — | P1 | active not recruiting | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. |
| NCT06302426 | — | P1 | recruiting | Trial of INI-4001 in Patients With Advanced Solid Tumours |
| NCT03767075 | BoB | P2 | recruiting | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) |
| NCT04896697 | XTX101 | P1/P2 | active not recruiting | Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors |
| NCT04440735 | — | P1/P2 | active not recruiting | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors |
| NCT05109442 | — | P1/P2 | terminated | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers |
| NCT05253053 | — | P1/P2 | completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
| + 3 more, see All trials below. | ||||
Carcinoma, Non-Small-Cell Lung (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03337698 | Morpheus Lung | P1/P2 | terminated | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) |
| NCT04471428 | CONTACT-01 | P3 | completed | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy |
| NCT04984811 | — | P2 | terminated | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC |
| NCT04194203 | — | P3 | completed | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) |
| NCT04426825 | — | P2 | completed | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer |
| NCT02813785 | IMpower210 | P3 | completed | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy |
| NCT03102242 | — | P2 | completed | Atezolizumab Immunotherapy in Patients With Advanced NSCLC |
| NCT03285763 | TAIL | P4 | completed | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
| + 3 more, see All trials below. | ||||
Colorectal Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06733038 | AtezoTRIBE2 | P3 | recruiting | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. |
| NCT05999812 | — | P2 | active not recruiting | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer |
| NCT07235293 | — | P2 | recruiting | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. |
| NCT05118724 | ANTONIO | P2 | active not recruiting | Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin |
| NCT05425940 | STELLAR-303 | P3 | active not recruiting | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer |
| NCT03866239 | — | P1 | terminated | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma |
| NCT03555149 | — | P1/P2 | terminated | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) |
| NCT02291289 | MODUL | P2 | completed | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) |
| + 2 more, see All trials below. | ||||
Small Cell Lung Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155174 | SEZanne | P2 | recruiting | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer |
| NCT06898957 | (DeLLphi-310) | P1 | active not recruiting | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) |
| NCT06717243 | STRATUS | N/A | recruiting | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) |
| NCT05797493 | PICASSO | N/A | recruiting | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer |
| NCT06771518 | — | P2 | recruiting | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab |
| NCT04256421 | SKYSCRAPER-02 | P3 | completed | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT04730999 | CeLEBrATE | P2 | completed | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer |
| NCT03059667 | — | P2 | completed | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer |
| + 2 more, see All trials below. | ||||
Extensive Stage Lung Small Cell Carcinoma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06287775 | — | P1/P2 | recruiting | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer |
| NCT04919382 | — | P2 | recruiting | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer |
| NCT06110572 | TESSERACT | P1/P2 | recruiting | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation |
| NCT04696575 | — | P2 | recruiting | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer |
| NCT04402788 | — | P2/P3 | recruiting | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial |
| NCT04560972 | LB-100 | P1 | active not recruiting | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT04334941 | — | P2 | active not recruiting | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker |
| NCT05191797 | — | P1/P2 | terminated | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer |
| + 1 more, see All trials below. | ||||
Melanoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04722575 | NEO-TIM | P2 | active not recruiting | Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma |
| NCT04107168 | — | N/A | unknown | Microbiome Immunotherapy Toxicity and Response Evaluation |
| NCT03289962 | RO7198457 | P1 | completed | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors |
| NCT04096638 | — | P1 | completed | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors |
| NCT02908672 | — | P3 | completed | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma |
| NCT05116202 | — | P1/P2 | completed | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) |
| NCT04091217 | — | P2 | completed | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma |
| NCT03901573 | — | P1/P2 | terminated | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 |
Hepatocellular Carcinoma (HCC) (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07293468 | BIIRTH | P2/P3 | recruiting | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) |
| NCT06725121 | MacroTrans | P1/P2 | recruiting | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant |
| NCT07291076 | HCC | P1/P2 | recruiting | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) |
| NCT06680258 | — | P3 | not yet recruiting | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy |
| NCT07192185 | — | P2 | recruiting | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab |
| NCT05022927 | — | P1 | active not recruiting | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma |
| NCT07272265 | — | N/A | completed | The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study |
Triple Negative Breast Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03756298 | — | P2 | active not recruiting | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer |
| NCT03281954 | — | P3 | active not recruiting | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo |
| NCT06690840 | AZALEA | P2 | recruiting | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients |
| NCT05498896 | BARBICAN | P2 | active not recruiting | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC |
| NCT03206203 | — | P2 | completed | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer |
| NCT03498716 | IMpassion030 | P3 | terminated | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
| NCT02425891 | — | P3 | completed | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) |
Neoplasms (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06551142 | PanTumor-101 | P1 | recruiting | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) |
| NCT05944237 | — | P1/P2 | recruiting | HTL0039732 in Participants With Advanced Solid Tumours |
| NCT05112965 | — | P3 | active not recruiting | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) |
| NCT02091141 | — | P2 | completed | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors |
| NCT02825940 | IMYO29233 | P1 | completed | A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT02410512 | — | P1 | completed | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT01688206 | RO5520985 | P1 | completed | A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
Lung Non-Small Cell Carcinoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04989283 | — | P2 | withdrawn | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer |
| NCT07388524 | — | P3 | not yet recruiting | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial |
| NCT05340309 | — | P2 | active not recruiting | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer |
| NCT04214262 | — | P3 | active not recruiting | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer |
| NCT05501665 | — | P1/P2 | recruiting | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer |
| NCT04310020 | — | P2 | active not recruiting | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients |
Advanced Hepatocellular Carcinoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06618664 | — | P3 | recruiting | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma |
| NCT07166406 | — | P3 | recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
| NCT05097911 | — | P1 | active not recruiting | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. |
| NCT06323382 | — | N/A | recruiting | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
| NCT05173298 | HCC | N/A | unknown | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab |
| NCT04862949 | — | N/A | completed | Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC |
Metastatic Breast Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03424005 | Morpheus-panBC | P1/P2 | recruiting | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer |
| NCT06342037 | TONIC-3 | P2 | recruiting | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial |
| NCT05266937 | — | P2 | unknown | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel |
| NCT04740918 | KATE3 | P3 | terminated | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) |
| NCT04408118 | ATRACTIB | P2 | completed | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC |
| NCT02924883 | KATE2 | P2 | completed | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy |
Carcinoma, Hepatocellular (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04180072 | — | N/A | active not recruiting | Atezolizumab Plus Bevacizumab With HCC and HBV Infection |
| NCT04102098 | IMbrave050 | P3 | active not recruiting | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation |
| NCT05908786 | — | P1/P2 | completed | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma |
| NCT04487067 | AMETHISTA | P3 | completed | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista |
| NCT04732286 | — | P3 | terminated | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy |
| NCT03434379 | IMbrave150 | P3 | completed | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma |
Renal Cell Carcinoma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04006522 | — | P2 | active not recruiting | 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma |
| NCT03693573 | — | P3 | withdrawn | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma |
| NCT03024996 | IMmotion010 | P3 | terminated | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy |
| NCT02420821 | IMmotion151 | P3 | completed | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) |
| NCT03063762 | RCC | P1 | completed | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) |
| NCT01984242 | IMmotion150 | P2 | completed | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma |
Small-cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07545954 | — | P1 | not yet recruiting | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer |
| NCT03540420 | ACHILES | P2 | active not recruiting | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer |
| NCT04923776 | — | P2 | terminated | Liver Directed RT + Chemo-immunotherapy for ES-SCLC |
| NCT04696939 | — | P2 | unknown | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients |
| NCT04610684 | SCLC | P2 | terminated | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases |
Unresectable Hepatocellular Carcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05096715 | — | P1 | recruiting | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC |
| NCT06117891 | REFINE-IO | N/A | active not recruiting | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery |
| NCT04770896 | IMbrave251 | P3 | active not recruiting | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab |
| NCT04829383 | AB7 | P2 | active not recruiting | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma |
| NCT06503250 | — | N/A | completed | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization |
Endometrial Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05542407 | — | P1 | recruiting | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer |
| NCT04486352 | EndoMAP | P1/P2 | recruiting | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer |
| NCT03526432 | — | P2 | active not recruiting | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer |
| NCT03694262 | EndoBARR | P2 | completed | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) |
| NCT03603184 | AtTEnd | P3 | completed | Atezolizumab Trial in Endometrial Cancer - AtTEnd |
Small Cell Lung Carcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05703997 | FASTIMMUNE | P2 | not yet recruiting | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction |
| NCT05224141 | MK-7684A | P3 | active not recruiting | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) |
| NCT04665856 | SKYSCRAPER-02C | P3 | active not recruiting | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT04028050 | MAURIS | P3 | completed | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT02763579 | IMpower133 | P3 | completed | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) |
Extensive Stage Small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05142696 | — | P1/P2 | active not recruiting | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
| NCT05361395 | ES-SCLC | P1 | active not recruiting | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| NCT05468489 | — | P3 | active not recruiting | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
| NCT05055947 | — | N/A | completed | Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer |
| NCT05055999 | — | N/A | completed | Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer |
Ovarian Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04931342 | BOUQUET | P2 | active not recruiting | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors |
| NCT03363867 | BEACON | P2 | unknown | BEACON - ABC in Recurrent Platinum Resistant HGSOC |
| NCT02891824 | ATALANTE | P3 | completed | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab |
| NCT03038100 | IMagyn050 | P3 | completed | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT03394885 | AdORN | P1/P2 | completed | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer |
Malignant Melanoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02902029 | ImmunoCobiVem | P2 | completed | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma |
| NCT04123470 | — | P1/P2 | completed | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma |
| NCT03178851 | — | P1 | completed | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma |
| NCT02303951 | NEO-VC | P2 | terminated | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC |
| NCT01656642 | — | P1 | completed | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma |
Small Cell Lung Cancer Extensive Stage (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07227597 | MK-6070 | P1/P2 | recruiting | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) |
| NCT05703971 | Acclaim-3 | P1/P2 | recruiting | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
| NCT06939036 | SANTANA-225 | P1/P2 | terminated | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) |
| NCT04462276 | TREASURE | P2 | completed | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease |
Advanced Solid Tumors (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04185883 | — | P1 | active not recruiting | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) |
| NCT05487235 | — | P1 | completed | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT06719973 | — | P1 | withdrawn | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) |
| NCT03841110 | — | P1 | completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors |
Metastatic Lung Non-Small Cell Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05935774 | — | P2 | withdrawn | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer |
| NCT06616623 | — | P1 | recruiting | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer |
| NCT04919369 | ATRA | P1 | active not recruiting | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer |
| NCT03600701 | — | P2 | active not recruiting | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer |
Solid Tumor, Adult (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06003621 | MoST-TAP | P2 | recruiting | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients |
| NCT06444815 | STEALTH-001 | P1 | recruiting | A Study of VET3-TGI in Patients With Solid Tumors |
| NCT03915678 | AGADIR | P2 | recruiting | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors |
| NCT05276284 | TEMPLE | P1/P2 | completed | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy |
Non-small Cell Lung Cancer (NSCLC) (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06267001 | SKYSCRAPER-15 | P3 | terminated | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy |
| NCT04619797 | SKYSCRAPER-06 | P2/P3 | completed | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer |
| NCT04267237 | — | P2 | withdrawn | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer |
| NCT04513925 | SKYSCRAPER-03 | P3 | completed | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
Hepatocellular Carcinoma Non-resectable (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06133062 | ProtonAB | P2 | recruiting | Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma |
| NCT05713994 | CCGLC-001 | N/A | recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
| NCT04224636 | DEMAND | P2 | recruiting | Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab |
| NCT05717738 | CCGLC-008 | N/A | recruiting | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma |
Squamous Cell Carcinoma of Head and Neck (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665843 | SKYSCRAPER-09 | P2 | completed | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck |
| NCT03829501 | KY1044 | P1/P2 | terminated | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies |
| NCT05053737 | — | P1 | completed | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC |
| NCT04939480 | PIONEER | P2 | completed | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN |
Metastatic Colorectal Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929223 | INTRINSIC | P1 | recruiting | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) |
| NCT03340558 | ATELIER | P2 | withdrawn | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer |
| NCT04659382 | SIRTCI | P2 | unknown | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer |
| NCT03721653 | AtezoTRIBE | P2 | completed | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients |
Triple-Negative Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04148911 | EL1SSAR | P3 | completed | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer |
| NCT04584112 | — | P1 | completed | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer |
| NCT04177108 | — | P3 | completed | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer |
| NCT03125902 | IMpassion131 | P3 | completed | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) |
Cervical Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03614949 | — | P2 | active not recruiting | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer |
| NCT03340376 | — | P2 | active not recruiting | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer |
| NCT04300647 | SKYSCRAPER-04 | P2 | completed | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer |
| NCT04405349 | — | P2 | completed | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer |
Advanced Lung Non-Small Cell Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07322341 | — | P2 | not yet recruiting | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer |
| NCT06731270 | — | P2 | recruiting | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy |
| NCT05334329 | NK | P1 | active not recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors |
Small Cell Lung Cancer (SCLC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07226999 | — | P2/P3 | recruiting | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer |
| NCT07472517 | — | P3 | recruiting | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy |
| NCT05652686 | PT217 | P1/P2 | recruiting | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) |
HCC - Hepatocellular Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07157969 | — | P2 | recruiting | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC |
| NCT07285850 | ABATE-MASLD | P2/P3 | recruiting | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD |
| NCT05665348 | TRIPLET | P2/P3 | completed | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy |
Squamous Cell Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05681039 | OCSCC | P2 | active not recruiting | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). |
| NCT06762808 | — | P2 | withdrawn | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC |
| NCT05038657 | AURORA | P2 | unknown | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). |
Recurrent Glioblastoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06069726 | MOAB | P2 | recruiting | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial |
| NCT05039281 | — | P1/P2 | recruiting | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma |
| NCT07538128 | — | Early P1 | recruiting | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma |
Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06572722 | ECTOP-1030 | P2 | withdrawn | Perioperative Immunotherapy for NSCLC (ECTOP-1030) |
| NCT05859217 | Cabatezo-1 | P2 | not yet recruiting | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) |
| NCT04367311 | NSCLC | P2 | active not recruiting | Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) |
Extensive-stage Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06719336 | STONE-001 | P3 | not yet recruiting | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) |
| NCT04487756 | VENEZO-LUNG | P1/P2 | completed | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer |
| NCT04373369 | — | P2 | terminated | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer |
Gastric Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03421288 | DANTE | P2 | active not recruiting | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness |
| NCT04661150 | — | P2 | active not recruiting | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction |
| NCT06098898 | — | Early P1 | unknown | Safety and Efficacy of NK510 to Treat Gastric Cancer |
NSCLC Stage IV (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04467723 | — | P1/P2 | recruiting | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC |
| NCT04549428 | — | P2 | terminated | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC |
| NCT03713944 | — | P2 | terminated | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer |
Carcinoma, Small Cell Lung (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04253145 | — | P1/P2 | unknown | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. |
| NCT04622228 | Match | P2 | completed | Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer |
| NCT04308785 | — | P2 | terminated | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer |
Pancreatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04820179 | — | P2 | active not recruiting | Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer |
| NCT04161755 | — | P1 | active not recruiting | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery |
| NCT02705196 | — | P1/P2 | completed | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer |
Prostate Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04751929 | — | P2 | active not recruiting | Abemaciclib With or Without Atezolizumab for mCRPC |
| NCT04812366 | GUNS | P2 | recruiting | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer |
| NCT04272645 | — | P2 | withdrawn | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer |
Esophageal Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04540211 | SKYSCRAPER-08 | P3 | completed | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma |
| NCT05007613 | — | P2 | completed | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
| NCT03818997 | DYNAMIC | P2 | withdrawn | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer |
Acute Myeloid Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03922477 | — | P1 | terminated | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia |
| NCT03154827 | AML | P1/P2 | terminated | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) |
| NCT02892318 | AML | P1 | completed | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) |
Multiple Myeloma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04045028 | PK | P1 | terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT03312530 | — | P1/P2 | completed | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma |
| NCT02431208 | MM | P1 | completed | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) |
Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02220842 | MPDL3280A | P1 | completed | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma |
| NCT03465891 | — | P2 | terminated | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma |
| NCT02729896 | FL | P1/P2 | completed | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Treatment-Refractory Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07170592 | — | P1 | not yet recruiting | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients |
| NCT07190833 | — | P1 | recruiting | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) |
Hepato Cellular Carcinoma (HCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07461675 | — | P3 | not yet recruiting | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection |
| NCT07276100 | — | P2 | recruiting | Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab |
Extensive Stage Small Cell Lung Cancer (ES-SCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07113691 | TIARA | P1 | recruiting | Iadademstat + SBRT With Atezo in ES-SCLC |
| NCT06663098 | CARRY-ON | P2 | recruiting | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
Resectable Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07018947 | ASPIRE | P2 | not yet recruiting | Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC |
| NCT04721132 | — | P2 | active not recruiting | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer |
Glioblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07263438 | Phenix | P2 | recruiting | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial |
| NCT03174197 | — | P1/P2 | completed | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma |
HCC (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06823375 | — | P2 | recruiting | SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis |
| NCT06584071 | — | P1/P2 | not yet recruiting | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC |
Solid Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06771622 | — | P1/P2 | active not recruiting | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors |
| NCT03721679 | — | P1/P2 | terminated | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 |
Extensive-stage Small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06712355 | — | P3 | recruiting | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer |
| NCT06807632 | — | P1 | recruiting | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer |
Triple Negative Breast Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06067061 | neoBREASTIM | P1/P2 | terminated | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer |
| NCT03371017 | IMpassion132 | P3 | completed | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer |
Chronic Lymphocytic Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06043674 | — | P2 | recruiting | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation |
| NCT02846623 | — | P2 | active not recruiting | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome |
NSCLC (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05798663 | — | P2 | active not recruiting | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC |
| NCT06097962 | — | Early P1 | recruiting | Safety and Efficacy of NK510 to Treat NSCLC |
Head and Neck Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05483400 | TIRACAN | P2 | recruiting | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors |
| NCT03818061 | ATHENA | P2 | completed | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck |
Early-stage Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05332561 | COGNITION-GUIDE | P2 | recruiting | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) |
| NCT03894007 | PREDIXIIHER2 | P2 | terminated | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer |
Platinum-Resistant Fallopian Tube Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05538091 | — | P2 | recruiting | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
| NCT03206047 | — | P1/P2 | completed | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Squamous Cell Carcinoma of the Head and Neck (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03946358 | VolATIL | P2 | completed | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) |
| NCT05459129 | — | P1/P2 | completed | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) |
Colon Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05482516 | MRD-GI | P3 | recruiting | Evaluating Novel Therapies in ctDNA Positive GI Cancers |
| NCT02912559 | — | P3 | active not recruiting | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
Malignant Pleural Mesothelioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05765084 | Immuno-MESODEC | P1/P2 | recruiting | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma |
| NCT04480372 | ORIGIN | P2 | completed | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II |
Advanced Breast Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05092373 | TTF | P1 | recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax |
| NCT05238831 | ACT | Early P1 | withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial |
Locally Advanced Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05377034 | STRATUM | P2 | recruiting | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients |
| NCT05168163 | — | P2 | recruiting | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer |
Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05450562 | — | P1/P2 | terminated | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors |
| NCT03637764 | SAR650984 | P1/P2 | terminated | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies |
Locally Advanced Bladder Urothelial Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04637594 | IMAGINE | P3 | active not recruiting | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy |
| NCT03237780 | — | P2 | active not recruiting | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
Rectal Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05009069 | — | P2 | active not recruiting | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer |
| NCT03127007 | R-IMMUNE | P1/P2 | completed | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer |
Colorectal Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05141721 | — | P2/P3 | active not recruiting | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
| NCT03698461 | CLIMB | P2 | completed | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab |
Large Cell Neuroendocrine Carcinoma of the Lung (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05470595 | LCNEC-ALPINE | P2 | active not recruiting | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung |
| NCT06049966 | LANCE | P1 | completed | Atezolizumab in Large Cell Neuroendocrine Carcinoma |
Small-Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04471727 | — | P1/P2 | active not recruiting | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) |
| NCT05091567 | IMforte | P3 | active not recruiting | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer |
Biliary Tract Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05052099 | COMBATBIL | P1/P2 | completed | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer |
| NCT04677504 | — | P2 | completed | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer |
Follicular Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04962126 | FLUORO | P2 | active not recruiting | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy |
| NCT03276468 | — | P2 | completed | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas |
Anatomic Stage IV Breast Cancer AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03853707 | — | P1/P2 | completed | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer |
| NCT04639245 | — | P1/P2 | terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer |
Non-Small Cell Lung Cancer (NSCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04832854 | — | P2 | terminated | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer |
| NCT03559647 | — | N/A | completed | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy |
Metastatic Triple Negative Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04739670 | BELLA | P2 | unknown | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer |
| NCT03256344 | — | P1 | completed | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases |
Triple-negative Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04770272 | neoMono | P2 | terminated | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy |
| NCT03197935 | IMpassion031 | P3 | completed | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
Metastatic Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04446117 | CONTACT-02 | P3 | active not recruiting | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC |
| NCT04262154 | — | P2 | active not recruiting | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer |
Clinical Stage III Cutaneous Melanoma AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04356729 | — | P2 | active not recruiting | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma |
| NCT03554083 | — | P2 | completed | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma |
Carcinoma, Renal Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04338269 | CONTACT-03 | P3 | terminated | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment |
| NCT02543645 | — | P1 | terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer |
Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03548428 | Stereosarc | P2 | recruiting | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) |
| NCT02609984 | — | P2 | terminated | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) |
Metastatic Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04109456 | — | P1 | completed | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma |
| NCT03625141 | — | P2 | completed | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases |
Malignant Glioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04160494 | — | P1 | active not recruiting | D2C7-IT With Atezolizumab for Recurrent Gliomas |
| NCT03973879 | — | P1/P2 | withdrawn | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma |
Sarcoma,Soft Tissue (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03474094 | RT-Immune | P2 | active not recruiting | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy |
| NCT04216953 | COTESARC | P1/P2 | completed | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma |
Anatomic Stage III Breast Cancer AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02849496 | — | P2 | active not recruiting | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer |
| NCT04249167 | — | Early P1 | withdrawn | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
NSCLC Stage IIIB (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04042558 | GFPC 06-2018 | P2 | completed | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies |
| NCT03647956 | — | P2 | unknown | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors |
Cervical Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03738228 | — | P1 | completed | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer |
| NCT02921269 | — | P2 | completed | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer |
Recurrent Ovarian Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03353831 | — | P3 | completed | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer |
| NCT03598270 | ANITA | P3 | completed | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer |
Metastatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03693014 | — | P2 | active not recruiting | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors |
| NCT03024437 | — | P1/P2 | terminated | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma |
HER2-positive Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03125928 | — | P2 | active not recruiting | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer |
| NCT03650348 | — | P1 | completed | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors |
Lymphoma, Non-Hodgkin (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02693535 | TAPUR | P2 | recruiting | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
| NCT03369964 | — | P1 | withdrawn | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
Carcinoma, Transitional Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02451423 | — | P2 | completed | Neoadjuvant Atezolizumab in Localized Bladder Cancer |
| NCT02450331 | IMvigor010 | P3 | terminated | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection |
Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02458638 | — | P2 | completed | A Study of Atezolizumab in Advanced Solid Tumors |
| NCT01375842 | — | P1 | completed | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors |
Solid Cancers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02323191 | — | P1 | completed | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors |
| NCT02174172 | — | P1 | completed | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors |
Small Cell Lung Cancer ( SCLC ) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07339059 | — | P2 | recruiting | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer |
Osteosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06492954 | AflacST2301 | P1 | recruiting | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma |
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07407933 | — | P1/P2 | recruiting | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors |
Advanced Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06908993 | COMET | P3 | recruiting | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated |
Extensive Stage Lung Small Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07172412 | — | P2 | not yet recruiting | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer |
Resectable Hepatocellular Carcinoma With High Risk of Recurrence (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07239245 | ATTACH | P2 | recruiting | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo |
Locally Advanced Alveolar Soft Part Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06066138 | — | P1 | recruiting | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing |
Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07049848 | SATURN-STS | P2 | recruiting | SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma |
Microsatellite Stable Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06603818 | MSS | P2 | withdrawn | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) |
Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05690048 | FLORA | P2 | recruiting | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) |
Lung Cancer, Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07284121 | — | N/A | recruiting | A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice |
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06971237 | IMSIRT | N/A | not yet recruiting | SIRT and Peri-immunotherapy : a New Concept |
Small Cell Carcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06830694 | AMG757 | P2 | recruiting | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment |
Recurrent Glioblastoma, IDH-Wildtype (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06328036 | — | P2 | withdrawn | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma |
Advanced Solid Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06760481 | TIGER | P1 | active not recruiting | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) |
Microsatellite Stable (MSS) Colorectal Cancer (CRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06784947 | — | P2 | active not recruiting | Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer |
Extensive-Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06646276 | TIGOS | P3 | recruiting | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). |
Metastatic Cancer Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06713798 | INDIGO | P2 | withdrawn | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
Solid Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06488716 | — | P1 | terminated | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors |
Resectable Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06632327 | — | P3 | recruiting | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer |
Advanced Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06439485 | — | P1/P2 | recruiting | Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion |
Advanced Non-squamous Non-small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06463665 | VIRO-25 | P2 | recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
Cancer-Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06537310 | — | P1 | active not recruiting | A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors |
Lung Cancer, Small Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06780826 | — | N/A | recruiting | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy |
Small Cell Carcinoma of the Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06161532 | SMART | P2 | recruiting | Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... |
Extensive Stage-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06362252 | — | P1/P2 | recruiting | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) |
Metastatic Microsatellite-stable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06012734 | CoLBAt | P1 | recruiting | LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients |
Non-small Cell Lung Cancer(NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06332755 | LB-LR1109 | P1 | recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC |
HPV-Related Cervical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06099418 | — | P2 | withdrawn | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. |
Small Cell Lung Carcinoma (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06077500 | DAREONᵀᴹ-8 | P1 | active not recruiting | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06179069 | — | P1 | recruiting | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer |
PIK3CA-Mutated Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06496568 | — | P1 | active not recruiting | A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers |
Advanced Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06157827 | — | P1/P2 | recruiting | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma |
Clinical Stage I Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05836584 | GEJ | P2 | active not recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer |
Non-Small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05689671 | ANTELOPE | P4 | active not recruiting | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
Recurrent Liver Cancer After Liver Transplantation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05833126 | — | P2 | unknown | Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation |
Locally Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06031441 | — | P1 | recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
Oropharynx Cancer, Stage I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06254911 | — | P2 | suspended | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma |
Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05770102 | DETERMINE | P2/P3 | recruiting | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition |
Adenocarcinoma, Pancreatic Ductal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05968326 | IMCODE003 | P2 | recruiting | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC |
Bladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05564416 | — | P2 | withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial |
Advanced Rare Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05715281 | — | P2 | active not recruiting | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial |
Oncology (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06031233 | MINUTE | P4 | recruiting | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06390059 | EF-39 PANOVA-4 | P2 | completed | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma |
Metastatic Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06006286 | — | P1/P2 | withdrawn | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma |
Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05510427 | — | P1 | withdrawn | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification |
Lung Cancer, Nonsmall Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04691817 | — | P1/P2 | recruiting | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy |
Refractory Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05733611 | — | P2 | terminated | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
PD-L1-selected Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05661578 | SKYSCRAPER-11 | P2 | completed | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors |
Locally Advanced Osteosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05019703 | — | P2 | recruiting | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study |
Urothelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05645692 | — | P2 | active not recruiting | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer |
Metastatic Papillary Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05411081 | — | P2 | active not recruiting | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial |
Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05717400 | — | P4 | terminated | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy |
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05063552 | — | P2/P3 | active not recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers |
Haematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05722886 | DETERMINE | P2/P3 | recruiting | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol |
Relapsed or Refractory Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05300282 | FIL_A-BEGEV | P1/P2 | recruiting | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients |
Metastatic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05394337 | — | P1/P2 | recruiting | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma |
Idiopathic Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05515627 | — | P1 | active not recruiting | Atezolizumab for Idiopathic Pulmonary Fibrosis |
Squamous Cell Carcinoma of the Anal Canal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05661188 | TIRANUS | P2 | recruiting | Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) |
BCLC Stage B Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05327738 | — | P2 | withdrawn | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma |
Combined Hepatocellular Carcinoma and Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05211323 | — | P2 | active not recruiting | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer |
Metastatic Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05259319 | IMMUNOs-SBRT | P1 | unknown | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) |
Atypical Teratoid/Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05286801 | — | P1/P2 | active not recruiting | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
Stage II Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05060003 | — | P2 | terminated | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection |
Refractory Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05468359 | — | P1/P2 | recruiting | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients |
Glioblastoma Multiforme (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05423210 | — | Early P1 | recruiting | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme |
Locally Advanced or Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05581004 | — | P1 | recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors |
SCLC,Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05595460 | — | P1 | active not recruiting | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC |
Advanced Alveolar Soft Part Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05333458 | — | P2 | recruiting | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial |
Brain Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317858 | LIMITLESS | P3 | recruiting | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets |
Advanced Extrapulmonary Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05058651 | — | P2/P3 | recruiting | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung |
Small Cell Neuroendocrine Carcinoma of Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05312671 | — | P2 | recruiting | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer |
Hereditary Leiomyomatosis and Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04981509 | — | P2 | recruiting | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer |
Colorectal Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05243862 | — | P2 | active not recruiting | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. |
Colonic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05456165 | — | P2 | withdrawn | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer |
Non-Hodgkin Lymphoma, Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05315713 | — | P1/P2 | terminated | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma |
Intrahepatic Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05174650 | — | P2 | active not recruiting | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements |
Locally Advanced Skin Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05085496 | — | P1 | recruiting | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC |
Peritoneal Malignant Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05001880 | — | P2 | recruiting | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma |
Diffuse Astrocytoma, IDH-Wildtype (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04729959 | — | P2 | active not recruiting | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma |
Castration-Resistant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05168618 | AtezoCab | P2 | recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer |
Gastric and Gastroesophageal Junction Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05251948 | — | P1/P2 | terminated | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma |
Unresectable Gastrointestinal Stromal Tumor (GIST) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05152472 | ATEZOGIST | P2 | recruiting | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments |
Non-squamous Non-small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04958811 | — | P2 | active not recruiting | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC |
Metastatic Distal Bile Duct Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04941287 | — | P2 | active not recruiting | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer |
Mesotheliomas Pleural (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04996017 | AtezoMeso | P3 | recruiting | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) |
Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05159245 | FINPROVE | P2 | recruiting | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs |
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05110781 | — | P2 | terminated | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site |
Bile Duct Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05000294 | — | P1/P2 | recruiting | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
Anal Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07280377 | GOBLET | P1/P2 | active not recruiting | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
Metastatic or Locally Advanced Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04551521 | CRAFT | P2 | completed | CRAFT: The NCT-PMO-1602 Phase II Trial |
Locally Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04975958 | — | P1 | completed | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors |
Premenopausal HR+/HER2- Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04819243 | Young-PALETTA | P2 | recruiting | PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study |
Stomach Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04933227 | GEJ | P2 | terminated | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) |
Ovarian Endometrioid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04510584 | — | P2 | withdrawn | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer |
Carcinoma, Non-Small Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04611776 | CATHAYA | P2 | withdrawn | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer |
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04802759 | — | P1/P2 | recruiting | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
Cutaneous Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04710498 | — | P2 | completed | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma |
Urogenital Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04624399 | ABACUS-2 | P2 | recruiting | Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer |
Lung Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04776447 | APOLO | P2 | active not recruiting | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) |
Muscle-invasive Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04660344 | IMvigor011 | P3 | active not recruiting | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy |
Venous Thrombosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04649489 | TALENTOP | P3 | active not recruiting | A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev |
Advanced Bladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04902040 | — | P1/P2 | terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies |
Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04817956 | IMPRESS-N | P2 | recruiting | Improving Public Cancer Care by Implementing Precision Medicine in Norway |
Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04739202 | IMMUNOGAST | P2 | completed | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) |
Chronic Phase-Chronic Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04793399 | — | P1/P2 | terminated | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients |
Head and Neck Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04477759 | DEHART | P1 | completed | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer |
Advanced Unresectable or Metastatic Solid Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04632992 | MyTACTIC | P2 | completed | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response |
NSCLC Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04865250 | iReP | P2 | recruiting | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC |
Locally Advanced or Metastatic Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04602078 | AUREA | P2 | completed | Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma |
Advanced Liver Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04524871 | MORPHEUS-LIVER | P1/P2 | recruiting | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) |
Central Chondrosarcoma, Grade 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04458922 | — | P2 | active not recruiting | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma |
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04245085 | ABC-lung | P2 | completed | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma |
Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04543617 | SKYSCRAPER-07 | P3 | active not recruiting | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy |
Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04020809 | — | P1 | active not recruiting | Neoadjuvant Atezolizumab in Cutaneous Melanoma |
Malignant Pleural Mesothelioma, Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03786419 | — | P2 | withdrawn | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma |
Rare Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04423185 | — | P2 | recruiting | PLATFORM Study of Precision Medicine for Rare Tumors |
Advanced Malignant Skin Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04387084 | — | P1 | active not recruiting | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy |
Carcinoma, Thymic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04321330 | — | P2 | completed | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma |
Castration-Resistant Prostatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04404140 | — | P1 | terminated | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). |
NSCLC Stage IIIB~IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04147351 | — | P2 | completed | A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. |
Non-small-cell Lung Cancer Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03896074 | BEAT | P2 | active not recruiting | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) |
Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04214418 | MEKiAUTO | P1/P2 | terminated | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies |
Metastatic Esophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04166721 | — | P1/P2 | active not recruiting | WaKING: Wnt and checKpoint INhibition in Gastric Cancer |
Invasive Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04134000 | BladderGATE | P1 | unknown | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) |
Adult Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04084951 | — | P1 | completed | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors |
SCLC, Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04221529 | SPACE | P2 | completed | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide |
Lung Neoplasm Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04059887 | BUDDY | P4 | completed | Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] |
Metastatic Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04167137 | — | P1 | terminated | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants |
Tumor, Solid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04196530 | EIK1001 | P1 | completed | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab |
Breast Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05609903 | Anastase | N/A | completed | Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer |
Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03979066 | NEOiPANC | P2 | terminated | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma |
Prostate Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03821246 | — | P2 | recruiting | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy |
Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04017455 | TARZAN | P2 | active not recruiting | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) |
CLL Transformation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04082897 | MOLTO | P2 | active not recruiting | ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation |
Stage III Hepatocellular Carcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03942328 | — | P1/P2 | recruiting | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer |
Refractory Lung Non-Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04081688 | — | P1 | terminated | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC |
Limited Stage Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03811002 | MPDL3280A | P3 | active not recruiting | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) |
Non Small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03977194 | ELDERLY | P3 | active not recruiting | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
Recurrent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03892525 | — | P1 | terminated | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma |
Acute Myeloid Leukemia (AML) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03730012 | FLT3 | P1/P2 | completed | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) |
Advanced Bladder Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03513952 | — | P2 | completed | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma |
Bladder Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03775265 | — | P3 | active not recruiting | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer |
Select Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03973333 | — | P1/P2 | withdrawn | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab |
Urothelial/Bladder Cancer, Nos (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03359239 | — | P1 | completed | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer |
Pleural Mesothelioma Malignant Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03762018 | BEAT-meso | P3 | completed | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma |
Metastatic Breast Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03199885 | — | P3 | terminated | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer |
Neoplasm Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03845166 | STELLAR-001 | P1 | active not recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
Advanced Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03830918 | — | P1/P2 | active not recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy |
Clinical Stage II Esophageal Adenocarcinoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03784326 | — | P2 | active not recruiting | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma |
Mesothelioma, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03654833 | MiST | P2 | unknown | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma |
OVARIAN CANCER (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03695380 | — | P1 | completed | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer |
Penile Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03686332 | PERICLES | P2 | completed | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study |
Carcinoma of the Cervix, Stage IVB (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03556839 | BEATcc | P3 | completed | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix |
Lymphoma, T-Cell, Cutaneous (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03357224 | PARCT | P2 | terminated | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
Recurrent Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03321643 | — | P1 | active not recruiting | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma |
Invasive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03595592 | APTneo | P3 | active not recruiting | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer |
NHL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03463057 | HO151DLBCL | P2 | active not recruiting | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL |
Locally Advanced Cervical Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03612791 | ATEZOLACC | P2 | completed | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab |
Mesothelin Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03455556 | — | P1 | terminated | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer |
Metastatic Castration-Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03568656 | — | P1/P2 | completed | Study to Evaluate CCS1477 in Advanced Tumours |
Biphasic Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03228537 | — | P1 | active not recruiting | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma |
Cancer of Unknown Primary Site (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03498521 | CUPISCO | P2 | completed | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site |
Stage III Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03566485 | — | P1/P2 | terminated | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer |
Non-small Cell Lung Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03526900 | ATEZO-BRAIN | P2 | completed | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis |
HPV-Associated Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03618953 | Kingfisher | P1 | terminated | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers |
HER2-positive Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03417544 | — | P2 | active not recruiting | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC |
Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03422523 | ARGO | P2 | terminated | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy |
Non-Hodgkins Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03533283 | — | P1/P2 | active not recruiting | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
Glioblastoma, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03158389 | N²M² | P1/P2 | completed | NCT Neuro Master Match - N²M² (NOA-20) |
Safety Issues (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03620435 | — | P2 | unknown | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer |
Stage I Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02599454 | — | P1 | completed | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer |
Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03456063 | — | P3 | completed | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) |
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03452137 | IMvoke010 | P3 | terminated | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Stomach Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03448835 | PANDA | P2 | active not recruiting | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) |
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03386721 | — | P2 | terminated | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors |
Gallbladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03201458 | — | P2 | completed | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer |
Small Cell Lung Cancer Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03262454 | Atezolizumab | P2 | unknown | Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC |
Metastatic Colorectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02997228 | — | P3 | active not recruiting | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study |
Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03280563 | MORPHEUS HR+BC | P1/P2 | completed | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer |
Advanced BRAFV600 Wild-type Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03273153 | — | P3 | terminated | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma |
MSI (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02982694 | — | P2 | terminated | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer |
Advanced Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03292172 | — | P1 | terminated | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer |
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03281369 | — | P1/P2 | completed | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) |
Cholangiocarcinoma Non-resectable (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03267940 | CIS | P1 | terminated | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma |
Recurrent Breast Inflammatory Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03202316 | — | P2 | active not recruiting | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer |
Recurrent Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02919449 | — | P1 | terminated | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab |
Invasive Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02883062 | — | P2 | active not recruiting | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer |
Metastatic Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03181100 | — | P2 | active not recruiting | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer |
Advanced Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03014648 | NSCLC | P2 | completed | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) |
Metastatic Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02873195 | — | P2 | completed | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer |
Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03193190 | — | P1/P2 | completed | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) |
Esophageal Cancer, Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03087864 | PERFECT | P2 | completed | PDL-1 Targeting in Resectable Oesophageal Cancer |
Fallopian Tube High Grade Serous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02839707 | — | P2/P3 | active not recruiting | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
BRAF V600 Wild Type (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03175432 | — | P2 | active not recruiting | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases |
Metastatic Kidney Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03050060 | — | P2 | terminated | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer |
Cancer, Breast (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03164993 | ALICE | P2 | completed | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer |
Advanced Gynecological Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03073525 | — | P2 | completed | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers |
Hematopoietic and Lymphoid Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02862275 | — | P1 | active not recruiting | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer |
Gynecologic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03101280 | — | P1 | completed | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer |
Metastatic Alveolar Soft Part Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03141684 | — | P2 | active not recruiting | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma |
Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03120676 | — | P2 | terminated | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma |
Skin Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03108131 | — | P2 | completed | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors |
Recurrent Bladder Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02844816 | — | P2 | completed | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
Appendix Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03074513 | — | P2 | active not recruiting | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
Asymptomatic Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02784483 | — | P1 | terminated | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma |
Prostate Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03024216 | — | P1 | completed | Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer |
Prostatic Neoplasms, Castration-Resistant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03016312 | IMbassador250 | P3 | completed | A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen |
Ovarian Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02659384 | — | P2 | completed | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer |
Nonsmall Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02994576 | PRINCEPS | P2 | completed | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer |
Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03115801 | — | P2 | terminated | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers |
Urinary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02928406 | — | P3 | completed | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract |
Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02992912 | SABR-PDL1 | P2 | unknown | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours |
Chronic Myelomonocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02935361 | — | P1/P2 | active not recruiting | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed |
Refractory Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02926833 | ZUMA-6 | P1/P2 | completed | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Castrate-Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02814669 | ATZ | P1 | completed | Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor |
Advanced Non-Clear Cell Kidney Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02724878 | — | P2 | completed | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma |
Advanced/Metastatic Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02794571 | PK | P1 | completed | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors |
Breast Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02530489 | — | P2 | completed | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer |
Renal Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02655822 | — | P1 | completed | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers |
Lymphoma, Follicular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02631577 | — | P1/P2 | completed | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma |
HER2-Positive Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02605915 | — | P1 | completed | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer |
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02596971 | CHOP | P1/P2 | completed | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) |
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02594384 | LAM-002A/NHL | P1 | completed | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma |
Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02508870 | — | P1 | completed | A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes |
Lymphocytic Leukemia, Chronic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02500407 | NHL | P1/P2 | completed | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) |
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02409342 | MPDL3280A | P3 | completed | A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] |
Squamous Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02367794 | NSCLC | P3 | completed | A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] |
Carcinoma, Non-Squamous Non-Small Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02367781 | IMpower130 | P3 | completed | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
NSCLC (Non-small Cell Lung Carcinoma) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02298153 | — | P1 | terminated | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma |
Non-Squamous Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02008227 | OAK | P3 | completed | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy |
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01810913 | — | P2/P3 | recruiting | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer |
Neoplasm Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00781612 | — | P2 | active not recruiting | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies |
Atezolizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MINUTE | NCT06031233 | P4 | recruiting | Oncology | 776 | — |
| ANTELOPE | NCT05689671 | P4 | active not recruiting | Non-Small Cell Lung Cancer Metastatic | 136 | PMID 32620471 |
| BUDDY | NCT04059887 | P4 | completed | Lung Neoplasm Malignant | 100 | PMID 30013197 |
| TAIL | NCT03285763 | P4 | completed | Carcinoma, Non-Small-Cell Lung | 619 | PMID 33737339 |
| Astefania | NCT04873362 | P3 | active not recruiting | Breast Cancer | 1,188 | PMID 36382554 |
| UmbrellaMAX | NCT05862285 | P3 | recruiting | Cancer | 100 | — |
| TIGOS | NCT06646276 | P3 | recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | — |
| IMAGINE | NCT04637594 | P3 | active not recruiting | Locally Advanced Bladder Urothelial Carcinoma | 3 | — |
| ARTEMIDE-HCC01 | NCT06921785 | P3 | recruiting | Hepatocellular Carcinoma | 1,220 | — |
| AtezoMeso | NCT04996017 | P3 | recruiting | Mesotheliomas Pleural | 162 | — |
| AtezoTRIBE2 | NCT06733038 | P3 | recruiting | Colorectal Cancer | 238 | — |
| MPDL3280A | NCT03811002 | P3 | active not recruiting | Limited Stage Lung Small Cell Carcinoma | 544 | PMID 36006678 |
| MRD-GI | NCT05482516 | P3 | recruiting | Colon Adenocarcinoma | 20 | — |
| STONE-001 | NCT06719336 | P3 | not yet recruiting | Extensive-stage Small Cell Lung Cancer | 182 | — |
| ALBAN | NCT03799835 | P3 | active not recruiting | Bladder Cancer | 517 | — |
| COMET | NCT06908993 | P3 | recruiting | Advanced Non Small Cell Lung Cancer | 133 | — |
| IMbrella B | NCT03768063 | P3 | active not recruiting | Cancer | 1,000 | — |
| TALENTOP | NCT04649489 | P3 | active not recruiting | Venous Thrombosis | 501 | — |
| LIMITLESS | NCT05317858 | P3 | recruiting | Brain Tumor | 30 | — |
| MPDL3280A | NCT02486718 | P3 | active not recruiting | Non-Small Cell Lung Cancer | 1,280 | PMID 37903590 |
| TACE | NCT04803994 | P3 | recruiting | Hepatocellular Carcinoma | 434 | — |
| MK-7684A | NCT05224141 | P3 | active not recruiting | Small Cell Lung Carcinoma | 460 | PMID 39230120 |
| SKYSCRAPER-07 | NCT04543617 | P3 | active not recruiting | Esophageal Squamous Cell Carcinoma | 760 | — |
| APTneo | NCT03595592 | P3 | active not recruiting | Invasive Breast Cancer | 650 | — |
| STELLAR-303 | NCT05425940 | P3 | active not recruiting | Colorectal Cancer | 901 | PMID 39041200 |
| ELDERLY | NCT03977194 | P3 | active not recruiting | Non Small Cell Lung Cancer Metastatic | 510 | PMID 21831418 |
| CONTACT-02 | NCT04446117 | P3 | active not recruiting | Metastatic Prostate Cancer | 575 | PMID 40523369 |
| IMvigor011 | NCT04660344 | P3 | active not recruiting | Muscle-invasive Bladder Cancer | 761 | PMID 41124204 |
| SKYSCRAPER-14 | NCT05904886 | P3 | active not recruiting | Hepatocellular Carcinoma | 687 | PMID 38861301 |
| IMforte | NCT05091567 | P3 | active not recruiting | Small-Cell Lung Cancer | 660 | PMID 40473449 |
| COSMIC-312 | NCT03755791 | P3 | active not recruiting | Hepatocellular Carcinoma | 837 | PMID 38364832 |
| IMbrave251 | NCT04770896 | P3 | active not recruiting | Unresectable Hepatocellular Carcinoma | 557 | — |
| SKYSCRAPER-02C | NCT04665856 | P3 | active not recruiting | Small Cell Lung Carcinoma | 123 | — |
| IMbrave050 | NCT04102098 | P3 | active not recruiting | Carcinoma, Hepatocellular | 668 | PMID 41580093 |
| AMBITION | NCT04732598 | P3 | completed | Breast Cancer | 281 | — |
| SKYSCRAPER-01 | NCT04294810 | P3 | completed | Non-Small Cell Lung Cancer | 620 | — |
| SKYSCRAPER-15 | NCT06267001 | P3 | terminated | Non-small Cell Lung Cancer (NSCLC) | 56 | — |
| BEATcc | NCT03556839 | P3 | completed | Carcinoma of the Cervix, Stage IVB | 410 | PMID 40968753 |
| SKYSCRAPER-08 | NCT04540211 | P3 | completed | Esophageal Cancer | 461 | PMID 41449151 |
| SKYSCRAPER-03 | NCT04513925 | P3 | completed | Non-small Cell Lung Cancer (NSCLC) | 829 | — |
| SKYSCRAPER-02 | NCT04256421 | P3 | completed | Small Cell Lung Cancer | 490 | PMID 37976444 |
| CONTACT-03 | NCT04338269 | P3 | terminated | Carcinoma, Renal Cell | 522 | PMID 35304832 |
| AtTEnd | NCT03603184 | P3 | completed | Endometrial Cancer | 549 | PMID 40590326 |
| CONTACT-01 | NCT04471428 | P3 | completed | Carcinoma, Non-Small-Cell Lung | 366 | PMID 38552197 |
| EL1SSAR | NCT04148911 | P3 | completed | Triple-Negative Breast Cancer | 184 | — |
| BEAT-meso | NCT03762018 | P3 | completed | Pleural Mesothelioma Malignant Advanced | 400 | PMID 33358660 |
| IMpassion132 | NCT03371017 | P3 | completed | Triple Negative Breast Neoplasms | 595 | — |
| AMETHISTA | NCT04487067 | P3 | completed | Carcinoma, Hepatocellular | 152 | PMID 39874903 |
| ANITA | NCT03598270 | P3 | completed | Recurrent Ovarian Carcinoma | 417 | PMID 33318079 |
| KATE3 | NCT04740918 | P3 | terminated | Metastatic Breast Cancer | 96 | — |
| IMvoke010 | NCT03452137 | P3 | terminated | Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 406 | PMID 40079944 |
| ATALANTE | NCT02891824 | P3 | completed | Ovarian Cancer | 614 | PMID 37643382 |
| IMvigor130 | NCT02807636 | P3 | completed | Urothelial Carcinoma | 1,213 | PMID 37954037 |
| IPSOS | NCT03191786 | P3 | completed | Non-Small Cell Lung Cancer | 453 | PMID 37423228 |
| IMpassion050 | NCT03726879 | P3 | completed | Breast Cancer | 454 | PMID 35763704 |
| IMpassion030 | NCT03498716 | P3 | terminated | Triple Negative Breast Cancer | 2,199 | PMID 39883436 |
| MAURIS | NCT04028050 | P3 | completed | Small Cell Lung Carcinoma | 155 | PMID 38377176 |
| IMpassion131 | NCT03125902 | P3 | completed | Triple-Negative Breast Cancer | 653 | PMID 34219000 |
| IMpower210 | NCT02813785 | P3 | completed | Carcinoma, Non-Small-Cell Lung | 565 | — |
| IMbassador250 | NCT03016312 | P3 | completed | Prostatic Neoplasms, Castration-Resistant | 759 | PMID 35013615 |
| NSCLC | NCT02657434 | P3 | completed | Non-Small Cell Lung Cancer | 578 | PMID 35511917 |
| IMmotion010 | NCT03024996 | P3 | terminated | Renal Cell Carcinoma | 778 | PMID 36099926 |
| IMbrave150 | NCT03434379 | P3 | completed | Carcinoma, Hepatocellular | 558 | PMID 40891895 |
| IMpassion031 | NCT03197935 | P3 | completed | Triple-negative Breast Cancer | 333 | PMID 32966830 |
| IMagyn050 | NCT03038100 | P3 | completed | Ovarian Cancer | 1,301 | PMID 37625235 |
| IMpower133 | NCT02763579 | P3 | completed | Small Cell Lung Carcinoma | 503 | PMID 31466854 |
| IMvigor010 | NCT02450331 | P3 | terminated | Carcinoma, Transitional Cell | 809 | PMID 37601688 |
| MPDL3280A | NCT02409342 | P3 | completed | Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | 572 | PMID 39532375 |
| IMmotion151 | NCT02420821 | P3 | completed | Renal Cell Carcinoma | 915 | PMID 31079938 |
| NSCLC | NCT02367794 | P3 | completed | Squamous Non-Small Cell Lung Cancer | 1,021 | — |
| IMpower130 | NCT02367781 | P3 | completed | Carcinoma, Non-Squamous Non-Small Cell Lung | 723 | PMID 31122901 |
| IMpower150 | NCT02366143 | P3 | completed | Carcinoma, Non-Small-Cell Lung | 1,202 | PMID 40379995 |
| OAK | NCT02008227 | P3 | completed | Non-Squamous Non-Small Cell Lung Cancer | 1,225 | PMID 37004206 |
| NSCLC | NCT02409355 | P3 | terminated | Non-Small Cell Lung Cancer | 8 | — |
| IMPRESS-N | NCT04817956 | P2 | recruiting | Cancer Metastatic | 3,000 | PMID 35568909 |
| ATHENEA | NCT07153445 | P2 | recruiting | Non Small Cell Lung Cancer | 97 | — |
| TAPISTRY | NCT04589845 | P2 | active not recruiting | Solid Tumors | 920 | PMID 40086048 |
| SEZanne | NCT07155174 | P2 | recruiting | Small Cell Lung Cancer | 180 | — |
| PhotonAB | NCT06339424 | P2 | recruiting | Hepatocellular Carcinoma | 45 | — |
| AB-LATE02 | NCT04727307 | P2 | recruiting | Hepatocellular Carcinoma | 202 | — |
| Stereosarc | NCT03548428 | P2 | recruiting | Sarcoma | 103 | PMID 32967883 |
| IMCODE003 | NCT05968326 | P2 | recruiting | Adenocarcinoma, Pancreatic Ductal | 260 | — |
| Phenix | NCT07263438 | P2 | recruiting | Glioblastoma | 59 | — |
| COGNITION-GUIDE | NCT05332561 | P2 | recruiting | Early-stage Breast Cancer | 240 | — |
| Triple-B | NCT01898117 | P2 | active not recruiting | Breast Cancer | 304 | PMID 33084020 |
| ASPIRE | NCT07018947 | P2 | not yet recruiting | Resectable Hepatocellular Carcinoma | 90 | — |
| ATTACH | NCT07239245 | P2 | recruiting | Resectable Hepatocellular Carcinoma With High Risk of Recurrence | 30 | — |
| TOMBOLA | NCT04138628 | P2 | active not recruiting | Bladder Cancer | 154 | — |
| ProtonAB | NCT06133062 | P2 | recruiting | Hepatocellular Carcinoma Non-resectable | 45 | — |
| NAUTIKA1 | NCT04302025 | P2 | recruiting | Non-small Cell Lung Cancer | 99 | — |
| ProTarget | NCT04341181 | P2 | recruiting | Cancer | 300 | PMID 36814246 |
| TONIC-3 | NCT06342037 | P2 | recruiting | Metastatic Breast Cancer | 60 | — |
| TERTIO | NCT05528952 | P2 | recruiting | Hepatocellular Carcinoma | 105 | PMID 37516867 |
| SATURN-STS | NCT07049848 | P2 | recruiting | Soft Tissue Sarcoma | 50 | — |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| IMperator | NCT06331598 | P2 | withdrawn | Solid Tumors | 0 | — |
| ECTOP-1030 | NCT06572722 | P2 | withdrawn | Lung Cancer | 0 | — |
| VIRO-25 | NCT06463665 | P2 | recruiting | Advanced Non-squamous Non-small-cell Lung Cancer | 142 | — |
| CARRY-ON | NCT06663098 | P2 | recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 142 | PMID 23890065 |
| BladderSpar | NCT03697850 | P2 | active not recruiting | Bladder Cancer | 79 | — |
| FASTIMMUNE | NCT05703997 | P2 | not yet recruiting | Small Cell Lung Carcinoma | 20 | PMID 34789537 |
| LCNEC-ALPINE | NCT05470595 | P2 | active not recruiting | Large Cell Neuroendocrine Carcinoma of the Lung | 67 | — |
| TAPUR | NCT02693535 | P2 | recruiting | Lymphoma, Non-Hodgkin | 4,200 | PMID 36753688 |
| SMART | NCT06161532 | P2 | recruiting | Small Cell Carcinoma of the Bladder | 60 | PMID 40548513 |
| MoST-TAP | NCT06003621 | P2 | recruiting | Solid Tumor, Adult | 96 | — |
| Cabatezo-1 | NCT05859217 | P2 | not yet recruiting | Lung Cancer | 40 | — |
| TIRANUS | NCT05661188 | P2 | recruiting | Squamous Cell Carcinoma of the Anal Canal | 45 | — |
| BOUQUET | NCT04931342 | P2 | active not recruiting | Ovarian Cancer | 176 | — |
| FLORA | NCT05690048 | P2 | recruiting | Immunotherapy | 48 | PMID 40930564 |
| STRATUM | NCT05377034 | P2 | recruiting | Locally Advanced Hepatocellular Carcinoma | 100 | — |
| (HCC) | NCT06789757 | P2 | recruiting | Hepatocellular Carcinoma | 19 | PMID 31954490 |
| MOAB | NCT06069726 | P2 | recruiting | Recurrent Glioblastoma | 80 | — |
| Young-PALETTA | NCT04819243 | P2 | recruiting | Premenopausal HR+/HER2- Metastatic Breast Cancer | 178 | — |
| AGADIR | NCT03915678 | P2 | recruiting | Solid Tumor, Adult | 247 | — |
| DANTE | NCT03421288 | P2 | active not recruiting | Gastric Cancer | 677 | PMID 37963317 |
| DRUP | NCT02925234 | P2 | recruiting | Cancer | 1,550 | PMID 37424386 |
| Kirros | NCT06096779 | P2 | recruiting | Hepatocellular Carcinoma | 30 | — |
| ASPRIA | NCT04434040 | P2 | recruiting | Breast Cancer | 40 | — |
| APOLO | NCT04776447 | P2 | active not recruiting | Lung Diseases | 38 | — |
| GEJ | NCT05836584 | P2 | active not recruiting | Clinical Stage I Gastric Cancer AJCC v8 | 240 | — |
| ATEZOGIST | NCT05152472 | P2 | recruiting | Unresectable Gastrointestinal Stromal Tumor (GIST) | 110 | — |
| CAPTIV-8 | NCT04273061 | P2 | recruiting | Breast Cancer | 200 | PMID 31011208 |
| TIRACAN | NCT05483400 | P2 | recruiting | Head and Neck Neoplasms | 97 | — |
| ATREZZO | NCT04759248 | P2 | active not recruiting | Breast Cancer | 55 | — |
| AMG757 | NCT06830694 | P2 | recruiting | Small Cell Carcinoma of Lung | 50 | — |
| NEO-TIM | NCT04722575 | P2 | active not recruiting | Melanoma | 95 | — |
| BEAT | NCT03896074 | P2 | active not recruiting | Non-small-cell Lung Cancer Patients | 206 | — |
| ANTONIO | NCT05118724 | P2 | active not recruiting | Colorectal Cancer | 80 | — |
| ACHILES | NCT03540420 | P2 | active not recruiting | Small-cell Lung Cancer | 212 | — |
| EMPHASIS | NCT05516628 | P2 | recruiting | Hepatocellular Carcinoma | 30 | — |
| AZALEA | NCT06690840 | P2 | recruiting | Triple Negative Breast Cancer | 45 | — |
| AtezoCab | NCT05168618 | P2 | recruiting | Castration-Resistant Prostate Carcinoma | 33 | — |
| HO151DLBCL | NCT03463057 | P2 | active not recruiting | NHL | 109 | PMID 40249860 |
| MOLTO | NCT04082897 | P2 | active not recruiting | CLL Transformation | 28 | PMID 39270702 |
| iReP | NCT04865250 | P2 | recruiting | NSCLC Stage II | 20 | — |
| RT-Immune | NCT03474094 | P2 | active not recruiting | Sarcoma,Soft Tissue | 62 | — |
| BoB | NCT03767075 | P2 | recruiting | Advanced Solid Tumor | 1,000 | — |
| FINPROVE | NCT05159245 | P2 | recruiting | Advanced Cancer | 250 | — |
| OCSCC | NCT05681039 | P2 | active not recruiting | Squamous Cell Carcinoma | 29 | — |
| PANDA | NCT03448835 | P2 | active not recruiting | Stomach Cancer | 20 | PMID 38191613 |
| INTEGRATE | NCT04563338 | P2 | active not recruiting | Hepatocellular Carcinoma | 36 | — |
| BARBICAN | NCT05498896 | P2 | active not recruiting | Triple Negative Breast Cancer | 146 | — |
| ADAPTABLE | NCT05781308 | P2 | active not recruiting | Non Small Cell Lung Cancer | 156 | — |
| IMMUNOGAST | NCT04739202 | P2 | completed | Gastric Adenocarcinoma | 54 | — |
| ABACUS-2 | NCT04624399 | P2 | recruiting | Urogenital Cancer | 58 | — |
| DYNAMIC | NCT04954339 | P2 | completed | Hepatocellular Carcinoma | 40 | PMID 28130846 |
| RAN | NCT05007769 | P2 | withdrawn | Non-small Cell Lung Cancer | 0 | — |
| GUNS | NCT04812366 | P2 | recruiting | Prostate Cancer | 315 | — |
| ALERT-HCC | NCT05992220 | P2 | recruiting | Hepatocellular Carcinoma | 138 | — |
| NSCLC | NCT04367311 | P2 | active not recruiting | Lung Cancer | 100 | — |
| EndoBARR | NCT03694262 | P2 | completed | Endometrial Cancer | 30 | PMID 28403786 |
| CATHAYA | NCT04611776 | P2 | withdrawn | Carcinoma, Non-Small Cell Lung | 0 | — |
| ABATE | NCT04289779 | P2 | active not recruiting | Bladder Cancer | 46 | — |
| SKYSCRAPER-11 | NCT05661578 | P2 | completed | PD-L1-selected Solid Tumors | 64 | — |
| EF-39 PANOVA-4 | NCT06390059 | P2 | completed | Metastatic Pancreatic Ductal Adenocarcinoma | 84 | — |
| NSCLC | NCT05746481 | P2 | terminated | Non-small Cell Lung Cancer | 3 | — |
| AB7 | NCT04829383 | P2 | active not recruiting | Unresectable Hepatocellular Carcinoma | 50 | — |
| BELLA | NCT04739670 | P2 | unknown | Metastatic Triple Negative Breast Cancer | 31 | — |
| INDIGO | NCT06713798 | P2 | withdrawn | Metastatic Cancer Lung | 0 | — |
| TARZAN | NCT04017455 | P2 | active not recruiting | Rectal Cancer | 38 | — |
| SKYSCRAPER-09 | NCT04665843 | P2 | completed | Squamous Cell Carcinoma of Head and Neck | 123 | — |
| MSS | NCT06603818 | P2 | withdrawn | Microsatellite Stable Metastatic Colorectal Cancer | 0 | — |
| FLUORO | NCT04962126 | P2 | active not recruiting | Follicular Lymphoma | 15 | PMID 41949430 |
| ROME | NCT04591431 | P2 | unknown | Breast Cancer | 400 | PMID 41963505 |
| BEACON | NCT03363867 | P2 | unknown | Ovarian Cancer | 30 | — |
| LOST-B | NCT05537402 | P2 | terminated | Hepatocellular Carcinoma | 1 | — |
| ATEZOLACC | NCT03612791 | P2 | completed | Locally Advanced Cervical Cancer | 189 | — |
| SPACE | NCT04221529 | P2 | completed | SCLC, Extensive Stage | 70 | — |
| GFPC 06-2018 | NCT04042558 | P2 | completed | NSCLC Stage IIIB | 150 | PMID 36801605 |
| DEMAND | NCT04224636 | P2 | recruiting | Hepatocellular Carcinoma Non-resectable | 106 | PMID 35081747 |
| ATELIER | NCT03340558 | P2 | withdrawn | Metastatic Colorectal Cancer | 0 | — |
| SKYSCRAPER-04 | NCT04300647 | P2 | completed | Cervical Cancer | 172 | PMID 38858106 |
| AURORA | NCT05038657 | P2 | unknown | Squamous Cell Carcinoma | 36 | PMID 37726695 |
| ATHENA | NCT03818061 | P2 | completed | Head and Neck Neoplasms | 33 | — |
| CRAFT | NCT04551521 | P2 | completed | Metastatic or Locally Advanced Malignancies | 72 | PMID 34808524 |
| BIS-Program | NCT05180006 | P2 | terminated | Breast Cancer | 33 | — |
| CUPISCO | NCT03498521 | P2 | completed | Cancer of Unknown Primary Site | 529 | PMID 39096924 |
| VolATIL | NCT03946358 | P2 | completed | Squamous Cell Carcinoma of the Head and Neck | 47 | PMID 35928870 |
| MEGALiT | NCT04185831 | P2 | active not recruiting | Solid Tumor | 167 | — |
| SIRTCI | NCT04659382 | P2 | unknown | Metastatic Colorectal Cancer | 52 | PMID 28781171 |
| SABR-PDL1 | NCT02992912 | P2 | unknown | Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) | 138 | PMID 38519913 |
| TELMA | NCT03836066 | P2 | completed | Non Small Cell Lung Cancer | 41 | PMID 36520426 |
| neoMono | NCT04770272 | P2 | terminated | Triple-negative Breast Cancer | 442 | PMID 24562447 |
| TREASURE | NCT04462276 | P2 | completed | Small Cell Lung Cancer Extensive Stage | 68 | PMID 36153496 |
| Atezolizumab | NCT03262454 | P2 | unknown | Small Cell Lung Cancer Recurrent | 35 | — |
| ABC-lung | NCT04245085 | P2 | completed | EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | 95 | PMID 40023017 |
| Match | NCT04622228 | P2 | completed | Carcinoma, Small Cell Lung | 56 | — |
| CeLEBrATE | NCT04730999 | P2 | completed | Small Cell Lung Cancer | 54 | PMID 19934295 |
| RamAtezo-1 | NCT03689855 | P2 | completed | Non-small Cell Lung Cancer | 21 | PMID 34409776 |
| ORIGIN | NCT04480372 | P2 | completed | Malignant Pleural Mesothelioma | 68 | — |
| ImmunoCobiVem | NCT02902029 | P2 | completed | Malignant Melanoma | 186 | — |
| PIONEER | NCT04939480 | P2 | completed | Squamous Cell Carcinoma of Head and Neck | 20 | — |
| ABE-LIVER | NCT05448677 | P2 | terminated | Hepatocellular Carcinoma | 3 | — |
| MyTACTIC | NCT04632992 | P2 | completed | Advanced Unresectable or Metastatic Solid Malignancy | 252 | PMID 41392942 |
| CHANCE | NCT03976518 | P2 | completed | Non-Small Cell Lung Cancer | 43 | PMID 28840008 |
| AUREA | NCT04602078 | P2 | completed | Locally Advanced or Metastatic Urothelial Carcinoma | 82 | — |
| CHEERS | NCT03511391 | P2 | completed | Urothelial Carcinoma | 99 | PMID 37410476 |
| SKYROCKET | NCT05034055 | P2 | unknown | Non-small Cell Lung Cancer | 45 | — |
| ARIANES | NCT04276376 | P2 | terminated | Solid Tumor | 130 | — |
| ATRACTIB | NCT04408118 | P2 | completed | Metastatic Breast Cancer | 100 | PMID 40467896 |
| GEJ | NCT04933227 | P2 | terminated | Stomach Neoplasms | 29 | — |
| MiST | NCT03654833 | P2 | unknown | Mesothelioma, Malignant | 186 | PMID 35157829 |
| CLIMB | NCT03698461 | P2 | completed | Colorectal Neoplasms | 20 | — |
| ALICE | NCT03164993 | P2 | completed | Cancer, Breast | 68 | PMID 36482103 |
| PERICLES | NCT03686332 | P2 | completed | Penile Cancer | 32 | PMID 37487169 |
| NSCLC | NCT02927301 | P2 | completed | Non-Small Cell Lung Cancer | 181 | PMID 36097216 |
| MARIO-3 | NCT03961698 | P2 | unknown | Breast Cancer | 91 | — |
| AtezoTRIBE | NCT03721653 | P2 | completed | Metastatic Colorectal Cancer | 218 | PMID 38865678 |
| ECLIPSE | NCT03395899 | P2 | completed | Breast Cancer | 71 | — |
| HCC | NCT04541173 | P2 | terminated | Hepatocellular Carcinoma | 6 | — |
| AZTEC | NCT03464942 | P2 | completed | Breast Cancer | 54 | — |
| PRINCEPS | NCT02994576 | P2 | completed | Nonsmall Cell Lung Cancer | 60 | — |
| TARA | NCT04690855 | P2 | terminated | Breast Cancer | 1 | — |
| SCLC | NCT04610684 | P2 | terminated | Small-cell Lung Cancer | 3 | — |
| ATEZO-BRAIN | NCT03526900 | P2 | completed | Non-small Cell Lung Cancer Stage IV | 40 | PMID 37603816 |
| PARCT | NCT03357224 | P2 | terminated | Lymphoma, T-Cell, Cutaneous | 26 | — |
| GELATO | NCT03147040 | P2 | terminated | Breast Cancer | 23 | PMID 37038006 |
| DYNAMIC | NCT03818997 | P2 | withdrawn | Esophageal Cancer | 0 | — |
| NSCLC | NCT03014648 | P2 | completed | Advanced Non-small Cell Lung Cancer | 28 | — |
| VinMetAtezo | NCT03801304 | P2 | completed | Non-small Cell Lung Cancer | 80 | PMID 31894704 |
| ARGO | NCT03422523 | P2 | terminated | Diffuse Large B Cell Lymphoma | 53 | — |
| PREDIXIIHER2 | NCT03894007 | P2 | terminated | Early-stage Breast Cancer | 6 | — |
| CONTESSA TRIO | NCT03952325 | P2 | terminated | Breast Cancer | 294 | — |
| MODUL | NCT02291289 | P2 | completed | Colorectal Cancer | 1,044 | PMID 36921494 |
| COM-IT-1 | NCT03644823 | P2 | terminated | Non-small Cell Lung Cancer | 21 | — |
| G1T28 | NCT03041311 | P2 | completed | Small Cell Lung Cancer | 107 | PMID 34777341 |
| NEO-VC | NCT02303951 | P2 | terminated | Malignant Melanoma | 47 | PMID 36648215 |
| KATE2 | NCT02924883 | P2 | completed | Metastatic Breast Cancer | 202 | PMID 33002436 |
| NEOiPANC | NCT03979066 | P2 | terminated | Pancreatic Ductal Adenocarcinoma | 1 | — |
| PERFECT | NCT03087864 | P2 | completed | Esophageal Cancer, Stage II | 40 | PMID 30902915 |
| B-F1RST | NCT02848651 | P2 | completed | Non-Small Cell Lung Cancer | 153 | PMID 35422531 |
| BIRCH | NCT02031458 | P2 | completed | Non-Small Cell Lung Cancer | 667 | PMID 38367405 |
| IMmotion150 | NCT01984242 | P2 | completed | Renal Cell Carcinoma | 305 | PMID 32233107 |
| PD-L1 | NCT01846416 | P2 | completed | Non-Small Cell Lung Cancer | 138 | — |
Terminated and withdrawn Atezolizumab trials (144)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04989283withdrawnTesting the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
- NCT06331598withdrawnA Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
- NCT06572722withdrawnPerioperative Immunotherapy for NSCLC (ECTOP-1030)
- NCT05109052withdrawnTrial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
- NCT05935774withdrawnOT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
- NCT06099418withdrawnEfficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
- NCT05327738withdrawnYttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
- NCT06254911suspendedPre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
- NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
- NCT05007769withdrawnRamucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- NCT04611776withdrawnA Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
- NCT06939036terminatedStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
- NCT05450562terminatedDose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
- NCT06267001terminatedA Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- NCT03337698terminatedA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- NCT05746481terminatedTiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- NCT06488716terminatedA Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- NCT03520686terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- NCT04303858terminatedA Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
- NCT04267237withdrawnA Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
- NCT06713798withdrawnTargeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
- NCT05251948terminatedAn Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- NCT05733611terminatedRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
- NCT06603818withdrawnImmunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
- NCT04373369terminatedVorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- NCT06762808withdrawnPhase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
- NCT06328036withdrawnTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
- NCT05109442terminatedStudy to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
- NCT05537402terminatedLOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
- NCT04549428terminatedAtezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
- NCT06719973withdrawnPhase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- NCT06067061terminated"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
- NCT03199885terminatedTesting the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- NCT04911166terminatedPhase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
- NCT04338269terminatedA Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
- NCT04832854terminatedA Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
- NCT03340558withdrawnAtezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
- NCT04902040terminatedPlinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- NCT04630210withdrawnInvestigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity
- NCT05180006terminatedImpact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- NCT05776875terminatedAtezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
- NCT04432207terminatedA Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
- NCT03829501terminatedA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
- NCT04770272terminatedStudy to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
- NCT04984811terminatedNT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
- NCT05717400terminatedImproving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- NCT04512430terminatedNeo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
- NCT06416436withdrawnDose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
- NCT05694013terminatedClinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
- NCT03024437terminatedAtezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
- NCT04740918terminatedA Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- NCT04101357terminatedSafety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
- NCT04081688terminatedAtezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
- NCT04732286terminatedA Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
- NCT05191797terminatedBomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
- NCT03866239terminatedA Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
- NCT05448677terminatedEzurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
- NCT03452137terminatedA Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- NCT03973879withdrawnCombination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
- NCT03693573withdrawnA Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
- NCT04642365terminatedA Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
- NCT05564416withdrawnTesting Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
- NCT04923776terminatedLiver Directed RT + Chemo-immunotherapy for ES-SCLC
- NCT04276376terminatedEfficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- NCT05060003terminatedTiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
- NCT04933227terminatedA Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- NCT06006286withdrawnA Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
- NCT03973333withdrawnSafety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
- NCT03901573terminatedHigh-Risk Skin Cancers With Atezolizumab Plus NT-I7
- NCT03498716terminatedA Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- NCT05395052terminatedFT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- NCT05510427withdrawnPhase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- NCT04308785terminatedA Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- NCT05315713terminatedAn Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT04541173terminatedStudy of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- NCT04099836terminatedAtezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
- NCT06090318withdrawnMilademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
- NCT05110781terminatedAtezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
- NCT04322643terminatedIntermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- NCT04471415terminatedStudy to Investigate DRP-104 in Adults With Advanced Solid Tumors
- NCT04045028terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT04510584withdrawnMaintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
- NCT04801966terminatedSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- NCT04690855terminatedA Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
- NCT03024996terminatedA Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- NCT04272645withdrawnAbemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
- NCT04404140terminatedA Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- NCT05093608terminatedSELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
- NCT03555149terminatedA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- NCT04610684terminatedChemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
- NCT05456165withdrawnStudy of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- NCT03138889terminatedBempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
- NCT03357224terminatedPARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
- NCT04639245terminatedGenetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
- NCT04214418terminatedStudy of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
- NCT03147040terminatedAssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer
- NCT02450331terminatedA Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
- NCT03737123terminatedTrial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- NCT03637764terminatedSafety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
- NCT03818997withdrawnCombination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
- NCT04102618terminatedA Window-of-opportunity Study of Pelareorep in Early Breast Cancer
- NCT03272217terminatedAtezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
- NCT03498222withdrawnStudy in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
- NCT03386721terminatedBasket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
- NCT03713944terminatedCarboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
- NCT04167137terminatedSafety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
- NCT03422523terminatedAtezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
- NCT04249167withdrawnCryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
- NCT04793399terminatedSafety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
- NCT02322814terminatedA Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
- NCT03894007terminatedImproving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- NCT03952325terminatedTesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- NCT03892525terminatedStudy of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
- NCT03618953terminatedThis is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
- NCT03273153terminatedA Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
- NCT03721679terminatedPoly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
- NCT03644823terminatedCombinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
- NCT03566485terminatedAtezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
- NCT02982694terminatedStudy With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
- NCT04422210terminatedA Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- NCT03922477terminatedA Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
- NCT03115801terminatedA Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
- NCT02792192terminatedSafety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
- NCT03786419withdrawnA Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
- NCT03050060terminatedImage Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- NCT02303951terminatedNeoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
- NCT03154827terminatedSafety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
- NCT03455556terminatedAnetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
- NCT03465891terminatedStudy of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
- NCT03267940terminatedStudy of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
- NCT03979066terminatedStudy Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
- NCT03369964withdrawnA Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- NCT02541604terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
- NCT02784483terminatedPilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
- NCT03292172terminatedA Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
- NCT02609984terminatedStudy to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
- NCT03399643terminatedA Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
- NCT03120676terminatedStudy of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
- NCT03208712terminatedRadium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
- NCT03029832terminatedA Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
- NCT02919449terminatedDose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
- NCT02409355terminatedA Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- NCT02298153terminatedA Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
- NCT02543645terminatedA Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
All Atezolizumab trials (746)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04817956 | IMPRESS-N | Improving Public Cancer Care by Implementing Precision Medicine in Norway | P2 | recruiting | 3,000 | Oslo University Hospital | Apr 2021 |
| NCT05620771 | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | P2 | recruiting | 200 | Northwestern University | Nov 2022 | |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | P1/P2 | recruiting | 64 | St. Jude Children's Research Hospital | Nov 2022 | |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | P3 | recruiting | 400 | Boehringer Ingelheim | Jan 2026 | |
| NCT07153445 | ATHENEA | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) | P2 | recruiting | 97 | Fundación GECP | Jul 2025 |
| NCT07293468 | BIIRTH | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) | P2/P3 | recruiting | 106 | Tuen Mun Hospital | Apr 2024 |
| NCT04873362 | Astefania | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | P3 | active not recruiting | 1,188 | Hoffmann-La Roche | May 2021 |
| NCT06725121 | MacroTrans | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant | P1/P2 | recruiting | 48 | University Health Network, Toronto | Dec 2024 |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | P2/P3 | recruiting | 550 | Pfizer | Dec 2025 | |
| NCT05538091 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | P2 | recruiting | 48 | Ronald Buckanovich | May 2023 | |
| NCT05862285 | UmbrellaMAX | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | P3 | recruiting | 100 | Hoffmann-La Roche | Jun 2023 |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | recruiting | 70 | Christine Ryan | Jan 2024 | |
| NCT04589845 | TAPISTRY | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | P2 | active not recruiting | 920 | Hoffmann-La Roche | Jan 2021 |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | P1 | recruiting | 20 | Massachusetts General Hospital | Aug 2022 | |
| NCT07322341 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | P2 | not yet recruiting | 32 | University of Washington | Sep 2026 | |
| NCT07291076 | HCC | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | P1/P2 | recruiting | 198 | Bristol-Myers Squibb | Mar 2026 |
| NCT07155174 | SEZanne | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | recruiting | 180 | AbbVie | Nov 2025 |
| NCT06646276 | TIGOS | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | P3 | recruiting | 530 | Bristol-Myers Squibb | Feb 2025 |
| NCT06898957 | (DeLLphi-310) | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | P1 | active not recruiting | 29 | Amgen | May 2025 |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Sep 2021 | |
| NCT06339424 | PhotonAB | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | P2 | recruiting | 45 | Chang Gung Memorial Hospital | Mar 2024 |
| NCT04727307 | AB-LATE02 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial | P2 | recruiting | 202 | University Hospital, Montpellier | Feb 2021 |
| NCT03548428 | Stereosarc | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) | P2 | recruiting | 103 | Centre Antoine Lacassagne | Jun 2020 |
| NCT05968326 | IMCODE003 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | P2 | recruiting | 260 | Genentech, Inc. | Oct 2023 |
| NCT07170592 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients | P1 | not yet recruiting | 24 | Bionoxx Inc. | Jan 2027 | |
| NCT07190833 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) | P1 | recruiting | 27 | Bionoxx Inc. | Mar 2026 | |
| NCT07263438 | Phenix | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial | P2 | recruiting | 59 | Centre Hospitalier Universitaire Vaudois | Nov 2025 |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma | P3 | recruiting | 590 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Oct 2024 | |
| NCT05332561 | COGNITION-GUIDE | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | P2 | recruiting | 240 | German Cancer Research Center | Jun 2023 |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | P2 | active not recruiting | 40 | ImmunityBio, Inc. | Dec 2018 | |
| NCT01898117 | Triple-B | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer | P2 | active not recruiting | 304 | The Netherlands Cancer Institute | Jul 2013 |
| NCT07227597 | MK-6070 | A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) | P1/P2 | recruiting | 170 | Merck Sharp & Dohme LLC | Jan 2026 |
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | P2 | recruiting | 158 | Peking Union Medical College Hospital | Dec 2025 | |
| NCT07018947 | ASPIRE | Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC | P2 | not yet recruiting | 90 | Fundacion Clinic per a la Recerca Biomédica | Nov 2025 |
| NCT07239245 | ATTACH | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo | P2 | recruiting | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Nov 2025 |
| NCT04138628 | TOMBOLA | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | P2 | active not recruiting | 154 | Jørgen Bjerggaard Jensen | Mar 2020 |
| NCT06109272 | LIVIGNO-2 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | P2/P3 | recruiting | 660 | AbbVie | Jan 2024 |
| NCT06133062 | ProtonAB | Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | P2 | recruiting | 45 | Chang Gung Memorial Hospital | Nov 2023 |
| NCT04637594 | IMAGINE | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | P3 | active not recruiting | 3 | Alliance for Clinical Trials in Oncology | May 2022 |
| NCT03424005 | Morpheus-panBC | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | P1/P2 | recruiting | 792 | Hoffmann-La Roche | Mar 2018 |
| NCT06760481 | TIGER | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) | P1 | active not recruiting | 7 | M.D. Anderson Cancer Center | Apr 2025 |
| NCT04929223 | INTRINSIC | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | P1 | recruiting | 542 | Hoffmann-La Roche | Oct 2021 |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | P3 | not yet recruiting | 740 | Tempest Therapeutics | Dec 2025 | |
| NCT04630730 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | P2 | active not recruiting | 46 | Swiss Cancer Institute | Jun 2022 | |
| NCT04302025 | NAUTIKA1 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | P2 | recruiting | 99 | Genentech, Inc. | Nov 2020 |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | P3 | recruiting | 1,100 | Alliance for Clinical Trials in Oncology | Dec 2024 | |
| NCT04341181 | ProTarget | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | P2 | recruiting | 300 | Ulrik Lassen | Aug 2020 |
| NCT00781612 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | P2 | active not recruiting | 720 | Genentech, Inc. | Oct 2008 | |
| NCT05300282 | FIL_A-BEGEV | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients | P1/P2 | recruiting | 122 | Fondazione Italiana Linfomi - ETS | Feb 2023 |
| NCT06342037 | TONIC-3 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial | P2 | recruiting | 60 | The Netherlands Cancer Institute | Jun 2024 |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | P1/P2 | active not recruiting | 86 | National Cancer Institute (NCI) | Nov 2022 | |
| NCT06921785 | ARTEMIDE-HCC01 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | P3 | recruiting | 1,220 | AstraZeneca | May 2025 |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | P3 | active not recruiting | 382 | Hoffmann-La Roche | Sep 2017 | |
| NCT05528952 | TERTIO | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | P2 | recruiting | 105 | Centre Hospitalier Universitaire de Besancon | Sep 2022 |
| NCT06439485 | Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | P1/P2 | recruiting | 25 | M.D. Anderson Cancer Center | Nov 2024 | |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | P1 | not yet recruiting | 20 | Washington University School of Medicine | Jul 2026 | |
| NCT07113691 | TIARA | Iadademstat + SBRT With Atezo in ES-SCLC | P1 | recruiting | 15 | Yale University | Jan 2026 |
| NCT07049848 | SATURN-STS | SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma | P2 | recruiting | 50 | M.D. Anderson Cancer Center | Sep 2025 |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | P3 | not yet recruiting | 30 | University of Geneva, Switzerland | Mar 2026 | |
| NCT07281664 | Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma | N/A | not yet recruiting | 30 | Third Affiliated Hospital, Sun Yat-Sen University | Jan 2026 | |
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | P2 | recruiting | 35 | Bindu R Potugari | Jun 2026 | |
| NCT05770102 | DETERMINE | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | P2/P3 | recruiting | 30 | Cancer Research UK | Oct 2023 |
| NCT05722886 | DETERMINE | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | P2/P3 | recruiting | 825 | Cancer Research UK | Mar 2023 |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | P2 | recruiting | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2022 | |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | P3 | not yet recruiting | 336 | National Cancer Institute (NCI) | Jun 2026 | |
| NCT06331598 | IMperator | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) | P2 | withdrawn | 0 | Hoffmann-La Roche | Nov 2024 |
| NCT06572722 | ECTOP-1030 | Perioperative Immunotherapy for NSCLC (ECTOP-1030) | P2 | withdrawn | 0 | Fudan University | Sep 2024 |
| NCT07543510 | Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | N/A | not yet recruiting | 38 | Third Affiliated Hospital, Sun Yat-Sen University | May 2026 | |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Early P1 | recruiting | 12 | Stony Brook University | Oct 2022 | |
| NCT03942328 | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | P1/P2 | recruiting | 85 | Mayo Clinic | Sep 2019 | |
| NCT05984511 | TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | N/A | recruiting | 234 | Third Affiliated Hospital, Sun Yat-Sen University | Aug 2023 | |
| NCT06463665 | VIRO-25 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | P2 | recruiting | 142 | Genelux Corporation | Sep 2024 |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy | P3 | recruiting | 670 | Boehringer Ingelheim | Apr 2026 | |
| NCT06287775 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | P1/P2 | recruiting | 45 | National Cancer Institute (NCI) | Apr 2025 | |
| NCT06754501 | A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary | P2 | active not recruiting | 4 | M.D. Anderson Cancer Center | Apr 2025 | |
| NCT04996017 | AtezoMeso | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) | P3 | recruiting | 162 | Gruppo Oncologico Italiano di Ricerca Clinica | Dec 2021 |
| NCT06551142 | PanTumor-101 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | P1 | recruiting | 845 | GlaxoSmithKline | Sep 2024 |
| NCT06663098 | CARRY-ON | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). | P2 | recruiting | 142 | Gruppo Oncologico Italiano di Ricerca Clinica | Jan 2025 |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | P1/P2 | recruiting | 316 | Hoffmann-La Roche | Jun 2021 | |
| NCT06733038 | AtezoTRIBE2 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | P3 | recruiting | 238 | Gruppo Oncologico del Nord-Ovest | Nov 2024 |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | P3 | recruiting | 621 | BioNTech SE | Feb 2025 | |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | P1/P2 | active not recruiting | 24 | Novartis Pharmaceuticals | Jul 2022 | |
| NCT05546879 | Liver-NET1 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC | P1 | active not recruiting | 43 | University Hospital, Grenoble | Mar 2023 |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | P3 | recruiting | 226 | NRG Oncology | Feb 2026 | |
| NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 118 | MediLink Therapeutics (Suzhou) Co., Ltd. | Mar 2026 | |
| NCT03811002 | MPDL3280A | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | P3 | active not recruiting | 544 | National Cancer Institute (NCI) | Jul 2019 |
| NCT03697850 | BladderSpar | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | P2 | active not recruiting | 79 | UNICANCER | Dec 2018 |
| NCT04712643 | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | P3 | active not recruiting | 342 | Hoffmann-La Roche | Mar 2021 | |
| NCT05703997 | FASTIMMUNE | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | P2 | not yet recruiting | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Jan 2023 |
| NCT05470595 | LCNEC-ALPINE | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung | P2 | active not recruiting | 67 | Technische Universität Dresden | Jan 2022 |
| NCT07276100 | Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab | P2 | recruiting | 15 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Jan 2026 | |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | P1/P2 | active not recruiting | 500 | FBD Biologics Limited | Mar 2025 | |
| NCT07172412 | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | P2 | not yet recruiting | 165 | Tianjin Medical University Cancer Institute and Hospital | Nov 2025 | |
| NCT07284121 | A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice | — | recruiting | 700 | Hoffmann-La Roche | Jul 2025 | |
| NCT06031233 | MINUTE | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | P4 | recruiting | 776 | Isala | Sep 2023 |
| NCT05482516 | MRD-GI | Evaluating Novel Therapies in ctDNA Positive GI Cancers | P3 | recruiting | 20 | Georgetown University | Mar 2023 |
| NCT05394337 | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | P1/P2 | recruiting | 10 | M.D. Anderson Cancer Center | Feb 2023 | |
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | P1/P2 | withdrawn | 0 | University of Rochester | Sep 2022 | |
| NCT07280377 | GOBLET | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | P1/P2 | active not recruiting | 122 | Oncolytics Biotech | Oct 2021 |
| NCT02693535 | TAPUR | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | recruiting | 4,200 | American Society of Clinical Oncology | Mar 2016 |
| NCT04919382 | Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | P2 | recruiting | 56 | Dwight Owen | Jan 2022 | |
| NCT06719336 | STONE-001 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | P3 | not yet recruiting | 182 | Anhui Shi, MD | Dec 2024 |
| NCT06717243 | STRATUS | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | — | recruiting | 111 | Oncology Center of Biochemical Education And Research | Feb 2025 |
| NCT06161532 | SMART | Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... | P2 | recruiting | 60 | National Cancer Institute (NCI) | Aug 2024 |
| NCT06003621 | MoST-TAP | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients | P2 | recruiting | 96 | Omico | Dec 2023 |
| NCT03614949 | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | P2 | active not recruiting | 21 | H. Lee Moffitt Cancer Center and Research Institute | Jan 2019 | |
| NCT03799835 | ALBAN | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients | P3 | active not recruiting | 517 | UNICANCER | Jan 2019 |
| NCT05999812 | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | P2 | active not recruiting | 22 | University of Texas Southwestern Medical Center | Dec 2023 | |
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | P2/P3 | recruiting | 189 | National Cancer Institute (NCI) | Jun 2022 | |
| NCT05652686 | PT217 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | P1/P2 | recruiting | 203 | Phanes Therapeutics | Sep 2023 |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | P1/P2 | recruiting | 45 | University of Alabama at Birmingham | Jul 2025 | |
| NCT05361395 | ES-SCLC | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | P1 | active not recruiting | 184 | Amgen | Aug 2022 |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | P4 | recruiting | 40 | Icahn School of Medicine at Mount Sinai | Jun 2026 | |
| NCT06823375 | SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis | P2 | recruiting | 40 | Chinese University of Hong Kong | Jul 2025 | |
| NCT05935774 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | University of Washington | Dec 2023 | |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | P1 | recruiting | 58 | UNC Lineberger Comprehensive Cancer Center | Oct 2023 | |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | recruiting | 450 | Genentech, Inc. | Oct 2022 | |
| NCT06908993 | COMET | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | P3 | recruiting | 133 | Intergroupe Francophone de Cancerologie Thoracique | Dec 2025 |
| NCT03768063 | IMbrella B | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | P3 | active not recruiting | 1,000 | Hoffmann-La Roche | Feb 2019 |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | P2 | recruiting | 60 | Replimune, Inc. | Aug 2024 | |
| NCT04423185 | PLATFORM Study of Precision Medicine for Rare Tumors | P2 | recruiting | 770 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aug 2020 | |
| NCT07093762 | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | — | not yet recruiting | 35 | Fuzhou General Hospital | Aug 2025 | |
| NCT05859217 | Cabatezo-1 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | P2 | not yet recruiting | 40 | Jun Zhang, MD, PhD | Dec 2024 |
| NCT06110572 | TESSERACT | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | P1/P2 | recruiting | 18 | Vanderbilt-Ingram Cancer Center | Apr 2024 |
| NCT05661188 | TIRANUS | Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) | P2 | recruiting | 45 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Feb 2023 |
| NCT03708224 | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | P2 | recruiting | 55 | Alain Algazi | Mar 2019 | |
| NCT06784947 | Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer | P2 | active not recruiting | 13 | University of Colorado, Denver | Mar 2025 | |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | P1 | recruiting | 70 | Myeloid Therapeutics | Jul 2024 | |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | P2 | withdrawn | 0 | Nykode Therapeutics ASA | Apr 2024 | |
| NCT04931342 | BOUQUET | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | P2 | active not recruiting | 176 | Hoffmann-La Roche | Oct 2021 |
| NCT05690048 | FLORA | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) | P2 | recruiting | 48 | Michael Dill | Jul 2025 |
| NCT06332755 | LB-LR1109 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC | P1 | recruiting | 76 | LG Chem | Jun 2024 |
| NCT04649489 | TALENTOP | A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | P3 | active not recruiting | 501 | Jia Fan | Apr 2021 |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | P1 | recruiting | 30 | National Cancer Institute (NCI) | Nov 2025 | |
| NCT05377034 | STRATUM | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients | P2 | recruiting | 100 | National Cancer Centre, Singapore | Oct 2022 |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | P1/P2 | active not recruiting | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Dec 2020 | |
| NCT06789757 | (HCC) | The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) | P2 | recruiting | 19 | Inova Health Care Services | Feb 2025 |
| NCT06731270 | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | P2 | recruiting | 20 | Emory University | Apr 2025 | |
| NCT06069726 | MOAB | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | P2 | recruiting | 80 | Duke University | Mar 2024 |
| NCT06584071 | A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | P1/P2 | not yet recruiting | 140 | Biotheus Inc. | Dec 2024 | |
| NCT06444815 | STEALTH-001 | A Study of VET3-TGI in Patients With Solid Tumors | P1 | recruiting | 60 | KaliVir Immunotherapeutics | Sep 2024 |
| NCT06031441 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | recruiting | 250 | Genentech, Inc. | Nov 2023 | |
| NCT05019703 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | P2 | recruiting | 40 | M.D. Anderson Cancer Center | Apr 2023 | |
| NCT05340309 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | P2 | active not recruiting | 5 | University of Southern California | Dec 2022 | |
| NCT05468489 | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | P3 | active not recruiting | 200 | Shanghai Henlius Biotech | Nov 2022 | |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | P1/P2 | recruiting | 6 | M.D. Anderson Cancer Center | Sep 2022 | |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | P2 | recruiting | 65 | National Cancer Institute (NCI) | Jun 2022 | |
| NCT04819243 | Young-PALETTA | PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study | P2 | recruiting | 178 | Samsung Medical Center | Aug 2021 |
| NCT03915678 | AGADIR | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | P2 | recruiting | 247 | Institut Bergonié | Mar 2021 |
| NCT04721132 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | P2 | active not recruiting | 16 | M.D. Anderson Cancer Center | Feb 2021 | |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | P1 | active not recruiting | 498 | Genentech, Inc. | Jul 2020 | |
| NCT04160494 | D2C7-IT With Atezolizumab for Recurrent Gliomas | P1 | active not recruiting | 18 | Darell Bigner | Feb 2020 | |
| NCT03756298 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | P2 | active not recruiting | 284 | National Cancer Center, Korea | Jan 2019 | |
| NCT03421288 | DANTE | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | P2 | active not recruiting | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sep 2018 |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | P2 | active not recruiting | 37 | M.D. Anderson Cancer Center | Aug 2017 | |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | P2 | active not recruiting | 16 | Fox Chase Cancer Center | Jun 2017 | |
| NCT02935361 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | P1/P2 | active not recruiting | 33 | University of Southern California | Nov 2016 | |
| NCT02925234 | DRUP | The Drug Rediscovery Protocol (DRUP Trial) | P2 | recruiting | 1,550 | The Netherlands Cancer Institute | Aug 2016 |
| NCT06096779 | Kirros | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | P2 | recruiting | 30 | Genentech, Inc. | Jul 2024 |
| NCT04434040 | ASPRIA | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | P2 | recruiting | 40 | Dana-Farber Cancer Institute | Jul 2020 |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | P2/P3 | active not recruiting | 430 | National Cancer Institute (NCI) | Mar 2023 | |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | P1 | active not recruiting | 610 | Amgen | Dec 2019 | |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | P2 | withdrawn | 0 | OHSU Knight Cancer Institute | Dec 2022 | |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | P1 | recruiting | 24 | Dwight Owen | Dec 2024 | |
| NCT05317858 | LIMITLESS | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | P3 | recruiting | 30 | InSightec | Aug 2022 |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | P3 | active not recruiting | 1,550 | NSABP Foundation Inc | Dec 2017 | |
| NCT04776447 | APOLO | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | P2 | active not recruiting | 38 | Fundación GECP | Jun 2021 |
| NCT05836584 | GEJ | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | P2 | active not recruiting | 240 | National Cancer Institute (NCI) | Dec 2023 |
| NCT05765084 | Immuno-MESODEC | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | P1/P2 | recruiting | 15 | University Hospital, Antwerp | Feb 2023 |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | P4 | recruiting | 24 | The Methodist Hospital Research Institute | Jan 2023 | |
| NCT05152472 | ATEZOGIST | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | P2 | recruiting | 110 | Centre Leon Berard | Jan 2022 |
| NCT04486352 | EndoMAP | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | P1/P2 | recruiting | 148 | Alliance Foundation Trials, LLC. | Oct 2021 |
| NCT04273061 | CAPTIV-8 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | P2 | recruiting | 200 | British Columbia Cancer Agency | Jun 2020 |
| NCT05434234 | A Study of YL201 in Patients With Advanced Solid Tumors | P1/P2 | recruiting | 312 | MediLink Therapeutics (Suzhou) Co., Ltd. | May 2022 | |
| NCT05483400 | TIRACAN | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors | P2 | recruiting | 97 | University Medical Center Groningen | Oct 2023 |
| NCT04691817 | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | P1/P2 | recruiting | 28 | Abramson Cancer Center at Penn Medicine | Jul 2023 | |
| NCT04524871 | MORPHEUS-LIVER | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | P1/P2 | recruiting | 518 | Hoffmann-La Roche | Nov 2020 |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | P1 | active not recruiting | 914 | Exelixis | Sep 2017 | |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | P2 | active not recruiting | 133 | M.D. Anderson Cancer Center | Mar 2017 | |
| NCT05085496 | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC | P1 | recruiting | 12 | City of Hope Medical Center | Apr 2022 | |
| NCT05703971 | Acclaim-3 | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | P1/P2 | recruiting | 62 | Genprex, Inc. | May 2024 |
| NCT04467723 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | P1/P2 | recruiting | 25 | University of Kansas Medical Center | May 2022 | |
| NCT02486718 | MPDL3280A | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | P3 | active not recruiting | 1,280 | Hoffmann-La Roche | Oct 2015 |
| NCT05047250 | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer | P3 | active not recruiting | 60 | Hoffmann-La Roche | Jun 2022 | |
| NCT04387084 | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | P1 | active not recruiting | 10 | University of Southern California | Aug 2020 | |
| NCT06537310 | A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors | P1 | active not recruiting | 34 | Hoffmann-La Roche | Sep 2024 | |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | recruiting | 339 | Zai Lab (Shanghai) Co., Ltd. | Jan 2024 | |
| NCT05595460 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | P1 | active not recruiting | 21 | RayzeBio, Inc. | Oct 2022 | |
| NCT04803994 | TACE | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | P3 | recruiting | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Jul 2021 |
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Jul 2017 | |
| NCT05878691 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | P1 | active not recruiting | 320 | Glenmark Specialty S.A. | Jun 2022 | |
| NCT06496568 | A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers | P1 | active not recruiting | 30 | Hoffmann-La Roche | Dec 2023 | |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | P2 | active not recruiting | 200 | National Cancer Institute (NCI) | Mar 2023 | |
| NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | P2 | recruiting | 28 | Roswell Park Cancer Institute | Jul 2021 | |
| NCT04759248 | ATREZZO | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | P2 | active not recruiting | 55 | SOLTI Breast Cancer Research Group | Mar 2021 |
| NCT06492954 | AflacST2301 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma | P1 | recruiting | 12 | Emory University | Jul 2026 |
| NCT06830694 | AMG757 | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | P2 | recruiting | 50 | Se-Hoon Lee | May 2025 |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | recruiting | 300 | Peking Union Medical College Hospital | Feb 2025 | |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | P1/P2 | recruiting | 150 | Cancer Research UK | Jul 2023 | |
| NCT05797493 | PICASSO | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | — | recruiting | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Oct 2022 |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | P1/P2 | recruiting | 29 | University of Florida | Dec 2021 | |
| NCT05112965 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | P3 | active not recruiting | 49 | Hoffmann-La Roche | Dec 2021 | |
| NCT04722575 | NEO-TIM | Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma | P2 | active not recruiting | 95 | Fondazione Melanoma Onlus | Oct 2020 |
| NCT03321643 | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma | P1 | active not recruiting | 24 | National Cancer Institute (NCI) | Sep 2018 | |
| NCT03237780 | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | P2 | active not recruiting | 72 | National Cancer Institute (NCI) | Jul 2018 | |
| NCT04214262 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | P3 | active not recruiting | 415 | National Cancer Institute (NCI) | Aug 2020 | |
| NCT05224141 | MK-7684A | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | P3 | active not recruiting | 460 | Merck Sharp & Dohme LLC | Mar 2022 |
| NCT05825625 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | P2 | active not recruiting | 35 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | May 2023 | |
| NCT03775265 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | P3 | active not recruiting | 475 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT02997228 | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | P3 | active not recruiting | 120 | National Cancer Institute (NCI) | Jan 2018 | |
| NCT03896074 | BEAT | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | P2 | active not recruiting | 206 | Fondazione Ricerca Traslazionale | Mar 2020 |
| NCT04186013 | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | P2 | active not recruiting | 39 | Spanish Oncology Genito-Urinary Group | Sep 2019 | |
| NCT03845166 | STELLAR-001 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | P1 | active not recruiting | 325 | Exelixis | Mar 2019 |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P2/P3 | active not recruiting | 444 | National Cancer Institute (NCI) | Jun 2017 | |
| NCT05333458 | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial | P2 | recruiting | 27 | National Cancer Institute (NCI) | Aug 2022 | |
| NCT07235293 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | P2 | recruiting | 90 | Kahr Bio Australia Pty Ltd | Jan 2026 | |
| NCT05515627 | Atezolizumab for Idiopathic Pulmonary Fibrosis | P1 | active not recruiting | 24 | Cedars-Sinai Medical Center | Feb 2023 | |
| NCT05118724 | ANTONIO | Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin | P2 | active not recruiting | 80 | AIO-Studien-gGmbH | Dec 2021 |
| NCT05097911 | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | P1 | active not recruiting | 33 | National University Hospital, Singapore | Aug 2021 | |
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | P2/P3 | recruiting | 138 | National Cancer Institute (NCI) | Jan 2021 | |
| NCT03821246 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | P2 | recruiting | 68 | David Oh | Oct 2019 | |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Early P1 | active not recruiting | 20 | Massachusetts General Hospital | Jun 2021 | |
| NCT06077500 | DAREONᵀᴹ-8 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer | P1 | active not recruiting | 46 | Boehringer Ingelheim | Feb 2024 |
| NCT03540420 | ACHILES | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer | P2 | active not recruiting | 212 | Norwegian University of Science and Technology | Jul 2018 |
| NCT05516628 | EMPHASIS | Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma | P2 | recruiting | 30 | National Cancer Centre, Singapore | Feb 2023 |
| NCT05525858 | KOSMOSII | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | recruiting | 1,000 | Seoul National University Bundang Hospital | Sep 2022 |
| NCT05141721 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | P2/P3 | active not recruiting | 700 | Seattle Project Corporation | Feb 2022 | |
| NCT04543617 | SKYSCRAPER-07 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | P3 | active not recruiting | 760 | Hoffmann-La Roche | Sep 2020 |
| NCT03093922 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | P2 | active not recruiting | 32 | Memorial Sloan Kettering Cancer Center | Mar 2017 | |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | P1 | recruiting | 50 | Inimmune Corporation | Jul 2024 | |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | P1/P2 | recruiting | 178 | Nanjing Leads Biolabs Co.,Ltd | Dec 2023 | |
| NCT03595592 | APTneo | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | P3 | active not recruiting | 650 | Fondazione Michelangelo | Sep 2018 |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | P1/P2 | recruiting | 193 | Tvardi Therapeutics, Incorporated | Mar 2023 | |
| NCT07192185 | Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | P2 | recruiting | 30 | Sun Yat-sen University | Sep 2025 | |
| NCT06867432 | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | P2 | not yet recruiting | 20 | Tianjin Medical University Cancer Institute and Hospital | Mar 2025 | |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | Early P1 | recruiting | 10 | Huashan Hospital | Jan 2025 | |
| NCT02846623 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | P2 | active not recruiting | 50 | M.D. Anderson Cancer Center | Jan 2017 | |
| NCT06690840 | AZALEA | Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients | P2 | recruiting | 45 | European Institute of Oncology | Mar 2025 |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | P1/P2 | recruiting | 25 | Vanderbilt-Ingram Cancer Center | May 2023 | |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | P1 | recruiting | 24 | Memorial Sloan Kettering Cancer Center | Jan 2025 | |
| NCT04796012 | VITAS | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | P1/P2 | recruiting | 23 | University of Texas Southwestern Medical Center | Apr 2023 |
| NCT05425940 | STELLAR-303 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | P3 | active not recruiting | 901 | Exelixis | Sep 2022 |
| NCT05168618 | AtezoCab | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | P2 | recruiting | 33 | University of Utah | Mar 2022 |
| NCT04820179 | Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer | P2 | active not recruiting | 30 | University of Arizona | Oct 2021 | |
| NCT03463057 | HO151DLBCL | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL | P2 | active not recruiting | 109 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Aug 2018 |
| NCT04560972 | LB-100 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | P1 | active not recruiting | 3 | City of Hope Medical Center | May 2021 |
| NCT04334941 | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | P2 | active not recruiting | 103 | National Cancer Institute (NCI) | Jul 2020 | |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | P1/P2 | active not recruiting | 59 | Jonsson Comprehensive Cancer Center | Mar 2019 | |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | P2/P3 | recruiting | 613 | National Cancer Institute (NCI) | Mar 2013 | |
| NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | P1 | recruiting | 219 | Chugai Pharmaceutical | May 2023 | |
| NCT05645692 | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | P2 | active not recruiting | 204 | Hoffmann-La Roche | Apr 2023 | |
| NCT05488522 | SBRT With Atezo/Bev for HCC | P1 | recruiting | 18 | Abramson Cancer Center at Penn Medicine | Sep 2022 | |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | P2 | recruiting | 122 | Academic and Community Cancer Research United | May 2022 | |
| NCT04958811 | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | P2 | active not recruiting | 29 | Georgetown University | Dec 2021 | |
| NCT04919369 | ATRA | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | P1 | active not recruiting | 18 | Dwight Owen | Oct 2021 |
| NCT04180072 | Atezolizumab Plus Bevacizumab With HCC and HBV Infection | N/A | active not recruiting | 51 | National Health Research Institutes, Taiwan | Mar 2020 | |
| NCT04082897 | MOLTO | ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation | P2 | active not recruiting | 28 | Niguarda Hospital | Oct 2019 |
| NCT04006522 | 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | P2 | active not recruiting | 46 | James Brugarolas | Oct 2019 | |
| NCT03977194 | ELDERLY | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | P3 | active not recruiting | 510 | Intergroupe Francophone de Cancerologie Thoracique | Jul 2019 |
| NCT03784326 | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma | P2 | active not recruiting | 43 | M.D. Anderson Cancer Center | Feb 2019 | |
| NCT02989584 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | P1/P2 | active not recruiting | 54 | Memorial Sloan Kettering Cancer Center | Dec 2016 | |
| NCT06362252 | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | P1/P2 | recruiting | 123 | Daiichi Sankyo | Jul 2024 | |
| NCT04865250 | iReP | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC | P2 | recruiting | 20 | University Hospital Heidelberg | Jan 2021 |
| NCT03474094 | RT-Immune | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy | P2 | active not recruiting | 62 | Centre Leon Berard | Aug 2018 |
| NCT02912559 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | P3 | active not recruiting | 712 | National Cancer Institute (NCI) | Oct 2017 | |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | P2 | active not recruiting | 27 | National Cancer Institute (NCI) | Oct 2020 | |
| NCT06254911 | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma | P2 | suspended | 20 | Emory University | Oct 2023 | |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | P2 | recruiting | 37 | Regina Elena Cancer Institute | Dec 2021 | |
| NCT06117891 | REFINE-IO | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | active not recruiting | 300 | Bayer | Nov 2023 |
| NCT05798663 | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | P2 | active not recruiting | 178 | Alliance Foundation Trials, LLC. | Dec 2023 | |
| NCT03767075 | BoB | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | P2 | recruiting | 1,000 | Vall d'Hebron Institute of Oncology | Dec 2018 |
| NCT05159245 | FINPROVE | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | P2 | recruiting | 250 | Helsinki University Central Hospital | Dec 2021 |
| NCT05715281 | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | P2 | active not recruiting | 12 | National Cancer Institute (NCI) | Sep 2023 | |
| NCT02862275 | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | P1 | active not recruiting | 40 | National Cancer Institute (NCI) | May 2017 | |
| NCT04161755 | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery | P1 | active not recruiting | 29 | Memorial Sloan Kettering Cancer Center | Dec 2019 | |
| NCT05009069 | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | P2 | active not recruiting | 58 | Hoffmann-La Roche | Mar 2022 | |
| NCT05681039 | OCSCC | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | P2 | active not recruiting | 29 | M.D. Anderson Cancer Center | Jun 2023 |
| NCT05689671 | ANTELOPE | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | P4 | active not recruiting | 136 | Nikolaj Frost MD | Dec 2023 |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | P2 | active not recruiting | 69 | Memorial Sloan Kettering Cancer Center | Oct 2018 | |
| NCT03448835 | PANDA | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | P2 | active not recruiting | 20 | The Netherlands Cancer Institute | Mar 2018 |
| NCT03178552 | B-FAST | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | P2/P3 | active not recruiting | 1,000 | Hoffmann-La Roche | Sep 2017 |
| NCT03141684 | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | P2 | active not recruiting | 63 | National Cancer Institute (NCI) | Apr 2017 | |
| NCT04446117 | CONTACT-02 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | P3 | active not recruiting | 575 | Exelixis | Oct 2020 |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | P1/P2 | active not recruiting | 211 | Hoffmann-La Roche | May 2018 | |
| NCT03600701 | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | P2 | active not recruiting | 51 | National Cancer Institute (NCI) | Nov 2018 | |
| NCT04660344 | IMvigor011 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy | P3 | active not recruiting | 761 | Hoffmann-La Roche | May 2021 |
| NCT04020809 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | P1 | active not recruiting | 20 | The Methodist Hospital Research Institute | Sep 2020 | |
| NCT04262154 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | P2 | active not recruiting | 28 | Memorial Sloan Kettering Cancer Center | Mar 2020 | |
| NCT03526432 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | P2 | active not recruiting | 110 | University of Oklahoma | Aug 2018 | |
| NCT03228537 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | P1 | active not recruiting | 28 | National Cancer Institute (NCI) | Jul 2018 | |
| NCT02883062 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | P2 | active not recruiting | 67 | National Cancer Institute (NCI) | Aug 2017 | |
| NCT04729959 | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | P2 | active not recruiting | 59 | National Cancer Institute (NCI) | Mar 2022 | |
| NCT05904886 | SKYSCRAPER-14 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) | P3 | active not recruiting | 687 | Hoffmann-La Roche | Sep 2023 |
| NCT05092373 | TTF | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | P1 | recruiting | 43 | M.D. Anderson Cancer Center | Apr 2022 |
| NCT04310020 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | P2 | active not recruiting | 47 | National Cancer Institute (NCI) | Jan 2021 | |
| NCT04356729 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | P2 | active not recruiting | 30 | Elizabeth Buchbinder, MD | Aug 2020 | |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | P2 | active not recruiting | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Apr 2022 | |
| NCT04563338 | INTEGRATE | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | P2 | active not recruiting | 36 | University Health Network, Toronto | Jun 2021 |
| NCT05498896 | BARBICAN | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | P2 | active not recruiting | 146 | Queen Mary University of London | Dec 2018 |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | P2 | active not recruiting | 81 | National Cancer Institute (NCI) | Mar 2017 | |
| NCT07285850 | ABATE-MASLD | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD | P2/P3 | recruiting | 20 | Eastern Hepatobiliary Surgery Hospital | Oct 2025 |
| NCT05001880 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | P2 | recruiting | 66 | National Cancer Institute (NCI) | Mar 2022 | |
| NCT05091567 | IMforte | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | P3 | active not recruiting | 660 | Hoffmann-La Roche | Nov 2021 |
| NCT06012734 | CoLBAt | LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients | P1 | recruiting | 37 | The Netherlands Cancer Institute | Jun 2024 |
| NCT03782207 | IMreal | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | — | active not recruiting | 2,756 | Hoffmann-La Roche | Feb 2019 |
| NCT03755791 | COSMIC-312 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | P3 | active not recruiting | 837 | Exelixis | Jun 2018 |
| NCT04661150 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | P2 | active not recruiting | 42 | Hoffmann-La Roche | Mar 2021 | |
| NCT06971237 | IMSIRT | SIRT and Peri-immunotherapy : a New Concept | — | not yet recruiting | 60 | Assistance Publique - Hôpitaux de Paris | Jun 2025 |
| NCT06097962 | Safety and Efficacy of NK510 to Treat NSCLC | Early P1 | recruiting | 12 | Base Therapeutics (Shanghai) Co., Ltd. | Jul 2023 | |
| NCT05867121 | A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 | P1 | active not recruiting | 102 | Genentech, Inc. | Oct 2023 | |
| NCT05781308 | ADAPTABLE | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | P2 | active not recruiting | 156 | Intergroupe Francophone de Cancerologie Thoracique | Apr 2023 |
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | P2 | active not recruiting | 88 | National Cancer Institute (NCI) | Dec 2022 | |
| NCT04770896 | IMbrave251 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | P3 | active not recruiting | 557 | Hoffmann-La Roche | Apr 2021 |
| NCT04665856 | SKYSCRAPER-02C | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | P3 | active not recruiting | 123 | Hoffmann-La Roche | Dec 2020 |
| NCT04158258 | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | — | active not recruiting | 2,907 | Hoffmann-La Roche | Feb 2020 | |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | P2 | active not recruiting | 29 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT04250155 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | active not recruiting | 195 | Genentech, Inc. | Mar 2020 | |
| NCT05334329 | NK | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | P1 | active not recruiting | 6 | University of California, Irvine | Jul 2022 |
| NCT04896697 | XTX101 | Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | P1/P2 | active not recruiting | 136 | Xilio Development, Inc. | Sep 2021 |
| NCT04739202 | IMMUNOGAST | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) | P2 | completed | 54 | Hospices Civils de Lyon | Mar 2021 |
| NCT05243862 | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | P2 | active not recruiting | 18 | Treos Bio Limited | Jun 2022 | |
| NCT05238831 | ACT | SMMART Adaptive Clinical Treatment (ACT) Trial | Early P1 | withdrawn | 0 | OHSU Knight Cancer Institute | Jan 2023 |
| NCT03417544 | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | P2 | active not recruiting | 19 | Nancy Lin, MD | May 2018 | |
| NCT04624399 | ABACUS-2 | Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer | P2 | recruiting | 58 | Queen Mary University of London | Jun 2021 |
| NCT04954339 | DYNAMIC | DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab | P2 | completed | 40 | Tae Won Kim | Oct 2021 |
| NCT04102098 | IMbrave050 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | P3 | active not recruiting | 668 | Hoffmann-La Roche | Dec 2019 |
| NCT05007769 | RAN | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | P2 | withdrawn | 0 | Washington University School of Medicine | Oct 2021 |
| NCT04751929 | Abemaciclib With or Without Atezolizumab for mCRPC | P2 | active not recruiting | 19 | Dana-Farber Cancer Institute | Aug 2021 | |
| NCT04941287 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | P2 | active not recruiting | 57 | National Cancer Institute (NCI) | Dec 2021 | |
| NCT04812366 | GUNS | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | P2 | recruiting | 315 | University of British Columbia | Sep 2021 |
| NCT05992220 | ALERT-HCC | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion | P2 | recruiting | 138 | Asan Medical Center | Oct 2022 |
| NCT04367311 | NSCLC | Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | P2 | active not recruiting | 100 | Nasser Hanna | May 2020 |
| NCT03673787 | IceCAP | A Trial of Ipatasertib in Combination With Atezolizumab | P1/P2 | active not recruiting | 87 | Institute of Cancer Research, United Kingdom | Aug 2018 |
| NCT04732598 | AMBITION | A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer | P3 | completed | 281 | Japanese Foundation for Cancer Research | Jan 2021 |
| NCT03694262 | EndoBARR | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | P2 | completed | 30 | Medical College of Wisconsin | Jul 2019 |
| NCT04147351 | A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. | P2 | completed | 22 | National Taiwan University Hospital | Apr 2020 | |
| NCT04611776 | CATHAYA | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | Hoffmann-La Roche | Jul 2021 |
| NCT06939036 | SANTANA-225 | Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | P1/P2 | terminated | 2 | Ariceum Therapeutics GmbH | Jul 2025 |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | P1 | active not recruiting | 179 | Chugai Pharmaceutical | Jun 2021 | |
| NCT04289779 | ABATE | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | P2 | active not recruiting | 46 | Deepak Kilari | May 2020 |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | P1/P2 | active not recruiting | 52 | Royal Marsden NHS Foundation Trust | Feb 2020 | |
| NCT03456063 | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | P3 | completed | 453 | Hoffmann-La Roche | Apr 2018 | |
| NCT05751343 | Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial | P2 | recruiting | 55 | Sun Yat-sen University | Mar 2023 | |
| NCT06323382 | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | recruiting | 240 | Sun Yat-sen University | Jan 2021 | |
| NCT05713994 | CCGLC-001 | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | recruiting | 300 | Ze-yang Ding, MD | May 2020 |
| NCT04294810 | SKYSCRAPER-01 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer | P3 | completed | 620 | Hoffmann-La Roche | Mar 2020 |
| NCT05661578 | SKYSCRAPER-11 | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors | P2 | completed | 64 | Hoffmann-La Roche | May 2023 |
| NCT05450562 | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | P1/P2 | terminated | 33 | Sanofi | Sep 2022 | |
| NCT03869190 | MORPHEUS-UC | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | P1/P2 | completed | 272 | Hoffmann-La Roche | Jun 2019 |
| NCT06267001 | SKYSCRAPER-15 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | P3 | terminated | 56 | Hoffmann-La Roche | Mar 2024 |
| NCT03337698 | Morpheus Lung | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | P1/P2 | terminated | 314 | Hoffmann-La Roche | Dec 2017 |
| NCT04619797 | SKYSCRAPER-06 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | P2/P3 | completed | 542 | Hoffmann-La Roche | Dec 2020 |
| NCT06390059 | EF-39 PANOVA-4 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | P2 | completed | 84 | NovoCure Ltd. | Aug 2023 |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | P1/P2 | completed | 51 | Lokon Pharma AB | Nov 2016 | |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | P2 | completed | 135 | Genentech, Inc. | Aug 2018 | |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | P1/P2 | completed | 62 | Hoffmann-La Roche | Dec 2023 | |
| NCT03483012 | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | P2 | completed | 6 | Dana-Farber Cancer Institute | May 2018 | |
| NCT07272265 | The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study | N/A | completed | 300 | Sun Yat-sen University | Oct 2020 | |
| NCT05746481 | NSCLC | Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | P2 | terminated | 3 | Liza Villaruz, MD | Aug 2023 |
| NCT06488716 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | P1 | terminated | 12 | Genentech, Inc. | Dec 2024 | |
| NCT05240131 | NSCLC | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | P1/P2 | unknown | 88 | Galecto Biotech AB | Mar 2022 |
| NCT04829383 | AB7 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | P2 | active not recruiting | 50 | Howard S Hochster | Mar 2021 |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | P3 | terminated | 102 | ImmunityBio, Inc. | May 2018 | |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | P1/P2 | completed | 214 | Hoffmann-La Roche | Oct 2017 | |
| NCT04303858 | RO7284755 | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | P1 | terminated | 189 | Hoffmann-La Roche | May 2020 |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | — | recruiting | 1,430 | Shanghai Pulmonary Hospital, Shanghai, China | Aug 2024 | |
| NCT04267237 | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | Hoffmann-La Roche | Mar 2021 | |
| NCT04739670 | BELLA | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | P2 | unknown | 31 | Peter MacCallum Cancer Centre, Australia | Mar 2021 |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | P1/P2 | active not recruiting | 125 | Kahr Medical | Oct 2020 | |
| NCT03340376 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | P2 | active not recruiting | 48 | Universitaire Ziekenhuizen KU Leuven | Aug 2017 | |
| NCT03174197 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | P1/P2 | completed | 60 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT06713798 | INDIGO | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures | P2 | withdrawn | 0 | Gustave Roussy, Cancer Campus, Grand Paris | Jan 2025 |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | P1 | completed | 40 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT04487756 | VENEZO-LUNG | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer | P1/P2 | completed | 20 | Instituto Oncológico Dr Rosell | Mar 2021 |
| NCT05251948 | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | P1/P2 | terminated | 40 | Hoffmann-La Roche | Mar 2022 | |
| NCT05276284 | TEMPLE | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy | P1/P2 | completed | 18 | Kristoffer Rohrberg | Sep 2022 |
| NCT02500407 | NHL | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | P1/P2 | completed | 713 | Genentech, Inc. | Sep 2015 |
| NCT04017455 | TARZAN | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) | P2 | active not recruiting | 38 | The Netherlands Cancer Institute | Oct 2019 |
| NCT03556839 | BEATcc | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | P3 | completed | 410 | Grupo Español de Investigación en Cáncer de Ovario | Sep 2018 |
| NCT04540211 | SKYSCRAPER-08 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | P3 | completed | 461 | Hoffmann-La Roche | Oct 2020 |
| NCT04665843 | SKYSCRAPER-09 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck | P2 | completed | 123 | Hoffmann-La Roche | Mar 2021 |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | P2 | terminated | 5 | Replimune, Inc. | Jun 2023 | |
| NCT06603818 | MSS | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Aug 2025 |
| NCT04373369 | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | P2 | terminated | 11 | Washington University School of Medicine | Oct 2020 | |
| NCT06762808 | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | May 2025 | |
| NCT04962126 | FLUORO | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy | P2 | active not recruiting | 15 | Olivia Newton-John Cancer Research Institute | Aug 2021 |
| NCT04513925 | SKYSCRAPER-03 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 829 | Hoffmann-La Roche | Aug 2020 |
| NCT04256421 | SKYSCRAPER-02 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | P3 | completed | 490 | Hoffmann-La Roche | Feb 2020 |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | P2 | completed | 30 | Coherus Oncology, Inc. | Apr 2022 | |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | — | unknown | 1,800 | CCTU- Cancer Theme | Jul 2020 | |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | P1/P2 | completed | 220 | CellCentric Ltd. | Jul 2018 | |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Apr 2025 | |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | P2 | recruiting | 120 | Hunan Province Tumor Hospital | Feb 2023 | |
| NCT03289962 | RO7198457 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | P1 | completed | 273 | Genentech, Inc. | Dec 2017 |
| NCT04591431 | ROME | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | P2 | unknown | 400 | Fondazione per la Medicina Personalizzata | Oct 2020 |
| NCT03363867 | BEACON | BEACON - ABC in Recurrent Platinum Resistant HGSOC | P2 | unknown | 30 | Peter MacCallum Cancer Centre, Australia | Jul 2018 |
| NCT05487235 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 57 | Genentech, Inc. | Aug 2022 | |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | P1/P2 | terminated | 112 | Affimed GmbH | Nov 2021 | |
| NCT05537402 | LOST-B | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC | P2 | terminated | 1 | University of Texas Southwestern Medical Center | Sep 2023 |
| NCT04549428 | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC | P2 | terminated | 12 | Oncology Institute of Southern Switzerland | Oct 2020 | |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | P1/P2 | unknown | 184 | Fundacion Oncosur | Dec 2019 | |
| NCT02530489 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | P2 | completed | 37 | M.D. Anderson Cancer Center | Feb 2016 | |
| NCT06719973 | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) | P1 | withdrawn | 0 | EMD Serono Research & Development Institute, Inc. | May 2025 | |
| NCT03612791 | ATEZOLACC | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab | P2 | completed | 189 | Gustave Roussy, Cancer Campus, Grand Paris | Aug 2018 |
| NCT05665348 | TRIPLET | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | P2/P3 | completed | 229 | Federation Francophone de Cancerologie Digestive | Mar 2023 |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | P1/P2 | completed | 35 | Inovio Pharmaceuticals | May 2018 | |
| NCT06067061 | neoBREASTIM | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | P1/P2 | terminated | 2 | Institut Curie | Apr 2024 |
| NCT03554083 | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | P2 | completed | 64 | Mayo Clinic | Oct 2018 | |
| NCT04477759 | DEHART | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer | P1 | completed | 18 | Medical College of Wisconsin | Jan 2021 |
| NCT04221529 | SPACE | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide | P2 | completed | 70 | AIO-Studien-gGmbH | Jan 2020 |
| NCT04042558 | GFPC 06-2018 | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | P2 | completed | 150 | Centre Francois Baclesse | Sep 2019 |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | P3 | terminated | 190 | National Cancer Institute (NCI) | Apr 2019 | |
| NCT05833126 | Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation | P2 | unknown | 25 | Shuhong Yi | Dec 2023 | |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | P1 | terminated | 13 | The Methodist Hospital Research Institute | Oct 2021 | |
| NCT04338269 | CONTACT-03 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | P3 | terminated | 522 | Hoffmann-La Roche | Jul 2020 |
| NCT03802604 | PROMETEO | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | Early P1 | completed | 28 | SOLTI Breast Cancer Research Group | Dec 2018 |
| NCT05750030 | FMT in IT-refractory HCC - FAB-HCC Pilot Study | P2 | completed | 12 | Medical University of Vienna | May 2023 | |
| NCT04216953 | COTESARC | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | P1/P2 | completed | 229 | Centre Leon Berard | Feb 2020 |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | P3 | completed | 574 | AGO Research GmbH | Sep 2018 | |
| NCT04832854 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | P2 | terminated | 50 | Hoffmann-La Roche | Apr 2021 | |
| NCT04224636 | DEMAND | Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab | P2 | recruiting | 106 | Ludwig-Maximilians - University of Munich | Jun 2020 |
| NCT03340558 | ATELIER | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | P2 | withdrawn | 0 | Niharika Mettu | May 2018 |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | P1/P2 | terminated | 19 | M.D. Anderson Cancer Center | Apr 2021 | |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | P1/P2 | completed | 341 | Hoffmann-La Roche | Jul 2017 | |
| NCT04300647 | SKYSCRAPER-04 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer | P2 | completed | 172 | Hoffmann-La Roche | Jun 2020 |
| NCT05038657 | AURORA | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). | P2 | unknown | 36 | University Hospital Southampton NHS Foundation Trust | May 2022 |
| NCT04630210 | AteBrO | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity | Early P1 | withdrawn | 0 | Universitaire Ziekenhuizen KU Leuven | Feb 2021 |
| NCT04975958 | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | P1 | completed | 47 | Adlai Nortye Biopharma Co., Ltd. | Sep 2021 | |
| NCT03603184 | AtTEnd | Atezolizumab Trial in Endometrial Cancer - AtTEnd | P3 | completed | 549 | Mario Negri Institute for Pharmacological Research | Oct 2018 |
| NCT04471428 | CONTACT-01 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | P3 | completed | 366 | Hoffmann-La Roche | Oct 2020 |
| NCT03818061 | ATHENA | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck | P2 | completed | 33 | Centre Leon Berard | Mar 2019 |
| NCT05717738 | CCGLC-008 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | recruiting | 300 | Tongji Hospital | Jan 2022 |
| NCT05173298 | HCC | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab | — | unknown | 100 | CHA University | Aug 2021 |
| NCT02724878 | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | P2 | completed | 65 | Dana-Farber Cancer Institute | Jul 2016 | |
| NCT04551521 | CRAFT | CRAFT: The NCT-PMO-1602 Phase II Trial | P2 | completed | 72 | German Cancer Research Center | Oct 2021 |
| NCT04109456 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | P1 | completed | 51 | InxMed (Shanghai) Co., Ltd. | Mar 2020 | |
| NCT05180006 | BIS-Program | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | P2 | terminated | 33 | Gustave Roussy, Cancer Campus, Grand Paris | Feb 2022 |
| NCT04148911 | EL1SSAR | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer | P3 | completed | 184 | Hoffmann-La Roche | Dec 2019 |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | P2 | terminated | 3 | Yale University | Jun 2023 | |
| NCT05259319 | IMMUNOs-SBRT | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) | P1 | unknown | 92 | Centre Georges Francois Leclerc | Dec 2022 |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | P2 | unknown | 40 | Sun Yat-sen University | May 2023 | |
| NCT05007613 | Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | P2 | completed | 24 | National Taiwan University Hospital | Jun 2021 | |
| NCT06503250 | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | — | completed | 113 | Hoffmann-La Roche | Jul 2024 | |
| NCT03762018 | BEAT-meso | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma | P3 | completed | 400 | ETOP IBCSG Partners Foundation | Apr 2019 |
| NCT02794571 | PK | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | P1 | completed | 518 | Genentech, Inc. | May 2016 |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | P3 | completed | 438 | Hoffmann-La Roche | Dec 2018 | |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | P1 | terminated | 24 | Imugene Limited | Nov 2020 | |
| NCT03498521 | CUPISCO | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | P2 | completed | 529 | Hoffmann-La Roche | Jul 2018 |
| NCT06098898 | Safety and Efficacy of NK510 to Treat Gastric Cancer | Early P1 | unknown | 9 | Base Therapeutics (Shanghai) Co., Ltd. | Nov 2023 | |
| NCT03946358 | VolATIL | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | P2 | completed | 47 | Centre Hospitalier Universitaire de Besancon | Feb 2020 |
| NCT04185831 | MEGALiT | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | P2 | active not recruiting | 167 | Uppsala University Hospital | Oct 2020 |
| NCT04659382 | SIRTCI | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | P2 | unknown | 52 | Federation Francophone de Cancerologie Digestive | Oct 2020 |
| NCT02992912 | SABR-PDL1 | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours | P2 | unknown | 138 | Gustave Roussy, Cancer Campus, Grand Paris | Nov 2016 |
| NCT05171777 | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | P2 | completed | 179 | Hoffmann-La Roche | Apr 2022 | |
| NCT03371017 | IMpassion132 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | P3 | completed | 595 | Hoffmann-La Roche | Jan 2018 |
| NCT03836066 | TELMA | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients | P2 | completed | 41 | Fundación GECP | May 2019 |
| NCT03127007 | R-IMMUNE | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer | P1/P2 | completed | 45 | Grand Hôpital de Charleroi | Apr 2017 |
| NCT03829501 | KY1044 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | P1/P2 | terminated | 222 | Kymab Limited | Jan 2019 |
| NCT04770272 | neoMono | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | P2 | terminated | 442 | Palleos Healthcare GmbH | Mar 2021 |
| NCT04134000 | BladderGATE | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) | P1 | unknown | 40 | Fundacion Oncosur | Feb 2020 |
| NCT03280563 | MORPHEUS HR+BC | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | P1/P2 | completed | 144 | Hoffmann-La Roche | Dec 2017 |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | P2 | terminated | 33 | NeoImmuneTech | Nov 2021 | |
| NCT05052099 | COMBATBIL | Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer | P1/P2 | completed | 20 | University Hospital, Essen | Oct 2021 |
| NCT04462276 | TREASURE | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | P2 | completed | 68 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Jul 2020 |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | P1/P2 | completed | 84 | TransThera Sciences (Nanjing), Inc. | Apr 2022 | |
| NCT05717400 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | P4 | terminated | 2 | M.D. Anderson Cancer Center | Mar 2023 | |
| NCT05459129 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | P1/P2 | completed | 12 | Hoffmann-La Roche | Apr 2023 | |
| NCT04196530 | EIK1001 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | P1 | completed | 40 | Eikon Therapeutics | Nov 2019 |
| NCT04487067 | AMETHISTA | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | P3 | completed | 152 | Hoffmann-La Roche | Aug 2020 |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | P2 | completed | 46 | SCRI Development Innovations, LLC | Aug 2019 | |
| NCT03598270 | ANITA | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | P3 | completed | 417 | Grupo Español de Investigación en Cáncer de Ovario | Nov 2018 |
| NCT03262454 | Atezolizumab | Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | P2 | unknown | 35 | National Cancer Center, Korea | Jan 2018 |
| NCT04245085 | ABC-lung | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | P2 | completed | 95 | ETOP IBCSG Partners Foundation | Sep 2020 |
| NCT04512430 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | P2 | terminated | 4 | Fundación GECP | Dec 2020 | |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | P1 | completed | 61 | invoX Pharma Limited | Sep 2019 | |
| NCT06416436 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | P1 | withdrawn | 0 | University of Kansas Medical Center | Jul 2024 | |
| NCT03473756 | FORT-2 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma | P1 | completed | 37 | Bayer | May 2018 |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | P2 | unknown | 49 | Consorzio Oncotech | Jul 2020 | |
| NCT02908672 | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | P3 | completed | 514 | Hoffmann-La Roche | Jan 2017 | |
| NCT05694013 | ORIGAMA | Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice | P2/P3 | terminated | 49 | Hoffmann-La Roche | Feb 2023 |
| NCT04622228 | Match | Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer | P2 | completed | 56 | Hoffmann-La Roche | Dec 2020 |
| NCT04194203 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | P3 | completed | 305 | Hoffmann-La Roche | Apr 2020 | |
| NCT02844816 | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | P2 | completed | 172 | National Cancer Institute (NCI) | Mar 2017 | |
| NCT03024437 | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | P1/P2 | terminated | 31 | Roberto Pili | Jun 2017 | |
| NCT05053737 | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | P1 | completed | 11 | University of Colorado, Denver | Nov 2021 | |
| NCT04740918 | KATE3 | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) | P3 | terminated | 96 | Hoffmann-La Roche | Jun 2021 |
| NCT04730999 | CeLEBrATE | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer | P2 | completed | 54 | Gruppo Oncologico Italiano di Ricerca Clinica | Jul 2020 |
| NCT04321330 | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | P2 | completed | 34 | Hoffmann-La Roche | Aug 2020 | |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | P1/P2 | completed | 110 | Hoffmann-La Roche | Feb 2022 | |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | P1/P2 | terminated | 54 | BioNTech SE | Jun 2020 | |
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | P1 | terminated | 16 | Rutgers, The State University of New Jersey | Sep 2019 | |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | P3 | terminated | 100 | Hoffmann-La Roche | May 2021 | |
| NCT03689855 | RamAtezo-1 | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | P2 | completed | 21 | Washington University School of Medicine | Jun 2019 |
| NCT05191797 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | P1/P2 | terminated | 3 | University of Washington | Apr 2022 | |
| NCT04480372 | ORIGIN | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | P2 | completed | 68 | Swiss Cancer Institute | Mar 2021 |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | P2 | completed | 49 | M.D. Anderson Cancer Center | Apr 2017 | |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | P2 | completed | 47 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT02902029 | ImmunoCobiVem | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | P2 | completed | 186 | University Hospital, Essen | Nov 2016 |
| NCT04939480 | PIONEER | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN | P2 | completed | 20 | University Hospital, Essen | Oct 2021 |
| NCT03866239 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | P1 | terminated | 47 | Hoffmann-La Roche | May 2019 | |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | P3 | unknown | 228 | Samsung Medical Center | Aug 2019 | |
| NCT05448677 | ABE-LIVER | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma | P2 | terminated | 3 | University Hospital, Grenoble | Dec 2022 |
| NCT03452137 | IMvoke010 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | P3 | terminated | 406 | Hoffmann-La Roche | Apr 2018 |
| NCT04632992 | MyTACTIC | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | P2 | completed | 252 | Genentech, Inc. | Jan 2021 |
| NCT02891824 | ATALANTE | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab | P3 | completed | 614 | ARCAGY/ GINECO GROUP | Sep 2016 |
| NCT02599454 | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | P1 | completed | 20 | Megan Daly, MD | Apr 2018 | |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | P2 | completed | 86 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT04710498 | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | P2 | completed | 20 | Stanford University | Jun 2021 | |
| NCT03976518 | CHANCE | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) | P2 | completed | 43 | Gruppo Oncologico Italiano di Ricerca Clinica | May 2019 |
| NCT02807636 | IMvigor130 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | P3 | completed | 1,213 | Hoffmann-La Roche | Jun 2016 |
| NCT04602078 | AUREA | Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma | P2 | completed | 82 | Spanish Oncology Genito-Urinary Group | Dec 2020 |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | P1/P2 | withdrawn | 0 | Darell Bigner | Feb 2020 | |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | P3 | withdrawn | 0 | Hoffmann-La Roche | Jan 2019 | |
| NCT05834348 | DELINOR | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | completed | 5,279 | Pfizer | Jun 2023 |
| NCT03511391 | CHEERS | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | P2 | completed | 99 | University Hospital, Ghent | Mar 2018 |
| NCT04857138 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | P1 | completed | 80 | Hoffmann-La Roche | May 2021 | |
| NCT04642365 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | P1 | terminated | 49 | Hoffmann-La Roche | Jan 2021 | |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Oct 2023 | |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | P2 | unknown | 42 | Fudan University | Jan 2022 | |
| NCT05034055 | SKYROCKET | Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer | P2 | unknown | 45 | Yonsei University | Dec 2021 |
| NCT05197504 | HCC | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy | — | completed | 166 | CHA University | Dec 2021 |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | P2 | terminated | 2 | Brian Henick, MD | Sep 2021 | |
| NCT04276376 | ARIANES | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | P2 | terminated | 130 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2019 |
| NCT04408118 | ATRACTIB | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | P2 | completed | 100 | MedSIR | Oct 2020 |
| NCT02873195 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | P2 | completed | 133 | Academic and Community Cancer Research United | Jul 2017 | |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | P2 | terminated | 7 | Washington University School of Medicine | Nov 2022 | |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | P2 | completed | 52 | Nykode Therapeutics ASA | Jul 2020 | |
| NCT04933227 | GEJ | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | P2 | terminated | 29 | Hoffmann-La Roche | Aug 2021 |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Aug 2023 | |
| NCT04696939 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | P2 | unknown | 100 | Shanghai Pulmonary Hospital, Shanghai, China | Jan 2021 | |
| NCT03654833 | MiST | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma | P2 | unknown | 186 | University of Leicester | Jan 2019 |
| NCT03191786 | IPSOS | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy | P3 | completed | 453 | Hoffmann-La Roche | Sep 2017 |
| NCT03698461 | CLIMB | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | P2 | completed | 20 | Asan Medical Center | May 2019 |
| NCT03206203 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | P2 | completed | 106 | Vanderbilt-Ingram Cancer Center | Aug 2017 | |
| NCT03164993 | ALICE | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | P2 | completed | 68 | Oslo University Hospital | Jun 2017 |
| NCT03973333 | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | P1/P2 | withdrawn | 0 | Immunocore Ltd | May 2019 | |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | P1/P2 | completed | 28 | City of Hope Medical Center | Mar 2019 | |
| NCT03686332 | PERICLES | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study | P2 | completed | 32 | The Netherlands Cancer Institute | Sep 2018 |
| NCT02927301 | NSCLC | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) | P2 | completed | 181 | Genentech, Inc. | Apr 2017 |
| NCT04091217 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | P2 | completed | 43 | Hoffmann-La Roche | Nov 2019 | |
| NCT03961698 | MARIO-3 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | P2 | unknown | 91 | Infinity Pharmaceuticals, Inc. | Dec 2019 |
| NCT03721653 | AtezoTRIBE | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | P2 | completed | 218 | Gruppo Oncologico del Nord-Ovest | Nov 2018 |
| NCT04677504 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | P2 | completed | 162 | Hoffmann-La Roche | Feb 2021 | |
| NCT03726879 | IMpassion050 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | P3 | completed | 454 | Hoffmann-La Roche | Jan 2019 |
| NCT03559647 | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | — | completed | 358 | Hoffmann-La Roche | May 2018 | |
| NCT03395899 | ECLIPSE | Pre-operative Immunotherapy Combination Strategies in Breast Cancer | P2 | completed | 71 | Queen Mary University of London | Dec 2017 |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | P1/P2 | terminated | 31 | NeoImmuneTech | Dec 2019 | |
| NCT03498716 | IMpassion030 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | P3 | terminated | 2,199 | Hoffmann-La Roche | Aug 2018 |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | P1 | terminated | 5 | Fate Therapeutics | May 2022 | |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Aug 2023 | |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | P1/P2 | completed | 24 | Lokon Pharma AB | Jan 2020 | |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | P2 | terminated | 24 | Hoffmann-La Roche | Dec 2021 | |
| NCT06199297 | Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma | — | completed | 188 | Sun Yat-sen University | Mar 2021 | |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | P1/P2 | terminated | 8 | Hoffmann-La Roche | May 2022 | |
| NCT04028050 | MAURIS | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | P3 | completed | 155 | Hoffmann-La Roche | Aug 2019 |
| NCT03695380 | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | P1 | completed | 77 | Hoffmann-La Roche | Jan 2019 | |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | P1 | completed | 3 | National Cancer Institute (NCI) | Apr 2021 | |
| NCT04541173 | HCC | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | P2 | terminated | 6 | Aiwu Ruth He, MD | Nov 2020 |
| NCT03464942 | AZTEC | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer | P2 | completed | 54 | Peter MacCallum Cancer Centre, Australia | Aug 2018 |
| NCT04099836 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | P2 | terminated | 7 | Duke University | Jul 2020 | |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | P1/P2 | withdrawn | 0 | Rain Oncology Inc | May 2023 | |
| NCT02091141 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | P2 | completed | 673 | Genentech, Inc. | Apr 2014 | |
| NCT06049966 | LANCE | Atezolizumab in Large Cell Neuroendocrine Carcinoma | P1 | completed | 22 | Oncology Center of Biochemical Education And Research | Mar 2018 |
| NCT04713891 | A Study of KF-0210 in Advanced Solid Tumors Patients | P1 | completed | 14 | Keythera Pharmaceuticals (Australia) Pty Ltd | Mar 2021 | |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | P2 | terminated | 1 | University of California, Davis | Dec 2021 | |
| NCT04322643 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | P2 | terminated | 4 | Case Comprehensive Cancer Center | Mar 2020 | |
| NCT03625141 | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | P2 | completed | 80 | Hoffmann-La Roche | Dec 2018 | |
| NCT02994576 | PRINCEPS | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer | P2 | completed | 60 | Gustave Roussy, Cancer Campus, Grand Paris | Dec 2016 |
| NCT02451423 | Neoadjuvant Atezolizumab in Localized Bladder Cancer | P2 | completed | 23 | Lawrence Fong | Mar 2016 | |
| NCT02594384 | LAM-002A/NHL | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma | P1 | completed | 62 | OrphAI Therapeutics | Oct 2015 |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | P1/P2 | terminated | 61 | Dracen Pharmaceuticals, Inc. | Aug 2020 | |
| NCT04045028 | PK | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | terminated | 41 | Genentech, Inc. | Jul 2019 |
| NCT04862949 | Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC | — | completed | 131 | CHA University | May 2021 | |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | P1 | completed | 83 | Hoffmann-La Roche | Sep 2020 | |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | P3 | completed | 242 | Hoffmann-La Roche | Nov 2019 | |
| NCT02108652 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | P2 | completed | 310 | Hoffmann-La Roche | May 2014 | |
| NCT02951767 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | P2 | completed | 119 | Hoffmann-La Roche | May 2014 | |
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | P2 | withdrawn | 0 | University Health Network, Toronto | Jul 2021 | |
| NCT03158389 | N²M² | NCT Neuro Master Match - N²M² (NOA-20) | P1/P2 | completed | 228 | University Hospital Heidelberg | May 2018 |
| NCT04426825 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | P2 | completed | 23 | Hoffmann-La Roche | Sep 2020 | |
| NCT04084951 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | P1 | completed | 30 | SQZ Biotechnologies | Jan 2020 | |
| NCT03125902 | IMpassion131 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | P3 | completed | 653 | Hoffmann-La Roche | Aug 2017 |
| NCT02926833 | ZUMA-6 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 37 | Kite, A Gilead Company | Sep 2016 |
| NCT04801966 | TAILOR | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | N/A | terminated | 3 | Peter MacCallum Cancer Centre, Australia | Sep 2021 |
| NCT02813785 | IMpower210 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy | P3 | completed | 565 | Hoffmann-La Roche | Jul 2016 |
| NCT04690855 | TARA | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | P2 | terminated | 1 | Mylin A. Torres, MD | Oct 2021 |
| NCT03016312 | IMbassador250 | A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen | P3 | completed | 759 | Hoffmann-La Roche | Jan 2017 |
| NCT02657434 | NSCLC | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | P3 | completed | 578 | Hoffmann-La Roche | Apr 2016 |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | P3 | completed | 1,004 | Hoffmann-La Roche | Nov 2016 | |
| NCT03024996 | IMmotion010 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy | P3 | terminated | 778 | Hoffmann-La Roche | Jan 2017 |
| NCT03434379 | IMbrave150 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | P3 | completed | 558 | Hoffmann-La Roche | Mar 2018 |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | P1 | completed | 37 | Fate Therapeutics | Feb 2019 | |
| NCT02825940 | IMYO29233 | A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 120 | Hoffmann-La Roche | Aug 2016 |
| NCT04272645 | Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer | P2 | withdrawn | 0 | University of Michigan Rogel Cancer Center | Oct 2020 | |
| NCT04404140 | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | P1 | terminated | 6 | Hoffmann-La Roche | Jul 2020 | |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | P1 | terminated | 2 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2021 | |
| NCT04045613 | FIDES-02 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer | P1/P2 | completed | 95 | Basilea Pharmaceutica | Aug 2019 |
| NCT03102242 | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | P2 | completed | 64 | Alliance Foundation Trials, LLC. | Nov 2017 | |
| NCT03197935 | IMpassion031 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | P3 | completed | 333 | Hoffmann-La Roche | Jul 2017 |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | P1/P2 | terminated | 96 | Hoffmann-La Roche | Sep 2018 | |
| NCT04610684 | SCLC | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | P2 | terminated | 3 | Jeffrey Clarke | Jan 2021 |
| NCT03526900 | ATEZO-BRAIN | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis | P2 | completed | 40 | Spanish Lung Cancer Group | Jul 2018 |
| NCT05456165 | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | P2 | withdrawn | 0 | Gritstone bio, Inc. | May 2022 | |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | P2 | completed | 136 | The Lymphoma Academic Research Organisation | Feb 2018 | |
| NCT03138889 | PROPEL | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | P1/P2 | terminated | 162 | Nektar Therapeutics | Jun 2017 |
| NCT03357224 | PARCT | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) | P2 | terminated | 26 | European Organisation for Research and Treatment of Cancer - EORTC | Sep 2018 |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | P1/P2 | terminated | 1 | Fred Hutchinson Cancer Center | Jul 2021 | |
| NCT03232593 | MFDS | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | — | completed | 1,758 | Hoffmann-La Roche | Nov 2017 |
| NCT03038100 | IMagyn050 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P3 | completed | 1,301 | Hoffmann-La Roche | Mar 2017 |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | P3 | completed | 101 | Hoffmann-La Roche | Jul 2019 | |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | P1 | completed | 41 | Pieris Pharmaceuticals, Inc. | Aug 2018 | |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | P2 | active not recruiting | 21 | Fox Chase Cancer Center | Nov 2017 | |
| NCT02763579 | IMpower133 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | P3 | completed | 503 | Hoffmann-La Roche | Jun 2016 |
| NCT04214418 | MEKiAUTO | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies | P1/P2 | terminated | 27 | Columbia University | Feb 2020 |
| NCT03147040 | GELATO | AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer | P2 | terminated | 23 | The Netherlands Cancer Institute | Nov 2017 |
| NCT04059887 | BUDDY | Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] | P4 | completed | 100 | Chonnam National University Hospital | Dec 2019 |
| NCT03835949 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | P1 | unknown | 36 | Tracon Pharmaceuticals Inc. | Jul 2019 | |
| NCT02450331 | IMvigor010 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection | P3 | terminated | 809 | Hoffmann-La Roche | Oct 2015 |
| NCT05609903 | Anastase | Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer | — | completed | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Nov 2019 |
| NCT03577132 | The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer | N/A | unknown | 20 | Seoul National University Hospital | Aug 2018 | |
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | P2 | terminated | 6 | Nabil Adra | Dec 2018 | |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | P2 | completed | 25 | Gradalis, Inc. | May 2017 | |
| NCT03637764 | SAR650984 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | P1/P2 | terminated | 107 | Sanofi | Aug 2018 |
| NCT03818997 | DYNAMIC | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | P2 | withdrawn | 0 | European Organisation for Research and Treatment of Cancer - EORTC | Dec 2019 |
| NCT04102618 | AWARE-1 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | Early P1 | terminated | 26 | Oncolytics Biotech | Mar 2019 |
| NCT03285763 | TAIL | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | P4 | completed | 619 | Hoffmann-La Roche | Oct 2017 |
| NCT03014648 | NSCLC | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | P2 | completed | 28 | Liza Villaruz, MD | Jul 2017 |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | P2 | completed | 122 | European Organisation for Research and Treatment of Cancer - EORTC | Dec 2016 | |
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | P2 | terminated | 16 | Arjun Balar, MD | Sep 2017 | |
| NCT03800836 | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | P1 | completed | 139 | Hoffmann-La Roche | Feb 2018 | |
| NCT02409342 | MPDL3280A | A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] | P3 | completed | 572 | Hoffmann-La Roche | Jul 2015 |
| NCT03801304 | VinMetAtezo | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | P2 | completed | 80 | University Hospital, Brest | Jan 2019 |
| NCT03498222 | iTRAP | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | P1 | withdrawn | 0 | Queen Mary University of London | Jun 2018 |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | P2 | terminated | 256 | Hoffmann-La Roche | Feb 2018 | |
| NCT03713944 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | P2 | terminated | 30 | Nasser Hanna | Nov 2018 | |
| NCT02420821 | IMmotion151 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) | P3 | completed | 915 | Hoffmann-La Roche | May 2015 |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | P1 | terminated | 32 | Synlogic | Dec 2019 | |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | P1 | completed | 36 | Amgen | Mar 2018 | |
| NCT03422523 | ARGO | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | P2 | terminated | 53 | University Hospital Southampton NHS Foundation Trust | May 2018 |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Early P1 | withdrawn | 0 | Mayo Clinic | Jan 2020 | |
| NCT02914470 | PROLOG | Carboplatin-cyclophosphamide Combined With Atezolizumab | P1 | completed | 12 | The Netherlands Cancer Institute | Jan 2017 |
| NCT03359239 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | P1 | completed | 10 | Matthew Galsky | May 2019 | |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | P1/P2 | terminated | 9 | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | Feb 2021 | |
| NCT02876510 | ACTolog | ACTolog in Patients With Solid Cancers | P1 | completed | 38 | Immatics US, Inc. | Jun 2017 |
| NCT02322814 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | P2 | terminated | 169 | Hoffmann-La Roche | Mar 2015 | |
| NCT05055947 | Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer | — | completed | 60 | Hunan Province Tumor Hospital | Apr 2019 | |
| NCT05055999 | Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer | — | completed | 60 | Hunan Province Tumor Hospital | Apr 2019 | |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | P3 | completed | 902 | Hoffmann-La Roche | Jun 2015 | |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | P1 | completed | 502 | Corvus Pharmaceuticals, Inc. | Jan 2016 | |
| NCT03894007 | PREDIXIIHER2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | P2 | terminated | 6 | Renske Altena | May 2019 |
| NCT03952325 | CONTESSA TRIO | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | P2 | terminated | 294 | Odonate Therapeutics, Inc. | Jul 2019 |
| NCT03730012 | FLT3 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | P1/P2 | completed | 11 | Astellas Pharma Global Development, Inc. | Jun 2019 |
| NCT03063762 | RCC | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | P1 | completed | 69 | Hoffmann-La Roche | Mar 2017 |
| NCT02715531 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | P1 | completed | 243 | Hoffmann-La Roche | Apr 2016 | |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | P1/P2 | completed | 49 | Hoffmann-La Roche | Nov 2017 | |
| NCT04869501 | Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer | — | no longer available | 0 | I-Mab Biopharma US Limited | — | |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | P1 | terminated | 4 | The Lymphoma Academic Research Organisation | Jul 2019 | |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | P1/P2 | completed | 89 | Syndax Pharmaceuticals | May 2016 | |
| NCT02291289 | MODUL | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | P2 | completed | 1,044 | Hoffmann-La Roche | Apr 2015 |
| NCT02431208 | MM | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | P1 | completed | 85 | Hoffmann-La Roche | Jul 2015 |
| NCT03618953 | Kingfisher | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers | P1 | terminated | 8 | Turnstone Biologics, Corp. | Jun 2018 |
| NCT03273153 | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | P3 | terminated | 446 | Hoffmann-La Roche | Dec 2017 | |
| NCT02367794 | NSCLC | A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] | P3 | completed | 1,021 | Hoffmann-La Roche | Jun 2015 |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | P2 | completed | 43 | Bavarian Nordic | Sep 2018 | |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | P1/P2 | terminated | 7 | Oncovir, Inc. | Sep 2018 | |
| NCT02367781 | IMpower130 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 723 | Hoffmann-La Roche | Apr 2015 |
| NCT02921269 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | P2 | completed | 11 | National Cancer Institute (NCI) | Mar 2017 | |
| NCT03644823 | COM-IT-1 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC | P2 | terminated | 21 | Oslo University Hospital | Aug 2018 |
| NCT03024216 | Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer | P1 | completed | 37 | University of Hawaii | Feb 2017 | |
| NCT03620435 | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer | P2 | unknown | 25 | McGill University Health Centre/Research Institute of the McGill University Health Centre | May 2018 | |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | P1/P2 | terminated | 12 | Vanderbilt-Ingram Cancer Center | Jul 2018 | |
| NCT02366143 | IMpower150 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | P3 | completed | 1,202 | Hoffmann-La Roche | Mar 2015 |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | P2 | completed | 73 | Intergroupe Francophone de Cancerologie Thoracique | Mar 2017 | |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | P2 | terminated | 46 | Vall d'Hebron Institute of Oncology | Nov 2017 | |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P1/P2 | completed | 12 | National Cancer Institute (NCI) | Nov 2017 | |
| NCT04422210 | ES-SCLC | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | P1 | terminated | 2 | Hoffmann-La Roche | Sep 2020 |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | P1 | terminated | 13 | Hoffmann-La Roche | Oct 2019 | |
| NCT03041311 | G1T28 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | P2 | completed | 107 | G1 Therapeutics, Inc. | Jun 2017 |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | P2 | terminated | 6 | Weill Medical College of Cornell University | Nov 2016 | |
| NCT02631577 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | P1/P2 | completed | 38 | Hoffmann-La Roche | Dec 2015 | |
| NCT02792192 | BCG | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | P1/P2 | terminated | 24 | Hoffmann-La Roche | Jun 2016 |
| NCT03178851 | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | P1 | completed | 155 | Hoffmann-La Roche | Jun 2017 | |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | P2 | withdrawn | 0 | Health Pharma Professional Research | Aug 2020 | |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | P1 | completed | 221 | Hoffmann-La Roche | Jan 2015 | |
| NCT03101280 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | P1 | completed | 29 | Hoffmann-La Roche | Apr 2017 | |
| NCT02458638 | A Study of Atezolizumab in Advanced Solid Tumors | P2 | completed | 474 | Hoffmann-La Roche | Jul 2015 | |
| NCT03394885 | AdORN | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | P1/P2 | completed | 18 | Duke University | Jun 2018 |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | P2 | terminated | 21 | University of Washington | Jun 2017 | |
| NCT03616691 | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | P2 | unknown | 46 | Samsung Medical Center | Aug 2018 | |
| NCT03264066 | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | P2 | completed | 87 | Hoffmann-La Roche | Nov 2017 | |
| NCT02303951 | NEO-VC | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | P2 | terminated | 47 | University Hospital Tuebingen | Jan 2015 |
| NCT02596971 | CHOP | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 91 | Hoffmann-La Roche | Dec 2015 |
| NCT03647956 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | P2 | unknown | 40 | The University of Hong Kong | Oct 2018 | |
| NCT03154827 | AML | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | P1/P2 | terminated | 1 | BioLineRx, Ltd. | Jan 2018 |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | P1 | completed | 67 | Genentech, Inc. | Aug 2012 | |
| NCT01633970 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 240 | Genentech, Inc. | Jul 2012 | |
| NCT02924883 | KATE2 | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy | P2 | completed | 202 | Hoffmann-La Roche | Sep 2016 |
| NCT02013219 | NSCLC | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | P1 | completed | 52 | Hoffmann-La Roche | Apr 2014 |
| NCT02220842 | MPDL3280A | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | P1 | completed | 96 | Hoffmann-La Roche | Dec 2014 |
| NCT02650713 | CEA | A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors | P1 | completed | 228 | Hoffmann-La Roche | Jan 2016 |
| NCT03455556 | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | P1 | terminated | 1 | Mayo Clinic | Aug 2018 | |
| NCT03465891 | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | P2 | terminated | 2 | Memorial Sloan Kettering Cancer Center | Mar 2018 | |
| NCT02350673 | IV | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | P1 | completed | 70 | Hoffmann-La Roche | Jun 2015 |
| NCT02892318 | AML | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | P1 | completed | 40 | Hoffmann-La Roche | Oct 2016 |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | P1 | completed | 29 | Regeneron Pharmaceuticals | Mar 2018 | |
| NCT02174172 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 158 | Hoffmann-La Roche | Aug 2014 | |
| NCT02410512 | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 610 | Genentech, Inc. | Apr 2015 | |
| NCT02605915 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | P1 | completed | 98 | Hoffmann-La Roche | Dec 2015 | |
| NCT03267940 | CIS | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | P1 | terminated | 85 | Halozyme Therapeutics | Oct 2017 |
| NCT02304393 | RO7009789 | A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | P1 | completed | 140 | Hoffmann-La Roche | Dec 2014 |
| NCT01988896 | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 153 | Hoffmann-La Roche | Dec 2013 | |
| NCT03979066 | NEOiPANC | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | P2 | terminated | 1 | Gulam Manji | Nov 2019 |
| NCT02729896 | FL | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 36 | Hoffmann-La Roche | Nov 2016 |
| NCT02471846 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 158 | Genentech, Inc. | Jul 2015 | |
| NCT03023423 | DARZALEX | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | P1/P2 | completed | 100 | Janssen Research & Development, LLC | Dec 2016 |
| NCT03369964 | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | P1 | withdrawn | 0 | Hoffmann-La Roche | Mar 2018 | |
| NCT02814669 | ATZ | Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor | P1 | completed | 45 | Hoffmann-La Roche | Sep 2016 |
| NCT03087864 | PERFECT | PDL-1 Targeting in Resectable Oesophageal Cancer | P2 | completed | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Jun 2017 |
| NCT02876224 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | P1 | completed | 51 | Hoffmann-La Roche | Sep 2016 | |
| NCT02508870 | A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes | P1 | completed | 46 | Hoffmann-La Roche | Sep 2015 | |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | P1/P2 | terminated | 87 | Hoffmann-La Roche | Nov 2015 | |
| NCT02848651 | B-F1RST | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer | P2 | completed | 153 | Genentech, Inc. | Sep 2016 |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | P1 | terminated | 2 | Yale University | Feb 2017 | |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | — | completed | 13 | Hoffmann-La Roche | Feb 2018 | |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | P1 | terminated | 36 | Hoffmann-La Roche | Nov 2017 | |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | P2 | terminated | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Apr 2015 | |
| NCT03399643 | Announce | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) | — | terminated | 22 | Hoffmann-La Roche | Dec 2017 |
| NCT02031458 | BIRCH | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | P2 | completed | 667 | Hoffmann-La Roche | Jan 2014 |
| NCT02008227 | OAK | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy | P3 | completed | 1,225 | Hoffmann-La Roche | Mar 2014 |
| NCT01984242 | IMmotion150 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma | P2 | completed | 305 | Hoffmann-La Roche | Jan 2014 |
| NCT02788279 | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) | P3 | completed | 363 | Hoffmann-La Roche | Jul 2016 | |
| NCT03228368 | TCR | The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients | — | unknown | 10 | First Affiliated Hospital of Zhejiang University | Mar 2017 |
| NCT03120676 | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | P2 | terminated | 3 | Memorial Sloan Kettering Cancer Center | Apr 2017 | |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | P3 | completed | 931 | Hoffmann-La Roche | Jan 2015 | |
| NCT01375842 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 661 | Genentech, Inc. | Jun 2011 | |
| NCT01903993 | A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | P2 | completed | 287 | Hoffmann-La Roche | Aug 2013 | |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | Early P1 | terminated | 1 | University of Michigan Rogel Cancer Center | Nov 2017 | |
| NCT03029832 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | P2 | terminated | 5 | Genentech, Inc. | Apr 2017 | |
| NCT01688206 | RO5520985 | A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 132 | Hoffmann-La Roche | Oct 2012 |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | P1 | terminated | 2 | Vyriad, Inc. | Aug 2017 | |
| NCT01846416 | PD-L1 | A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | P2 | completed | 138 | Genentech, Inc. | May 2013 |
| NCT02409355 | NSCLC | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | P3 | terminated | 8 | Hoffmann-La Roche | May 2015 |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma | P1 | terminated | 29 | Incyte Corporation | Jan 2015 | |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | P1 | terminated | 18 | Celldex Therapeutics | Oct 2015 | |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | — | approved for marketing | 0 | Genentech, Inc. | Nov 2015 |
Atezolizumab clinical trials: frequently asked questions
- How many Atezolizumab clinical trials are there?
- 746 Atezolizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 162 are actively recruiting participants. 232 are marked completed.
- Are Atezolizumab clinical trials recruiting in 2026?
- Yes — 162 Atezolizumab trials are actively recruiting in 2026, with 1934 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Atezolizumab being studied for?
- Atezolizumab is being studied for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer and 966 more. The trials are grouped by indication on this page.
- What phase is Atezolizumab in?
- Atezolizumab clinical trials span 7 Phase 4, 106 Phase 3, 323 Phase 2, 138 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Atezolizumab clinical trials?
- The lead sponsor across the most Atezolizumab trials is Hoffmann-La Roche, with 316 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Atezolizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: